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latentvirusinrestingmemoryCD + Tcells. Chapter modelsinfection
dynamicsduringtreatmentinterruption,inordertoassessinvestigational
therapiesthatreducethesizeofthelatentreservoir. Calculationssuggestthat
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growthandevolutionundervarioustreatmentregimes[  ,  ,   ]. Highly
activeantiretroviraltherapy(HAART)inhibitsHIVreplicationandcanmaintain
alowviralloadinde nitely,butitcannoteradicatetheinfectionduetoareservoir


















levels[  ,   ]. InChapter ,Ipresentamathematicalmodelthatexplainsthese

































methodforcuringHIVbycompleteeradicationofthelatentreservoir[   ],
bothearlytreatmentinitiation[  ,   ,   ]anduseofdrugstoinducetargeted
activationoflatentlyinfectedcells[ –  ,  ,   ,   ,   ,   ,   ]mayreduce
thesizeofthelatentreservoir. Itisnotyetknownhowreservoirreduction,short














roughly  -foldasmeasuredinvitro,whilethe rstproteaseinhibitor,saquinavir,
approvednineyearslater,inhibitsreplicationoveronemillion-foldbythesame
measurement[   ],renderingvirusundetectablebyclinicalassays. As
mathematicalmodelsdesignedintheearlyHAARTeraservedtoframedebates
abouttherapeuticgoalsandvirologicalconsequencesofantiretroviral















onvaccinationeﬀortsofothers[  ]. Asmemoriesofthevirulentconsequences
ofapathogenwane,deniersofvaccinationeﬃcacyandsafetymaygain













evolution[   ],havebeenshowntobeoptimalundercertainconditionsof
boundedrationality[   ],andhavebeenusedtodescribelearnedforaging
behavioradequatelyinatleastonenonhumanspecies[   ].
















consequencesofmutationrateevolution[  ,   ]. Inthecontextofinfections,
boththemutationrateandintra-hostpopulationsizeofapathogengovernthe
rateatwhichitmayescapehostdefenses,aphenomenonthathasbeenstudiedin
greatdetailinthecontextofHIVepitopeevolution[  ,   ]. Inmammals,the
adaptiveCD + Tcellresponseisaformof“domesticatedevolution”that
exploitsstrongselectivepressuresforantigenicspeci cityinalargepopulation
(       cellsinhumans)tocombatthisshi ingpathogenthreat. Inbacterial
speciesconfrontingphageparasites,hypermutationmayplayasimilarprotective
role[   ],albeitwiththea endantrisksofincreasedmutationalload.
 eoreticalargumentssuggestthathost-pathogencoevolutionmaydrive











































rock-paper-scissorsmatecompetition[   ,   ]. Cyclicalcompetitionshould
becommonwhereindividualsface tnesstradeoﬀsinmultipleinteracting






 .  I           
T             HIV         hasdramaticallyimprovedsincethe
introductionofhighlyactiveantiretroviraltherapy(HAART),which,when
successful,canbringviralloadsbelowthedetectionlimit,improveimmune




virologicfailureandtheemergenceofdrugresistance[   ,   ,   ,   ].
Becauseoftheirhighantiviralactivity,proteaseinhibitorsarecrucialinHIV- 
treatmentandareusedinthreeofthe verecommendedinitialregimensand
manysalvageregimens[   ]. Clinicaltrialshaveshownthatformanydrug
combinationsinvolvingproteaseinhibitors,treatmentfailureoccurswithout









multiplemutationsintheproteasegene[  ]. Proteaseinhibitorresistancealso
typicallyoccursatanarrowerrangeofadherencelevelsthanresistancetoother
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Antiretroviraldrugsreduceviral tnessinadose-dependentmanner(Fig.
 . . a). Viral tnesscanbesummarizedasasingleparameter,thebasic









)m ( . )
HereDisdrugconcentration,IC   istheconcentrationatwhich   
inhibitionoccurs,andmisaparameterdeterminingsteepnessofthecurve






















R0 < 1, R’0 <1 
2) mutant grows,
WT suppressed
R0 < 1 < R’0  
3) Both grow,
mutant selected
1 < R0 < R’0  
4) Both grow,
WT selected






































Figure 2.2.1: Drug concentrations determine the relative ﬁtness of the wild-
type virus and a resistant mutant. (a) The ﬁtness of the wild-type virus (R ,
blue line) decreases with increasing drug concentration (here shown normal-
ized by wild-type IC  ), following equation (1). A drug-resistant strain (R′
 ,
red line) is less ﬁt than the wild type at low concentrations but more ﬁt at
higher concentrations, owing to an increased IC   or a reduced slope. The
MSW is the range of concentrations where a resistant mutant, if present, will
grow faster than the wild type and still has R′
     . The WGW is the range
of low concentrations where the wild type has R     , leading to treatment
failure without the need for resistance. For drug concentrations in the over-
lapping range of these windows, virologic failure can occur even without re-
sistance but will be hastened by the appearance of a faster-growing mutant.
(b) As drug concentrations decay after the last dose is taken, the viral ﬁtness
passes through four diﬀerent selection ranges. Depending on the drug, dose
level and mutation, not all of these ranges may exist. The time spent in each
selection window is also determined by the drug half-life. WT, wild type.













)m( +σ) ( . )
Mutationshavea tnesscost,meaningthatthedrug-free tnessofthemutant
virusisreducedbyafractions(    s    ). Inthepresenceofthedrug,the
mutationconfersabene t,multiplyingtheIC   byafactor ρ(thefoldchangein
IC  , ρ    ). Manymutationsalsoreducetheslope(m)ofthedose-response
curvebyafractionσ    (ref. [   ]).
Virologicfailureoccurswhentreatmentfailstopreventthegrowthofvirusto
highlevels. AviralstraingrowswhenR     .  estrainwithhighestR 
outcompetesothers[   ].  erangeofdrugconcentrationswherearesistant
mutantcancausevirologicfailureiscalledthemutantselectionwindow(MSW)
[  ,  ]. AbovetheMSW,evenreplicationofthemutantissuppressed
(R′
 (D)    ),althoughtoxicitymaypreventthesedrugconcentrationsfrom
beingachievedclinically. Weherede nethewild-typegrowthwindow(WGW),
wheredrugconcentrationsaresolowthatwild-typevirusisnotadequately
suppressedandfailurecanoccurevenwithoutresistance(R (D)    ).





increase. Uptofourselectionrangescanbeidenti ed(Fig.  . . b). Using
pharmacokineticandpharmacodynamicdata[   ,   ](Supplementary
Table . . ),wedeterminedthetimespentintheserangesfor  drug-mutation
pairs(Fig.  . . a)onthebasisoftheirspeci cdose-responsecurves(Fig.
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Figure 2.2.2: Selection windows can be calculated for particular drug-
mutation pairs. (a) The distance to the right along each horizontal bar is the
time since the last dose, and the color corresponds to the selection window
during that time interval (described in Fig. 2.2.1b). (b-e) Examples of dose-
response curves (showing drug concentration normalized by wild-type IC  ) for
drug-mutation combinations indicated in a. Shading indicates the MSW. If
the cost of a mutation is too high or its beneﬁt (ρ or σ) too low, it is possible
that the MSW does not exist. (f) Rank of each drug for relative risk of wild-
type versus mutant virus growth, independent of the overall risk of therapy
failure. For each drug, we show a ‘synthetic’, worst-case, single-nucleotide mu-
tation (Supplementary Methods and Supplementary Fig. 7.2.12). PI, protease
inhibitors; FI, fusion inhibitors; II, integrase inhibitors; ABC, abacavir; FTC,
emtricitabine; ATV, atazanavir; TPV, tipranavir; EVG, elvitegravir; ENF, en-
fuvirtide. Protease inhibitors are often boosted (co-formulated) with ritonovir
(/r), which interferes with breakdown in the liver and increases half-life.









failurea ershorttreatmentinterruptions.  isfeatureisdepictedschematically
byplo ingthedrugsalongasingleaxis,whichmeasurestherelativeriskof
mutantgrowthversuswild-typegrowth,independentoftheoverallriskof
virologicfailure(Fig.  . . fandSupplementaryMethods).





developedastochasticmodelofviralevolution(Fig.  . . andMethods). Our
modelbuildsonthelargebodyofpreviousworkmodelingHIVtherapy
[   ,   ,   ,   ,   ]byintegratingnewdataonclass-speci cdrug
properties[   ]andrealisticcostsandbene tsofmutations[   ]. Wealso
  modi edpastapproachesbyallowingdrugconcentrations,andhenceR ,to
 uctuate,ratherthantakingtime-averages.
We rstsimulated  -weektrialsofsingleagentsinacohortofpatients.  e
resultsarepresentedintwoways: asoutcomeversuspatientadherenceatthe
trialendpoint(Fig.  . . a)andasoutcomeversustimeforadistributionof
patientadherencelevels(Fig.  . . b,c).
Consistentwithapreviousmeta-analysisofcombinationtherapyclinicaltrials
[  ],ourmodelpredictsthatthelevelofadherencenecessaryformutant
virologicfailurediﬀersbydrugclass(Fig.  . . ). Speci cally,fortheNNRTIs
efavirenz(EFV)andetravirine(ETV),theriskofmutantvirologicfailureis
greatestatlowadherencelevels;forunboostedproteaseinhibitors,theriskpeaks




explainingthesegeneraltrends[   ,   ]. Byincorporatingthesefactorsas
parameters,ourmodelformalizesthisargument.
Inexaminingsimulationsofeachdrugindividually(Supplementary
Figs. . . – . . ),wefoundfourqualitativepa ernsofoutcome,which
















































































































































G → A    5 x 10-5




M184V    2 x 10-5
K103N    5 x 10-6
.....
Output:        Viral load and % mutant versus time
Figure 2.2.3: Schematic of algorithm for simulating viral dynamics in a pa-
tient undergoing treatment. (a) A single simulated patient takes a particular
drug (or drug combination) with a designated adherence level, starting with
an initial viral load (VL). Over a 48-week clinical trial, drug levels ﬂuctuate
and viral load levels are simulated according to a viral dynamics model. (b)
Drug levels ﬂuctuate according to patient’s dosing pattern and pharmacoki-
netics (dose size, half-life, bioavailability); gaps show missed doses (ﬁgure
shows single drug). (c) Wild-type viral ﬁtness (R ) ﬂuctuates in response to
drug concentration depending on the dose-response curve. (d) Fitness of drug-
resistant strain (R′
 ) depends on an altered dose-response curve; at high drug
concentrations, mutant ﬁtness exceeds that of the wild type. (e) Wild-type
viral load depends on viral dynamics equations, which account for active repli-
cation, exit from the latent reservoir and competition between strains. (f) A
mutant virus may appear (red star) but be below the threshold for detection
(dotted red line) before eventually leading to virologic failure.
  3TC EFV NFV DRV/r ETV ATV/r


































































Suppresed viral load  Detectable viral load with resistance Detectable viral load, wildtype only 
0 12 24 36 48 12 24 36 48 12 24 36 48 12 24 36 48 12 24 36 48 12 24 36 48
Adherence (%) Adherence (%) Adherence (%)
Time (weeks) Time (weeks) Time (weeks)
c
I II III IV
Figure 2.2.4: Outcomes for simulated patients in a clinical trial. (a-c) The
height of the area shaded indicates probability of the corresponding outcome
at a given adherence level (a) or time point (b,c). (a) Adherence is deﬁned
as the fraction of scheduled doses taken. These are maintenance trials (see
Methods). (b,c) Measurements are taken every 2 weeks for simulated patients
with a distribution of adherence levels (Supplementary Methods and Sup-
plementary Fig. 7.2.13b). (b) Suppression trials (see Methods). (c) Mainte-
nance trials. (1) 3TC therapy (pattern includes AZT, ABC, d4T, ENF, EVG,
FTC, NVP, RAL, TDF). (2) EFV and ETV therapy. (3) NFV therapy (pat-
tern includes ddI). (4) DRV/r and ATV/r therapy (pattern includes ATV,
TPV/r; variation on this pattern described in the Results includes LPV/r,
SQV, SQV/r IDV, IDV/r).
  adherenceledtomutantvirologicfailureinallsimulatedpatients. Asadherence
declined,somewild-typevirologicfailureoccurred. Virologicfailureand


















clinicalse ings(adherence<   ),ourmodelpredictsthatthesedrugsperform
similarlytomonotherapywithotherNRTIs,typicallyleadingtomutantvirologic
failure.



















































































Figure 2.2.5: Our calculated adherence-resistance relations are in agreement
with those observed in clinical trials. (a) Adherence versus simulated prob-
ability of resistance in a 48-week suppression trial for a protease inhibitor, a
boosted protease inhibitor and an NNRTI. The inset shows a qualitative sum-
mary of results from a meta-analysis of clinical trials [15], which agrees with
our simulations. (b) Adherence versus fraction of time spent in the MSW for
the same drugs. Adherence-resistance trends demonstrate that time in MSW
is a good proxy for the risk of mutant-based virologic failure. For both plots,
curves were generated by averaging over all boosted protease inhibitors, all
unboosted protease inhibitors, and the NNRTIs EFV and ETV. Protease in-
hibitor curves in a were ﬁtted to skewed-T distributions to smooth step-like
behavior. NVP, which was excluded from this ﬁgure, shows a diﬀerent pattern
from the other two NNRTIs; speciﬁcally, mutant virologic failure can occur












(SupplementaryFigs. . . , . . ).
Wealsoexaminedthesensitivityofourresultstochangesinthebaselineviral
 tness,R   (SupplementaryFigs. . . , . . ). Astheintracellularhalf-livesof
severalNRTIsarenotde nitivelyestablished,wetestedarangeofhalf-livesfor
lamivudine( TC),azidothymidine(AZT),stavudine(d T),ddIandtenofovir





   . .  E                                     
Equippedwithamodelofdruginteraction,wewereabletoextendthe
simulationstocombinationtherapy(SupplementaryMethodsand
SupplementaryFig. . .  ). Forproofofconcept,weuseatwo-drug
combinationoftheboostedproteaseinhibitordarunavir(DRV/r)withthe
integraseinhibitorraltegravir( L). ecombinedeﬀectofthesetwodrugsis
givenbyaBliss-independent[  ]interactionpa ern[   ],whichdescribes
drugsactingondiﬀerenttargets,thereforereducingviralreplication
multiplicatively. InarecentDRV/r- Lclinicaltrial[   ],patients
experiencingvirologicfailurehadtheirplasmaviralpopulationgenotyped.
Although   ofpatientstestedpositivefor L-resistancemutationsinthe
geneencodingintegrase,nopatientstestedpositiveforDRVresistanceinthe
geneencodingprotease[   ]. Oursimulationisconsistentwiththisstudy:
treatmentfailureoccurredwithoutDRVresistance(Fig.  . . a).
 L-resistantmutantswereselectedforonlywhentheconcentrationof
DRV/rwaslowandtheconcentrationof Lwasmoderatetohigh






  Figure 2.2.6 (following page): Outcomes of DRV/r plus RAL dual suppres-
sion therapy simulations, considering resistant mutants for both drugs. (a)
Each drug is taken independently, and adherence may diﬀer between them.
The brightness of each color at a particular point indicates the probability
of the corresponding outcome, with the black contours showing where each
outcome occurs 95% of the time. Success depends largely on adherence to
DRV/r (success is almost certain if adherence is  50%), whereas the type
of failure is determined by adherence to RAL (resistance is almost certain if
adherence is  30%). All failure via resistance is due to RAL mutant-based vi-
rologic failure. DRV mutant-based virologic failure (virologic failure) never oc-
curs in the simulations. (b,c) Drugs are taken with equal average adherence.
The height of the area shaded indicates probability of the corresponding out-
come at that adherence level. (b) Drugs are taken as separate pills. Average
adherence is the same, but pills are taken independently. (c) Drugs are pack-
aged as a combination pill and are always taken together. Mutant virologic
failure occurs only when the two drugs are given in separate pills; combination
pills eliminate mutant virologic failure but increase the adherence required for
near-certain success.
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Therapy success  Failure with resistance Failure with wildtype only
c  b 
a 
Figure 2.2.6 (continued)
  resistancecameatacost: higheradherencewasrequiredtopreventwild-type
virologicfailure. Forexample,toensurea   chanceofsuccessinthe
simulation,apatienttakingseparatepillsmustbe   adherenttoeachpill(Fig.
 . . b),but   adherenttoacombinationpill(Fig.  . . c). Weexpectthis
trendtoapplytootherdrugcombinations.
 .  D         





literature.  emodelwasnot tortrainedtomatchclinicaldata. Despiteour
model’ssimplicity,itcanexplaintheclinicallyobserveddrug-class-speci c
relationshipbetweenadherenceandoutcome[  ](Fig.  . . ). Evenwithoutfull
viraldynamicsimulations,astraightforwardanalysisofthemutantselection
windowcanexplainwhycertaindrugsaremorelikelytoselectforresistance




[  ,   ,   ,   ]. Althoughitispossiblethatmutationsmayoccuroutsidethe
  protease-encodinggene[  ,   ,   ,   ]andescaperoutinedetection,our
modelprovidesamorestraightforwardexplanation: duetothesharpslopeof












owingtoitshavingthelowestslopeandsecond-highestIC   oftheprotease













interactionsbetweendrugs[   ]arecharacterized;theseinteractionsaﬀectthe




butalsoposesresistancerisks[   ]. Speci cally,onthebasisofoursimulations,
weproposethatEFVandETVmonotherapymaybepromisingavenuesfor
furtherstudy,despitethedishearteningperformanceofmonotherapywiththe
 rstapprovedNNRTI,NVP[  ],andtheambiguousperformanceof






[  ,   ,   ,   ]. However,inourmodel,frequentreactivationfromthelatent
reservoirprovidesasuﬃcientsourceofmutantsduringbothphases
(SupplementaryTables . . , . . ),andongoingreplicationisanadditional






reacheddetectablelevels,consistentwithclinicalmeta-analysis[   ]. Also
consistentwithclinicalobservations[   ],continuationofmaintenancetrials
a erreboundallowedthepossibilityofre-suppression,butitsometimesledto








ofvirologicfailure[   ,   ,   ,   ,   ].  ird,asiscommoninmodelsof
viraldynamics,weassumedthattheviruspopulationishomogeneousandwell
mixed. Actualinfectionsmayincludesubpopulationsthatgrowfaster(higherR ,
forexample,owingtocell-to-celltransmission[   ])orthatresideintissuesthat
drugsdonotfullypenetrate[   ,   ,   ]. Forexample,theconcentrationof
EFVinthecerebrospinal uidisonly .  ofplasmaconcentrations[  ]. Asour
  predictionsrelyonplasmadrugconcentrations,theymaybeoptimisticinthe





thefuture[   ,   ,   ],buttheprecisereasonsforthisarenotclear.  e
simplestexplanationisthatgrowthofaresistantstrainduringpriortreatment










[   ,   ]. Tobuildsuchmodels,itwillbeimportanttounderstandinteractions
betweenmutations(includingcompensatorymutations[   ])andaccountfor
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 . .  P               ,                                      -
          
Viral tnessfollowedequation( . )withparametersR  ,IC   andm. Fitnessof
resistantmutantsfollowedequation( . )withparameterss, ρandσ.
(SupplementaryTables . . – . . ). Relativewild-typeandmutantviral tness
valuesR (D) R   andR′
 (D) R   weremeasuredusinginvitroassaysandwere
 ttoHillcurvestodeterminetheparametersIC  ,m,σ, ρands;thesevalues




  decayingexponentially(withhalf-lifeT = )tothetroughconcentration(Cmin)
beforethesubsequentdose. Whendosesweremissed(representingsuboptimal
adherence),theconcentrationcontinuedtodecay,andasubsequentdose
increasedtheconcentrationby ΔC = Cmax   Cmin.
WedeterminedtheboundsoftheMSWbysolvingforDinR (D) = R′ (D)
andR′ (D) =  . WedeterminedtheupperboundoftheWGWbysolvingR (D)
= . Wecomputedthetimea erasingledosewhenaparticularconcentrationD




resistance,butthoseoutsideitdonot(reviewedinref. [  ]). Althoughsome
studiesofantibiotic-resistantEscherichiacolihavefoundnoupperlimittothe
MSW[   ],nosuchresultsareknownforantiretroviralresistance.  e
de nitionoftheMSWmostcommonlyusedinantibioticworkisslightly
diﬀerentfromtheoneweuse,withthelowerlimitde nedasR (D) =  because
ofexperimentalconstraints[  ]. Wehavechosentomodifythisde nition,as
selectionforthemutantcanoccurevenatlowerdrugconcentrationswhere
R (D)    (ref. [   ]).  eMSWandWGWcanbedescribedforeachdrug
duringcombinationtherapy(SupplementaryMethods).
   . .  S                                .
OurmodelforHIVdynamicsduringantiretroviraldrugtreatmentuses
equationscommonintheliterature[   ].  eseequationstrackthenumberof










hencetherateofinfectionofnewCD + cells,isdeterminedbythebaselineR 
andthedrugconcentration. Allequationsandparametersaregiveninthe






duringtheearlydaysoftreatment[   ,   ]. Summarizingviral tnessbya
singleparameter(R )smoothesoutthesedynamics.





acidsubstitution(SupplementaryTables . . , . . , . . ).  ebalancebetween
thesetwoprocessesresultsinallmutationsbeingpresentinthepopulationatan














consideredthreestrains: wild-type,resistanttodrug ,andresistanttodrug .
Simulationsmodeled  -weektrials,usingdiscretetime-stepsof Δt=  min. All
  simulationsweredoneinMatlabR    b.  efulldetailsofthealgorithmfor
simulatingasinglepatientaregivenintheSupplementaryMethods.
Inmaintenancetrials,patientsbeganwithfullviralsuppression( RNAcopies
perml,cml  )andunderwentmonotherapyfor  weeksoruntilvirologic
failure,whicheveroccurs rst. virologicfailureisde nedas‘con rmedrebound’:
twoconsecutiveweeklymeasurements(startingatweek )withviralloadabove
   cml  . Insuppressiontrials,patientsbeganwitharealisticdistributionof
treatment-naiveviralloads(between ,   and    cml  )(Supplementary
Fig. . .  a)andunderwentmonotherapyforafull  weeks. Wetracked
measurementsevery weeks. Virologicfailureisde nedasaviralloadabove  
cml  atweek  . Inbothtypesoftrials,virologicfailureisclassi edas‘with




adherencelevelstakenfromastudyusingunannouncedpillcounts  . For
simulationswithtwodrugs,thevalueofadherencemaybediﬀerentforeach
drug,allowingfor“diﬀerentialadherence,”whichhasbeenobservedinmany




   .  S                   
 . .  V                 
 efollowingsystemofequationsmodelsthedynamicsofmultiplestrains
(i =         n)ofHIVinapatient:
_ x = λ  
n ∑
i= 
βixvi   dxx
_ yi = βixvi + Ai   dyyi
_ vi = kiyi   dvvi
( . )






dv.  einfectivityparameter βi determinestherateatwhichvirusofstraini
infectssusceptiblehostcells. Hostcelldynamicsaredeterminedbyproduction
rate λ anddeathratedx.
WhenAi =  forastraini,thismodelreducestothetraditionalviraldynamics
model[   ]. Forthatmodelwecandescribethebasicreproductiveratio,whichis
de nedasthenumberofnewinfectionsgeneratedbyaloneinfectedcellbeforeit
  dies. Strainiwillonlyhaveapositivegrowthrateandbecapableofsustainingan






































Inourmodel,forR i    ,strainigrowstoahighsteadystatethatdependson
availabilityofhostcellsandtheabundanceofotherstrains.  ereareseveral
limitingcasesthatcanbederivedfromequation( . ). Intheabsenceofother
strains(orifR j ≪  forallj ̸= i),andforsmallreactivationAi ≪ λ,straini




.  evalue ~ Yi isthe
setpointviralloadthatismaintainedbyreplicationalone,withoutadditional
contributionfromthelatentreservoir.  eresidualactiveinfectionmaintained
bythelatentreservoirincompleteabsenceofviralreplication(R i =  )is
~ y i := Ai dy. ForpositiveR i    ,strainireachesalowsteadystate
yi   ~ yi := ~ y i (    R i). Sinceanti-HIVdrugsactbydecreasing βi andki,the
valueofR i isunderstoodtodependonthecurrentdrugconcentration(s).
Toeliminatesomeofthemodelparametersandsmooththehigh-frequency
   uctuationsthatmayhaveli leclinicalimpactoverthecourseofadrugtrial,we
studyasimpli edversionofthemodelinequation( . ). Weassumethatvi andx
areatequilibriumrelativetoyi.  isallowsustoderiveareducedn-dimensional
model:





j=  R jdyyj




_ yi   Ai + dyyi (R i    ). ForR i ≪  ,nearlyallofstrainiisproducedbyexit
fromthereservoir;yi thereforeapproachesavaluenear~ y i. Asthetotalinfection
grows(assumingR i    foroneormorei),thefractionaltermapproaches ,
describingsaturationofthelimitingresource,atwhichpointnewinfectionevents
arebalancedpreciselybydeathofinfectedcellsandyi approachesavaluenear ~ Yi.
 isreducedmodelhasidenticalsteadystatevaluesofvirusandCD + cellsas
thefullmodel,butsmoothsout uctuationsininfectionsizecausedbythe
dynamicsoftotalCD + cells. Becausewefocusoninitialvirologicfailure,which





  _ yi = Ai +
λdy
∑n
j=  yjR jQij
λ +
∑n
j=  R jdyyj
  dyyi ( . )
 . .  M              
 evalueofR i ateachpointintimedependsonthebaselinebasicreproductive
ratio(R   =   ,seebelow),thecurrentdrugconcentration(s),andparameters
describingresistanceofthestrain,asdescribedbyequations( . )and( . )in
themaintext.  edeathrateofactivelyinfectedcells,dy,is perday[   ].
SupplementaryTable . . summarizestheparametersusedinthemodel.
B                     
 ebasicreproductiveratio(R )combinesvariouscomponentsofviral tness
intoasinglenumber. R     isrequiredforthevirustohaveapositivegrowth




develops,typicalvaluesforR   are  -  (ref.   ;  ). A erthisinitialphase,R  
declinesto - ,withsomeoutliersashighas -  (ref.   -  ). Basedonthese
 ndings,wechoseavalueofR  =  topresentourresults. Wealsochecked
sensitivitytothisparameterbyusinglargerandsmallerR   values
(SupplementaryFigures . . - . . ).
  Wecanalsodouble-checkthatourvalueofR   fromtheliteratureisconsistent
withanindependentsetofmeasurements.  egrowthrateofamutantstrainin
theabsenceofdrugisR     (    s)(seeequation( . )inthemaintext),wheres
isthereductioninthereplicationcapacityofthemutantvirus. If
R     (    s)    ,thenamutantstrainwillexpandintheabsenceofdrug. Ifthis
conditionfails,thenthemutantstrainwouldneverbedetectedathighabundance
(ignoringsecondaryorcompensatorymutations). Sincealltheresistance
mutationsthatwestudydooccurclinically,weexpectthatR       (    s)
shouldalmostalwayshold.    ofthemutationsstudiedhaves      ,forwhich
thepositivegrowthconditionissatis edforthevalueR   =   .
TomaintainconsistencywiththechosenvalueR   =   ,wecappedthecost
ofmutationsusedintheviraldynamicssimulationats =    ,guaranteeingthat





s =     torepresentasmallcosttothesemutations.










maximallysuppressiveHAART[  ].  erateofexitfromthereservoirmustbe
enoughtoaccountforthisresidualviralload,sinceongoingreplicationis
negligible.  isviralloadcorrespondsto          plasmavirions(fora  kg
personwith Lplasma). Ithasbeenshown,forawiderangeofviralloads,that
thetotalnumberofinfectedcellsinapatientisroughlyequaltothenumberof
plasmavirions[   ].  einfectionsize
∑
yi   (
∑
Ai) dy istherefore       ,




established[  ],freevirusinlymphtissuesis   timesasabundantasvirusin
theextracellular uid,andsowouldbeabout          virions(basedon  L
ECF)forthisexample.  ispaperalsodeterminedthattheratioofviralburst
sizetoviralclearancerateistypically   virionspercell(e.g.,ki =  ,   
virionsperdaypercell;dv =  perday).  ese guresagainimplyaninfection
sizeof    cells.
Ourcalculationsalsoagreewiththeresultsofamodelwhichexaminedthe
manyyears-longdecayofthelatentreservoirinHAARTpatients[   ].
Althoughthismodeluseddiﬀerentsourcesforparametervalues,itisconsistent
  withanexitrateof    cellsperday,aslongasthereservoirisnotsigni cantly
depleted.
H                     
Forasinglewild-typestrainintheabsenceofdrug,themodel(equation( . ))
provides λ = ~ YdyR   (R      ),where ~ Yisthetotalnumberofinfectedcellsat
infectionsetpoint. Asestablishedabove,thisvalueisapproximatelyequaltothe
numberofplasmavirionsatsetpoint. Weconsideredsetpointviralloadsfrom
    to    RNAcopiespermlplasma,or          to          totalplasma
virions.  esevaluesgivearangeof        to          cellsperdayfor λ.
R                      
 emutationratematrixentryQij describestheprobabilitythatstrainj
reproducestocreatestraini. Weincludeonlysinglestepmutationsfromthewild
type(j =  )toanotherstraini(atrateui)andignoreback-mutation.  erefore
Qi  = ui fori    ,Q ;  =    
∑n
k=  uk,Qii =  fori    andQij =  forallother
entries.
 eoverallmutationrateforHIVis         perbaseperreplicationcycle
[   ],andrecentworkhasshownthattheratevariesconsiderablydependingon
thespeci cbasechangesinvolved.  enucleotidemutationmatrixusedinthis
studywasderivedbynormalizingmutationaccumulationdatafromastudyof
HIVreplicationoflacZα reportersequence[ ].  enormalizeddatawasthen
rescaledtoconvertfromthelacZα basecompositiontotheHIVconsensus
  sequencebasecomposition[   ]. Speci cally:
 . De nethevariables:
• u =          istheaverageper-sitemutationrateofHIV.
• sxy isthetotalnumberofsingle-nucleotidesubstitutionsfrombasex
tobasey,combiningdatafromboththeforwardandreverse
orientationsoflacZα inTable AofAbrametal. [ ].







– nT =   ,nC =   ,nA =   ,nG =   ;N =    
– n′
T =     ,n′
C =     ,n′
A =     ,n′
G =     ;N′ =     
 . Calculatetherelativemutabilityofeachbasexinthereportersequence,
rx = (sx  nx) (S N). Avaluerx    indicatesthatbasexismore
mutablethantheaverage,whilerx    indicatestheopposite.




TuT  + n′
CuC  + n′
AuA  + n′
GuG  equalsN′u,thegenomicmutationrate
  ofHIV(about . substitutionsperreplication).  ecorrectscalingfactor




 . Todeterminetheindividualratesuxy,partitioneachvalueux  proportional
tothesubstitutionscountedinthereportedsequence;thatis,














(usedinSupplementaryTables . . , . . ).
 . .  S                  
Weusedstochasticsimulationstostudythedynamicsofthesystemdescribedin





  typey  andmutanty . Simulationsmodeled  -weektrials,usingdiscrete











yi   (
∑
Ai) dy =  c.ml  (RNA
copiesperml).
 . Assigneachinfectedcelltothemutantpopulation(y )withprobability
u s;otherwisethecellisinthewild-typepopulation(y ).






  • Inthesuppressionphase,theinitialdrugconcentrationiszero.
• Inthemaintenancephase,theinitialdrugconcentrationisCmax.
 . Calculatethebasicreproductiveratiosforthewildtypeandthemutant

















(d) Eachinfectedcelldieswithprobability    exp( dyΔt).
 . Determiningoutcomeat  weeks:
• Inthesuppressionphase,thepatient’sstatusisobservedattheendof
the  -weektrial. Ifviralloadisbelow  c.ml  ,thetrialisdeclared
successful;otherwisevirologicfailureoccurs.
• Inthemaintenancephase,thepatient’sstatusisobservedeachweek
for  weeks,beginningatWeek . Ifanytwoconsecutive
  observationsshowaviralloadofatleast   c.ml  ,virologicfailure
occurs;otherwisethetrialsucceeds.




• Patient’sstatuswasevaluatedevery weeks,for  weeks.




weekfor  weeks,beginningatWeek . Ifanytwoconsecutive
measurementsatorbeforetheevaluationshowaviralloadofatleast






















misleadinginthiscontext[   ],andinlieuofamoreinformedvalue,wesimply
usethecensussize.  isapproachlikelyoverestimatesprobabilitiesofmutant
emergenceandunderestimatesvariabilityamongpatients[   ,   ].
Fordualtherapy,weconsiderthreestrains: wildtype,resistanttoDrug ,






   . .  G                             
Foreachmonotherapy,  ,   patientsweresimulated,withexpectedadherence
α rangingfrom to (roughlyequalnumbersofpatientsweresimulatedforeach
  increment,including  patientswithα =  and  patientswith α =  ).  e
x-axismeasurestheexpost adherenceforpatients thatis,theactualpercentage
ofdosestaken,whichmaydiﬀerfromtheexpectationα. Resultswereplo edfor
overlapping  windows,centeredevery  between and ,aswellasforthe
points and themselves.
Analysisofdualtherapywithacombinationpillwassimilartothatof
monotherapy,butwith   ,   patients(including   patientswithα =  and
   patientswithα =  ).
Fordualtherapywithseparatepills,   ,   patientsweresimulated,with
expectedadherencesα  α  rangingfrom to (roughlyequalnumbersof
patientsweresimulatedforeach     increment,including  ,   patients
ontheborderofthedistributionwhereatleastoneαi isequalto or .) Aswith
monotherapy,theaxesmeasureexpost adherence. Resultswereplo edfor





   . .  G                      
Analysiswasperformedseparatelyforeachoverlapping  adherencewindow,
centeredevery  between and ,aswellasforthepoints and themselves.
 eresultinggraphshowsaweightedaverageoftheseresults,usingthe
adherencedistributioninSupplementaryFigure . .  . Measurementswere
takeneverytwoweeks,andthegraphsshowtheproportionofthepopulation
witheachoutcome. Asthereisnocensoringofdata,theanalysisisequivalentto
theKaplan-Meiermethod[   ].
 . .  MSW                     
Forcalculationsinvolvingcombinationtherapy(limitedtotwodrugsinthis
paper),viral tnessisin uencedbythedose-responsecurvesofalldrugs. DRV
and Lbelongtodiﬀerentclassesandhavebeenshowntoreduce tnessina
multiplicative(Bliss-independent)fashion,whichiso enexpectedfordrugs
actingondiﬀerenttargets[  ,   ].  eequationdescribingviral tnesswith
twoBliss-independentdrugsisgivenby:
R  (D  D ) =









IC  ; 
)m ) ( . )
whereD  D  aretheconcentrationsofeachdrugintherelevantcompartment,
IC  ;  IC  ;  aretheconcentrationsatwhich  %inhibitionoccurs,andm  m 
aretheslopeparameters.  enumeratorR   isthebaselinebasicreproductive
ratiointheabsenceofdrugtreatment. Mutationsthatconferresistancetoagiven






WGW,orstrictlyintheWGW.SupplementaryFigure . .  showsthepossible
windowsforthe L+DRV/rcombination.
 . .  D           F  . . .  :                        -        
      -     VF                       
Fig . . franksdrugsbytherelativeriskofmutantversuswild-typefailure,
regardlessofthetotalriskoffailure,basedonthetimespentineachselection
window.  eranksareplo edalongalinewithvaluesrangingfrom- (DRV/r
andd T,highestrelativeriskofwild-typefailure)to (FTC,thehighestrelative













  x  ( . )
whereymax       days,themaximumtimethatadrugspendsintheMSW
(obtainedforFTC).Sincebothxandy ymax rangebetween and ,thescale






  WGWisreachedsoona ertheMSW,orwithouteverenteringtheMSW,andso
“wild-typerisk”ishighand“mutantrisk”islow. Whilexconsidershowquickly
theinfectioncanstarttogrow,itdoesnotconsiderthelengthoftimeinthe
MSW.EveniftheMSWbeginsassoonasadoseistaken(sothatx =  ),onestill
needstoconsiderforhowlongthemutantstrainisselectedoverthewild-typeto
determinewhethermutant-basedorwildtype-basedvirologicfailureismore
likelytooccur. Figure . .  showsasca erplotofyversusx.






R  MH     ). SimulationswererunontheOdysseyclustersupportedbythe
ResearchComputingGroupofHarvardUniversity. Wearegratefulforsupport
fromtheUSNationalInstitutesofHealth(R  AI      (R.F.S.,S.A.R.),R  
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 .  I           
T                 (LR)   HIV-              oflong-livedresting
memoryCD + TcellswithHIV- DNAintegratedintotheirgenomes[  ,  ].
A erthereservoirisestablishedduringacuteinfection[  ],itincreasesto
          cellsandthenremainsstable. Asonlyactivelyreplicatingvirusis
targetedbycurrentanti-HIVdrugs,latentlyinfectedcellspersistevena eryears





theLR[  ,  ]. Collectivelycalledlatencyreversingagents(L ),thisclass
includesthehistonedeacetylaseinhibitorssuchasvorinostat[ ,  ]andvalproic
acid[ ,   ],thealcoholismdrugdisul ram[   ],proteinkinaseCactivators










initiationofHAART[   ,   ,   ],theroleofongoingreplicationinslowing
therateofLRdecay[   ],andtheappearanceofviral“blips”during
treatment[  ,   ,   ]. RecentstudieshaveconsideredtheroleoftheLRin





 .  M              
Weconsiderproposedtherapyprotocolsforlatencyreversingagents(L s)that










 emodeltrackstwocelltypes: productivelyinfectedactiveCD + Tcells,
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Figure 3.1.1: Schematic of LRA therapy and stochastic model of rebound
following therapy. A) Proposed treatment protocol, illustrating possible viral
load and size of latent reservoir before and after LRA therapy. When HAART
is started, viral load decreases rapidly and may fall below the limit of detec-
tion. The latent reservoir is established early in infection (not shown) and
decays very slowly over time. When LRA is adminstered (either continuously,
as shown, or in intervals), the latent reservoir declines. Depending on the eﬃ-
cacy of LRA therapy, the infection may be cleared, or viremia may eventually
rebound. B) LRA eﬃcacy is deﬁned by the parameter Q, the number of log  -
reductions in LR size. C) Stochastic model of viral dynamics following LRA
therapy, tracking both latently (rectangles) and actively (ovals) infected cells.
Each arrow represents a type of event that occurs in the model and its rate,
described in the text. D) The expected number of “oﬀspring” for each pro-
ductively infected cell is the basic reproductive ratio R  =  . The “infectivity
variance” parameter λ determines variance of the oﬀspring distribution. The
oﬀspring distribution conditional on event b occurring is given by a Poisson:
P(c) = λce λ c!





variance λ (Fig.  . . (D)),seeSec . . .
 etotaldeathrateofproductivelyinfectedcells(dy = b + d)hasbeenwell
characterizedtobe day   fromtreatmentinitiationstudies.  erateof
reactivationofcellsfromthelatentreservoircanbeestimatedbasedonthesize
andcompositionoftheLR(Fig. . . )andthelevelofresidualplasmavirusfor
patientsonfullysuppressiveHAART(  copiesHIV- RNApermilliliter
plasma,cml  ). Weestimateatobe         day   andconsidervaluesinthe
range     to        .  edeathrateoflatentlyinfectedcellsisestimatedfrom
studiesoftherateofdecayoftheLRtobedz =            day  
(correspondingtoa  monthhalf-life). Wealsopresentresultsfortwo
extremes: ahalf-lifeofonly months,and,dz =  .  ebasicreproductiveratio
forthismodel,de nedastheexpectednumberofnewinfectedcellsthatasingle
activelyinfectedcellproduces,isR  = λb (b + d).  eaverageR  valueis
estimatedfromtime-to-reboundinHAART-interruptionstudiestobeR  =  
(whichislowerthanthevaluesestimatedforacuteinfection). R  doesnot
uniquelydeterminethedynamicsofthestochasticmodelbecauseband λ cannot
besimultaneouslyidenti ed. HoldingR  constant,theparameter λ controlsthe
strengthofrandomdri intheinfection: forhigh λ,reproductionresemblesa
  “jackpot”eventwhereafewinfectedcellsgiverisetomanynewinfectionevents,
whilemanyotherinfectedcellsdiebeforeinfectingadditionalcells. Herewevary
λ intherange –  (seeSec. . . ).
 einitialconditionsdependuponthenumberoflatentlyinfectedcellsthat
surviveL therapy.  isquantityisde nedbythelatentreservoirsizepriorto






(viralloadabove  –   cml  )arewellbelowcarryingcapacity(typical




whichwede neasthenumberofrestingCD + TcellswithintegratedHIVthat
arecapableofproducinginfectiousvirusuponreactivation(Fig.  . . ). We
consideredthreecasesfortheLRsizedistributionamongpatients. Limiting
dilutionco-cultureassays[   ]arecurrentlythegoldstandardforLRsize
measurement. Incase(i),weassumeallpatientshaveareservoirsizeequaltothe
averagemeasuredintheseassays(           cells),andincase(ii)we
  Figure 3.2.1 (following page): Experimental scheme for classifying rest-
ing CD4+ T cells based on HIV-1 infection and viral production, using data
from [89, 125]. Scheme starts at the top, with puriﬁed resting CD4+ T cells,
and proceeds downward through the experimental analyses listed. The f vari-
ables represent fractions of this resting CD4+ T cell pool with the charac-
teristics listed. “PCR”: Digital droplet PCR identiﬁed cells containing HIV-1
DNA, nearly all of which is expected to be integrated. “Co-culture”: PHA
was used to induce viral replication in latently infected cells. “Seq. defect”:
Non-induced cells were analyzed for genetic defects preventing production of
replication-competent virus. A fraction i of these non-induced cells had no ob-
servable defects (all open reading frames intact); this fraction constitutes fNII
of all resting CD4+ T cells. Question marks indicate that it was not possible
to determine by this analysis what fraction of cells would produce replication-
competent virus in vivo, due to integration site eﬀects and undetectable se-
quence defects. Even defective provirus may be able to produce defective
virons that contribute to residual viremia (gray arrow). The latent reservoir
(shaded box) consists of induced and replication-capable non-induced cells.
Values shown are averages and ranges of      patients.
  Puriﬁed resting 
CD4+ T cells"

















fCC ≈ 1 × 10-6 
(0.05, 20)"
DNA+"
fD ≈ 300 × 10-6"
(20, 3000)"
PCR +" PCR –"
Co-culture +" Co-culture –"
Seq. defect +" Seq. defect –"
i  ≈ 0.14 (0.06, 0.36)"
Intact provirus, fNII!









framesintact[   ]. Incase(iii),weincludethesecellsintheLR.Forallcaseswe
assumeatotalrestingCD + cellcountof    .  eresultingdistributionsare
showninFig.  . . (A),seeSec. . . .
 ebest-caseoutcomeofL therapy,barringcompleteeradicationofthe
reservoir,isthatnoneofthesurvivinglatentlyinfectedcellsactivateandleadtoa
resurgentinfection. Inthiscase,wesaythatL hasclearedtheinfection. We
usedthemodeltopredicttherelationshipbetweenL log-eﬃcacy(denoted
Q)andclearanceprobability(Sec. . . ). Fig.  . . (B)showsresultsforthe
threepossiblereservoirdistributions(i)–(iii)describedabove.Incases(i)and




latentreservoir(caseiii),thenQoffourtosixisrequiredfor   clearance. Inall
threecases,theclearanceprobabilitydecreaseswithreservoirhalf-life. Clearance
probabilityalsoincreaseswithinfectivityvariance λ,asthisparametercontrols
thelikelihoodofvirallineageextinctionbydri (Fig. . . B).
IfL therapyfailstocleartheinfection,thenext-bestoutcomeissubstantial
extensionofthetimeuntilvirologicrebound,de nedasaviralloadof   cml  
  (Sec. . . ). WecomputedtherelationshipbetweeneﬃcacyofL therapyand
themediantimeuntilrebound,amongthepatientswhodonotclearthe
infection(Fig.  . . (C)).ForanLRsizeof    (casei),onlymodestincreasesin
medianreboundtimearepredictedforupto   -foldreductionsinthesizeof
thereservoir(Q    ). Inthisrange,thereboundtimeisindependentoflatent
celllifespan,anditisdrivenmainlybythereactivationrateandtheviral
reproductiveratio.  ecurvein ectsupwardatQ =  (onalogscale)and
reachesaceilingasclearanceoftheinfectionbecomesthedominantoutcome
(Fig.  . . (C)(i)). Ifcellsinthereservoirareextremelylong-lived,itispossible
forreboundtooccurevena erdecadesofapparentcure. IftheLRsizeislarger
(caseiii),thenthemedianreboundtimecurveisshi edrightwards,requiring
higherL eﬃcacyforthesameoutcomes(Fig.  . . (C)(iii)). Inallthreecases,
thein ectionpointdecreasesin λ. Incase(i),thispointvariesbetweenQ =    
(for λ =   )andQ =  (for λ =  ). Accordingly,themedianreboundtime








  Figure 3.2.2 (following page): Clearance probabilities and rebound
times following LRA therapy predicted from model. A) Three cases for the
population-level distribution of LR size (Sec. 3.4.1). Case i) All patients have
the same latent reservoir size, MLR =    , estimated from the geometric
mean number of cells that are capable of producing infection in laboratory
co-culture assays. Case ii) Latent reservoir size is distributed according to
variation observed in co-culture assays, with geometric mean    . Case iii)
The latent reservoir includes many cells that fail to be detected in co-culture
but have intact viral genomes. B) Probability that the reservoir is cleared by
LRA. Clearance occurs if all cells in the reservoir die before a reactivating lin-
eage leads to viral rebound. C) Median viral rebound times, among patients
who do not clear the infection. D) Survival curves for patients following LRA
therapy. The percentage of patients who have not yet experienced viral re-
bound is plotted as a function of the time after interruption of LRA therapy
and HAART. Curve color indicates the eﬃcacy of LRA in reducing the size
of the LR (Q =   to 6, see legend). Results are shown for a half-life of 44
months; other half-lives are shown in Fig. 7.3.3 Solid lines represent simu-
lations, and open circles represent approximations from a branching process
calculation (Sec. 3.4.3). All simulations included           patients and used
parameters a =         , λ =    and R  =  .
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in ectionsareobserved(Fig.  . . (A)).
 escopeofpredictedinterpatientvariabilityinoutcomescanbeseenin
survivalcurves,plo ingthefractionofsimulatedpatientsmaintainingvirologic
suppressionovertime(Fig.  . . D).ForsmallreductionsinLRsize(Q    )
patientsuniformlyreboundwithinafewmonths,sincerebounddynamicsare
notintheactivation-limitedregime(Fig.  . . (D)(i)). IfL therapymanages




withoutrebound(Fig.  . . (A)(ii)). Rebounddelaysofoverthreeyearsare
achievedfor   ofsimulatedpatientsatQ =  ,versusonly  incase(i).  e
fortunatefewwhocompletelycleartheinfectionstartedwithanLRsmallerthan
theaveragesizeof    priortotreatment. Survivalcurvesdeclinemorerapidlyif
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Figure 3.2.3: Eﬃcacies required for successful LRA therapy. Target LRA
eﬃcacy values based on three diﬀerent treatment goals are plotted versus
reservoir half-life (
ln( )
a+dz) and the reservoir reactivation rate (a). A) The target
eﬃcacy Q at which at least 50% of patients still have suppressed viral load
one month after treatment interruption. B) The target eﬃcacy Q at which at
least 50% of patients still have suppressed viral load one year after treatment
interruption. C) The target eﬃcacy Q at which at least 50% of patients have
eradicated the reservoir without experiencing viral rebound. Because some pa-
tients may go for a year without rebound but then rebound later, the target
Q for one year oﬀ therapy is always less than that for a lifetime oﬀ therapy.
Results were calculated from the branching process description of the stochas-
tic process, which agrees with simulation (Sec. 3.4.3). All calculations used
λ =    and varied R  to ensure baseline rebound time was constant (12 days).
Worst-case: a =          R  =     , high: a =            R  =    , estimated:
a =          R  =  , best-case: a =      R  =     .
reboundinthefollowingsixmonths,foreﬃcaciesQ =  ,Q =  ,orQ =  ,
respectively(Fig. . . (A)(ii)).
Tosetgoalsfortreatmenteﬃcacy,wecalculatethree“targetvalues”ofQ,
assumingapretreatmentreservoirsizeof   . Onemonthisneartheupperlimit
ofreboundtimeswithoutL therapy,andwe rstcalculatede nethe
log-eﬃcacyforwhich  %ofpatientsexceedthislimit(Fig.  . . (A)). is
valueisinsensitivetotheestimateforreservoirhalf-lifeandincreases
logarithmicallywiththeactivationrate. Forabroadrangeofactivationrates,a
   . -to -logreductionisneededforaone-monthdelay. Wenextcalculatethe
targeteﬃcacyforone-yeardelays(Fig.  . . (B)).Usingestimatedparameter
values,thisgoalrequiresa -logreductioninreservoirsize.  isvalueisonly
mildlysensitivetoreservoirhalf-life(decliningonlyforveryshorthalf-lives,at
whichreservoirclearanceislikely)andalsoscaleslogarithmicallywithactivation
rate. Ifactivationexceedstheestimatedrate,thenthetargetQiscloserto   –a
      -foldreduction. Finally,sincetheultimategoalofL therapyistoclear
thereservoircompletely,wedeterminethelog-eﬃcacyforwhichatleasthalfof
patientscleartheinfection(Fig.  . . (C)). isvalueconsistentlyexceedsthe
moremodestone-yeartargetandscaleslogarithmicallywiththeproductof
activationrateandhalf-life. Parameterscalingrelationshipsfollowfroma








settoalowvalue.  eresultingtargetQforaone-monthdelayincreasedby ,












co-cultureassayscannotdetectreservoirssmallerthanabout    cells[  ]. Since
currentapproachestoL therapyseektoreducereservoirsizebyinducing
activationoflatentlyinfectedcells,Qmaybeestimatedbymeasuringthe
dynamicsofviralloadduringsimultaneousHAART/L therapy(Sec. . . ).
SincetheeﬀectofL therapyonrestingCD + Tcellphenotypeisnotfully
characterized[   ,   ],thereisconsiderableuncertaintyinthisrelationship;
nonethelessasharp,transientpeakviralloadofatleastseveralhundredcml   is
expectedforhighlyeﬀectivetherapy(Q    )(Table . . ).
 .  D         
Ourmodelisthe rsttodescribetheactionofinvestigationallatencyreversing
agentsandsetquantitativegoalsforL therapy,oﬀeringguidanceforthe
designandtestingoftreatmentprotocols.  ereiscurrentlyli leunderstanding
ofthedegreeofreservoiractivationrequiredtoprovidemeaningfulbene t. We
  analyzedexperimental ndingsregardingreservoirsizeandcompositionto




byatleast . – ordersofmagnitudetoseeameaningfulincreaseinthetimeto
virologicrebounda erHAARTinterruption(upwardin ectioninFig. . . C
andFig. . . C),andthat – ordersofmagnitudeareneededforhalfofpatients













Clinicalandlaboratory ndingsconstrainthebasicreproductiveratioR  and
activecelldeathratedy inarelativelynarrowrange.  ereboundpopulationsize,





andinfectivityvariance λ  haveprofoundimpactsontreatmentoutcome,and
theyarenotwell-establishedtowithinanorderofmagnitude. WhileLRsizeis
generallyestimatedat   ,recentstudieshaveshownthatevenco-cultureassays
 recognizedasthegoldstandardforlatencymeasurement maydrastically
underestimatereservoirsize(Fig. . . (A)(ii)versus . . (A)(iii)). We
accountedforthesestudiestoshowthatthisunderestimatemaycause
expectationsofL therapyoutcomestobeundulyoptimistic(Figs.
 . . (B,C)(ii)and . . (ii)versusFigs.  . . (B,C)(iii)and . . (iii)).
Consideringbothvariationinpretreatmentreservoirsizeandlatentcell
half-lives,thelog-reductionneededtodelayreboundforoneyearinhalfof
patientsis   to      areductionof     -to      -fold(Fig. . . (C)(ii)
vs. (A)(iii)). Whenbroadvariationinaand λ isalsoconsidered,therange

















byearlytreatmentinitiation[  ,   ,   ]orstemcell
transplantation[   ,   ],bothofwhichalsoreducetheLRsize.
   .  S                   
 . .  C                               
 issectiondetailsthecalculationssummarizedinFig. . . .
C                             
LetMbethetotalnumberofrestingCD + Tcellsinanindividual.  efraction
ofthesecellscontainingHIV- DNA,wri enfD,ismeasuredusingPCRon
puri edrestingCD + Tcells[  ].  etotalnumberofrestingCD + Tcells
withHIV- DNAisMD = fDM.
Manyofthesecellsmaynotbecapableofproducinginfectiousvirionsupon
reactivation. Limiting-dilutionco-cultureassays[   ]measurethefractionfCC
ofrestingCD + Tcellsthatproducereplication-competentvirusfollowing







identi ed[   ]. Amongthosecellsinfectedwithprovirusbutundetectedin
co-culture,letibethefractionthatnonethelessareshownbysequencingtohave
allopenreadingframesintact.  enfNII,de nedasthefrequencyof
  non-induced,intactprovirus-containingcells,isfNII = i
(
fD   fCC
)
.
 equantityofinterestforourmodelisthenumberofrestingCD + Tcells
harboringproviralDNAcapableofcausinginfectionofothercells.  islatent





S                                                
 esizeandcompositionofthelatentreservoircanvarysigni cantlybetween
patients.  isvariationisrelevanttovariationinreboundtime. Basedonresults
in[  ,   ],wecancalculatetheaverageparametersandestimatethepopulation
leveldistributions:
Quantity Average Distribution
fD            LogNormal(        )
fCC      LogNormal(      )
i  .   LogNormal(         )
 edistributionswereestimatedbyassumingtherangesobservedinthese
studyofapproximately  patientsrepresentthecenter  %ofthedistribution
(ie standarddeviations). Weexamininethreediﬀerentcasesforinter-patient
variability:
  Case : AllpatientshavethesameLRsize,whichequalstheaveragevalue
measuredinco-cultureassays(fLR = fCC).
Case :  efractionfCC variesamongpatientsasinthetableabove,and
fLR = fCC foreachpatient.
Case :  efractionsfD,fCC,andiaresampledfromtheabovedistributions,











 .  roughoutthispaper,weassumetheonlyparametersthatvarybetween
patientsarethoserelatedthecompositionofthereservoir.
E                          -              




WhilefLR   fV   fD,wecannotestablishtherelationshipbetweenfV andfNII,as
somecellsinfNII mayharbortranscriptionallysilencedprovirus,andconversely
somecellsinfV mayharborproviruswithdetectabledefects. Asanintermediate
estimateweassumefV = fCC + fNII =          ,thoughwealsoconsiderthe
twoextremevaluesinthebestandworstcasescenariosdiscussedinthemain
text.
   . .  E                                
D                               dy
 eparameterdy hasbeenmeasuredinmanytreatmentinitiationstudiestobe 
day   [   ]. Inthestochasticmodelweconstrainb + d = dy =  day  .
A                                    a
ParameteraisestimatedfromobservedviremiaduringfullysupressiveHAART
treatment(R  =  ). Amongpatients,residualviralloadishighlycorrelatedto
LRsize[  ]. Sincereservoirdecayisslowcomparedtothedynamicsofactively
infectedcells,theresidualviralloadreachesaquasi-steady-staterelativetothe
sizeofthelatentreservoir(Section . . ). Atthislevel,thenumberofactively
infectedcellsis






Section . . ,above.




ascertainedisthetotalnumberofvirionsw ,whichexceedsv . Assumingthat
  infectiousnessofthereleasedvirionaﬀectsneitherviralburstratenordecayrate,
thesameproportionalityconstantσ appliestothenumberofcellscapableof
producing(infectiousornoninfectious)virions,wri en^ y ,resultinginthe





Areasonableestimatefortheproportionalityconstantisσ =  ,asdiscussedin
Suppl. Materialsof[   ]. Weusew  =  HIV- RNAcopiespermilliliter
plasma,cml  ,correspondingto     plasmavirionsfora  kgpersonwith L
plasma,andweuseM =     . BasedontheobservedaveragesfD =         ,
fCC =     ,andi =     ,weestimatefV =            anda =          day  .





viremia(fV = fCC =      anda =         ). Forabest-casescenariooflow
activationrate,wesupposethatresidualviremiaisseededfromallcellsharboring
HIV- DNA(fV = fD =          anda =     ). Resultsforthesescenariosare
showninFigs. . . and . . .
  V                    n
Aviralreboundthresholdof   cml   correspondsto        plasmavirions
(fora  kgpersonwith Lplasma). Usingtheestimateσ    above,the
numberofactivelyinfectedcellsatreboundisn          . Modelresultsarenot
sensitivetothisvalue,asreboundprobabilitydependsonthelogarithmofn
(Section . . ,below).
D                               dz
RestingmemoryCD + Tcellsdieataratedz,whichmaybeestimatedfrom
studiesmeasuringthetotaldecayrateofthereservoir,a + dz. Givenamean
half-lifeof  months[   ],weestimatedz tobe
dz =
ln( )
    days
  a




 isparameterisvariedtoexplorearangeofhalf-livesinFigs. . . , . . ,
 . . .
V           R 
 ecombinedviral tnessparameterR  canbeestimatedfromreboundtimes
measuredinHAART-interruptionstudies[  ,   ].  eaveragereboundtime
inthesestudiesistwelvedays,whichconsistsofboththetimeneededfordrug
  levelstodecaysuchthattheinfectioncangrowandthesubsequenttimeneeded
forexponentialviralgrowthtoreboundlevelscomputedinEquation( .  ). For
estimatingthedrugdecaytime,weusedthemethodof[   ,   ]withatypical
regimenofAZT, TC,andSQV.ForEquation( .  ),weusedareboundfactor
(describedinSection . . )ofr =      ,basedonresidualviralload
w  =  cml
  ,infectiousresidualviralloadv  = w 
fCC
fV =       cmL   (using
averagevaluesoffCC andfV inSection . . ,above),anddetectionat   cml  .
WecomputeavalueofR  =  ,atwhichittakesaboutfourdaysfordruglevelsto
decayandanothereightforviralgrowthtoreboundlevels.
I                   λ
Basedontherateatwhichpatientsfailtherapyduetodrugresistance,aprevious
studyestimatedtherateatwhichcellsthatarefatedtoestablishalineageactivate
fromthelatentreservoirtobeabout perday,intheabsenceoftreatment[   ].
 isestimateishighlyuncertain,asitissensitivetomeasuredmutationratesand
 tnesscostsofresistancemutations.
Usingourbaselinevaluesofa =          andMLR =    ,thenumberofcells
activatingperdayis  . Anextinctionprobabilityofh  =          =     
(de nedinEquation( . ))wouldmakeourbaselinevaluesconsistentwiththe
aboveestimate. UsingR  =  ,theimplied λ toobtainthislineageextinction
probabilityis  . Toaccountforuncertainty,weconsider λ between and  .
  B                      b   d
R  anddy donotuniquelydeterminethedynamicsofthestochasticmodel
becauseband λ cannotbesimultaneouslyidenti ed. A erchoosingavaluefor λ
between and  ,theparameterbiscalculatedusingtherelationship
R  = bλ dy.  eparameterdisthenobtainedfromtherelationshipb + d = dy.
 . .  S                             
S                
 estochasticmodelofviraldynamicsdescribedinthetextcanbeformally
representedasthereactionsbelow:
Z   Y... rateconstant: a
Z    ... rateconstant: dz
Y   cY... rateconstant: b   pλ(c)









c! . A eraburstevent,theoriginalcelldies. Sinceeachbirthevent
  causesthedeathoftheparentcell,thetotaldeathrateisdy := b + d.  ismodel
describesatwo-typebranchingprocess.  ereproductiveratioforthismodelis
R  = bλ







inSection . . ,above.
G                                   
Let




z(t)  y( ) =  &z( ) =  
]
 




z(t)  y( ) =  &z( ) =  








= b(exp[λ(f     )]   f ) + d(    f ) 
 f 
 t
= a(f    f ) + dz (    f ) 
( . )
withboundaryconditionsf (ξ ζ  ) = ξ andf (ξ ζ  ) = ζ.  ebirthterm
exp(λ(f     ))followsfromthePoisson-distributedoﬀspringdistributionwith
parameter λ.
A erL therapy,theinitialreservoirsizeisz .  eresidualviremiay  is
determinedbyactivation-deathequilibriumduringHAART,andsoitis
Poisson-distributedwithmean az 
dy .  eprobabilitygeneratingfunction
correspondingtothisinitialconditionisthen





(f (ξ ζ t)    )
]




z  pz gz (ξ ζ t),wherepz  istheprobabilitythata
patienthasz  latentlyinfectedcellsfollowingL therapy.
P              L                          .
 e xedpointsofthediﬀerentialequations( . )givetheultimateextinction
probabilitiesh  andh ,startingwithasingleactivecellandasinglelatentcell,
  respectively.  eprobabilityh  isthesmallestrootoftheequation








h   ( . )
Usingtheaboveinitialcondition
(











(    h )
]
  ( .  )
De neÆ =










 Æz  
( .  )
wherethesecondapproximationfollowsfromthefactthatactivecelldynamics
arefasterthanlatentcelldynamics,dy ≫ a + dz.  ekeyparameterdetermining
clearanceprobabilityisthereforeÆz ,theexpectednumberoflatentcellsfated
toactivateandestablishareboundinglineage.




















= h   ( .  )
andthesameexpectedgrowthrate(andthusthesameR )
be   de = b(λ    )   d  ( .  )






    f ) + d(    f )  ( .  )
  whilethediﬀerentialequationforlatentcellsisthesameasin( . ).  ebasic
generatingfunctionsforthissimpli edprocesscanbesolvedinclosedform,
f (ξ ζ t) =
beξ   de + de(    ξ)exp[(be   de)t]
beξ   de + be(    ξ)exp[(be   de)t]
 







exp[a + dz]τ (dz + af (ξ ζ τ))dτ
 
  
( .  )
forthesupercriticalcasebe   de.
 egeneratingfunctiongz (ξ ζ t)fortheprocessstartingattheinitial
conditiondescribedaboveisagainde nedasinEq.( . ),nowusingthenew
functionsf ,f .  eprobabilitythatthereareyactivecellsattimet,wri en
P(y t),isequaltothecoeﬃcientof ξ
y intheTaylorexpansionofg(ξ ζ t)around
ξ =  ,ζ =  . Repeateddiﬀerentiationiscomputationallycostlyandsubjectto
compoundedroundingerrors,andCauchy’sintegralformulaprovidesan
eﬀectivealternative. Following[  ],theprobabilitythattherearemorethann
activecellsattimetequals








iθ   t)
    e i(n+ )θ
    e iθ
]








=  forintegers    k   n+ 
  . Wetreat
eachhalf-periodseparately,de ningasequenceofapproximationsak
(k =         n)whereak  
∫ (k+ ) π
n+ 
k π




n+  (k +  ) π
n+ 
]
into   equal-width
  segments. Sinceasharppeakappearsatθ =  forcertainparametervalues,the
valuea  isde nedusingaglobaladaptivenumericalintegrationroutine(quadgk
inMatlabR    b).




E         “      Q”                          
Aroughestimateoftheinitialreservoirsizez  suchthathalfofpatientshave
reboundedattimetcanbeobtaineddirectlyfromthegeneratingfunction
gz (ξ ζ t)above. Weusedthisroughestimateasaninitialguessforthesearch
algorithmdescribedinSection . . belowtoidentifythetargetQvaluesin
Fig. . . B,C.
 eprobabilitythattherearenoactivelyinfectedcellsattimetisgz (    t). If
suﬃcienttimehaspassedtoallowforsubstantialexponentialgrowth(i.e.,
e(be de)t ≫  ),thentheintegralinEq.( .  )isdominatedbyvaluesatlarge τ,
andsothefractionwithintheintegralmaybetreatedasaconstant,
ade
be .  e
probabilityisthen




az  (    h )
dy (    h e rt)
][
   
a
a + dz
(    h )
(




( .  )




    e (a+dz)t)
≪  andtheexpressioncanbe
approximated:
P(  t)   exp
[






  ( .  )
Notethatdz hasdroppedoutofthisestimate;therateatwhichactivecells





r .  ereboundestimatethenbecomes
P(  n t)       exp
[









  ( .  )
 erequiredinitialreservoirsize andthecorrespondingtargetQ can
thenbesolvedfor,usingP(  n t) =    andthedesiredvalueoft. Itfollows
fromthiscomputationthattherequiredz  scalesinverselywitha. Since







S                   
WeusetheGillespiealgorithmtotrackthenumberoflatentlyandactively
infectedcellsinacontinuoustimestochasticprocess. Westartwithanintial
  numberoflatentcellsz  =    QMLR andaninitialnumberofactivelyinfected
cellsy  chosenfromaPoissondistributionwithparametera   QMLR dy,where
MLR isthepretreatmentlatentreservoirsize(describedinSection . . ).  e
simulationproceedsuntilthenumberofactivelyinfectedcellsreachesthe
thresholdforclinicaldetectiongivenbyaviralloadof   cml   (equivalentto






    . ForeachQvalueweperform    simulations.
 . .  A                                                          
     
A                           E .( .  )
 esum
∑n
k=  ak describedfollowingEq.( .  ),above,wasapproximatedusing
thefollowingalgorithm:
 . Computeak fork =  tok = I      B    S       . Storethesumof
thesevaluesasS.
 . SetN   K = I      B    S   . SetB    S    = M  B    S   .
SetN  T C       = M  N  T C      .
 . WhileN   K   n,do:
(a) InitializeA =  ,B =  .
  (b) Splittheblockcontainingthevaluesak fromk = N   Kto
k = N   K + B    S       intothreesections:
i. F    P   containsak forkfromN   Kto
N   K + N  T C          ;
ii. L   P   containsak fork
N   K + B    S      N  T C      to
N   K + B    S       ;
iii. M     P   containsallak inbetween.  esevaluesofak are
notcomputed.
(c) ComputeanU    E       forthesum
∑N   K+B    S     
k=N   K ak
byaddingtogetherallak inF    P   andL   P   ,andthen
approximatingthevalueofeachak inM     P   astheaverageof
the naltwovaluesinF    P   .
(d) ComputeaL    E       forthesumsimilarly,exceptnow
approximatingthevalueofeachak inM     P   astheaverageof
the rsttwovaluesinL   P   . Sincethesequenceak decreasesin
analternatingmanner,L    E          U    E       .
(e) IfL    E       andU    E       aretoofarapart(see
Notesbelow),increaseN  T C      by andreturnto
Step b. Otherwise,addtheaverageofthetwoestimatestoSand
continue.
(f) IfN  T C       = M  N  T C      (indicatingthatthe
  errorbetweenupperandlowerestimateswasneversofarapartasto
requireincreasingN  T C      ),incrementAby ;otherwise
incrementBby .
(g) SetN   K = N   K + B    S       . ResetN  T C      
toM  N  T C      .
(h) IfA    B + N  R     B     ,thenincreaseB    S   bya
multiplicativefactorofB    I       F     ,roundingtothe
nearesteveninteger. ResetA =  ,B =  .
N    . L    E       andU    E       arerequiredtohavea
diﬀerenceoflessthan  π
n        (ensuringatotalerrorinSofunder    ),anda
log-ratiooflessthan    .  eparameterB    I       F     isitself
adaptive,increasingby    (  +       (B    I       F         )
immediatelya erStep hifB =  ;butdecreasingby   (neverdroppingbelow
    )ifB    .
P             . I      B    S    =    . M  B    S    =   .
M  N  T C       =  . B    I       F      =     .
N  R     B      =  .
B              Q                          
 eestimateinSection . . isusedasaninitialguessforthepost-therapy
reservoirsizez  thatwouldproducea   chanceofrebound. Survival
probabilityPsurv wascomputedforthisinitialguess,usingthemethodof
  Section . . . WhilePsurv wasnotwithin     of   ,anewguessforz  wasmade
usingabisectionmethod: IfPsurv istoolow(high),butapreviouslycomputed
valuewastoohigh(low),thenlinearinterpolationwasusedbetweenthecurrent
andpreviousvaluestoselectanewz  thatisestimatedtohavePsurv =    . If
Psurv istoolow(high),butnopreviouslycomputedvaluewastoohigh(low),
thentheguessforz  wasdivided(multiplied)by  . Forallresultsreported,
between and iterationswererequiredtoobtainthedesiredPsurv. Resultswere
thenconvertedtoQvaluesforagivenpre-treatmentreservoirsize.
 . .  D                                
Adeterministicmodelwasusedfortwopurposes: toprovideanestimateofR 
(describedinSection . . ,above)andtoestimatethethresholdQseparatingthe
growth-limitedandactivation-limitedregimes.  ethresholdvalueisde nedas
thatwhichequalizesthedeterministicreboundtimeandtheexpectedwaiting
timeuntilactivationofthe rstcellfatedtoestablish.
M              
Acompletemodelofviraldynamicsincludingthelatentreservoirisshowninthe
 owdiagramofFig. . . . Allvariablesrespresenttotalamountspresentinthe








diﬀerentialequations[   ,   ,   ,   ]:
_ x = θ   βxv   dxx
_ y = βxv   dyy + az   γy
_ v = ky   dvv
_ z = γy   az   dzz





trackinfectedcelllevels. Formally,thisisaccomplishedbyse ing _ v =  ,leading
tov = ky dv andonlythreediﬀerentialequations. Forviralloadsatorbelow
reboundlevels,uninfectedCD + Tcellsdonotbecomelimitedandcanbe
assumedtoremainattheirpre-infection/post-long-term-HAARTsteady-state
levelofx = θ dx,andhence _ x =  . Moreover,atlowviralloads,newin uxinto















Figure 3.4.1: Schematic of the deterministic viral dynamics model including
the latent reservoir. State variables x, y, v, and z are the number of infectable
CD4+ T cells, the number of productively infected cells, the number of free
virus particles, and the number of latently infected cells, respectively. Pro-
ductively infected cells produce virus at rate k, die at rate dy, and transition
into latency at a rate γ. Virus is cleared at rate dv. The infectivity parame-
ter β determines the rate at which virus infects susceptible host cells. Host
cell dynamics are determined by production rate θ and death rate dx. Latently
infected cells reactivate at a rate a and die at a rate dz.
   eseassumptionsleadtothereducedsetofequations:
_ y = az + (R     )dyy
_ z =  (a + dz)z 
( .  )







Section . . ,theinitialconditions
(




slowerthanactivecelldynamics(a + dz ≪ dy) theresidualactiveinfectionis
y    az  dy.
C                                              
FollowingHAARTinterruption(withorwithoutL therapy),thenumberof
infectedcells(andthusviralload)growsaccordingtoEquation( .  )with
latentcellsatatransientlyconstantvaluez . Letyr = ry  betheinfectionsizeat




y(t) = y 
R edy(R   )t    
R     





 +r(R   )
R 
)
dy(R     )
  ( .  )
 isequationisappropriatewhencellsexitthereservoirfrequently(i.e.
withouthighlyeﬀectiveL therapy). Incorporatingreservoirdecaynegligibly
changestheresultsbecausea + dz ≪  . InSection . . above,thisequationwas
usedtocalibrateR  basedonobservedreboundtimet .
FollowingL therapy,thesizeofthereservoirisreducedto   QMLR. Let
q =    Q. Sincetheresidualactiveinfectiony  alsoscalesbyq,therebound




 +(r=q)(R   )
R 
)
dy(R     )
( .  )
Eradicationtherapythereforeextendsthereboundtimebyanamount Δt:
Δt = t    t 
=
 
dy(R     )
ln
(
  + (r q)(R     )




dy(R     )
( .  )
wheretheapproximationisvalidforr(R     )     .  isorderrelationshipis
verylikelytoholdasthereboundfactoris    ormore.  eonlywayforthe
relationshiptofailwouldbeforR  tobeinaverynarrowrangejustabove .
  A              Q,                                            -







model(Fig. . . ). Asaroughestimate,thewaitingtimeinthestochasticmodel
is  
a(  h )z ,whereh  istheprobabilitythatareactivatinglineagegoesextinct
(de nedinEquation( . )).  ethresholddrugeﬃcacyQT de nesthe
boundarybetweenthetworegimes. Itcanbeestimatedbysolvingnumerically




 +r  QT(R   )
R 
)
dy(R     )
=
 
a(    h )MLR    QT  ( .  )
 isthresholdcanbeobservedintheupwardin ectioninthereboundtime
curvesinFigs. . . Cand . . occurringatQ   – .
Fig.  . . showsthatQT increaseswithpretreatmentreservoirsizeMLR and
decreaseswithvarianceparameter λ,sincehighervaluesof λ increasethe
extinctionprobabilityh . ForpretreatmentreservoirsizeMLR =    ,reduction










































































Figure 3.4.2: A fully deterministic model is a poor predictor of rebound
times. A) Equation ( .  ) was used to calculate the time to rebound for a
given LRA drug eﬃcacy, Q. The deterministic model assumes that LRA re-
duces the size of the reservoir and hence the residual viral load by Q orders of
magnitude and then tracks the time for the viral population to grow to 200 c
ml  . B) Rebound times calculated from the deterministic model for R  =  
are compared to median rebound times calculated from the stochatic process.
The models agree only for small Q. The Q values where the models diverge
corresponds to the transition between the growth-limited regime and the acti-
vation limited regime.
ofapproximately  -to     -foldisrequiredtoreachtheactivation-limited
regime,inwhichsubstantialincreasesinreboundtimemaybeachieved.




































Figure 3.4.3: Schematic of viral dynamics during LRA therapy. (A) The
model tracks latently infected cells, actively infected cells, and free virus, dis-
tinguishing between cells in which HIV-1 transcription is reactivated by LRA
(y′) or naturally (y). (B) Illustration of typical viral load dynamics during
course of LRA therapy. LRA therapy increases the reactivation rate of cells
from the LR, causing residual viral load to increase. The timing and magni-
tude of this peak allow for an estimation of the eﬃcacy Q. We assume that
HAART is administered for a short while beyond the end point of LRA ther-
apy, preventing the reactivated cells from starting new infections. All symbols
are deﬁned in the text.
attheHIV- LTRmaybereactivatedinrestingCD + Tcellswhilethecell
otherwiseretainsarestingphenotype,cellularfunctionsintheseL -activated
cellsmayproceedataslowerrate[   ]. Wethereforetrackthosecellsreactivated
byL separatelyfromthosereactivatednormallybyantigenicstimulus.
 emodelweusetoconsiderthisscenarioisshownschematicallyin




(fV versusfLR,Fig.  . . ),andsincetherapyincreasesactivationrate,large
numbersofcellscanbeassumedtoactivatedaily,andadeterministicmodel





y (whichmaybelowerthandy)[   ]. Freevirusisproducedatarate
kfromnaturallyreactivatedcellsandaratek
′ fromL -reactivatedcells. Since
inducedcellsmayhavesmallerburstsizes[   ],k
′ maybelessthank.
Weusethismodeltorelatechangeinresidualviremiaovertimetothe
log-eﬃcacyofL therapy,Q. De neαz = a + a′ + dz,thetotalrateatwhichz
decaysduringtreatment. Assumingthatthisdecayaﬀectslatentcellsregardless
ofwhethertheproviralsequenceisabletoreplicate,thefractionofthelatent
reservoirthatremainsa ertreatmentduration τ isq = e αzτ. Log-eﬃcacyof





decayingslowly(attheslowerofthetworates)(Fig.  . . B).
 eheightofthispeakandthetimea ertreatmentinitiationatwhichit
occursare


















ln(  )   Q
aτ
 




y)   ln(αz)
d
′
y   αz
  ( .  )
   wherew    cml   istheresidualviralload(notnecessarilyinfectious)before
L therapy.  ispeakisreachedbeforetreatmentendsif τ     d
′
y and
Q    
ln(  )       . Derivationsfortheseresultsareprovidedinthenextsection,
andexamplesforselectedtreatmentparametersareproviedinTable . . . Even





′ k    ). IfL -inducedcellshavealongerlifespan
(dy d
′




 . . ). ItisimportanttonotethatthisconclusionappliesonlytoformsofL 
thatreactivatelatentlyinfectedcellswithoutdamagingviralproductioninthese
cells.
D                   
WeextendEquations .  and .  ,trackinglatentlyinfectedcellsz,
productivelyinfectedcellsreactivatednaturallyy,productivelyinfectedcells
   Table 3.4.1: The timing and size of peak viremia, as well as viremia at treat-
ment end, depend on the eﬃcacy and duration of LRA therapy, the change
in burst size, and the change in infected cell lifespan. Therapy protocol is
described in the text and illustrated in Fig. 3.4.3. Time to peak viremia
was calculated using Eq. 3.28. Peak viremia was calculated using Eq. 3.34,
of which Eq. 3.27 is an approximation. Symbol deﬁnitions are provided in
the text. Parameters used: a =          day  , dz =            day  ,
z  = Mv =          cells, dy =   day  , and w  =   c ml   (implying
k
dv =  
     c ml   cell  ).
Log-eﬃcacy Treatment Foldincrease Foldincrease Timeto Peak Viremiaat
L (Q) time inburst inlifespan peak viremia treatment
(τ)(days) size(k
′ k) (dy d
′
y) (days) (cml  ) end(cml  )
                      
                  
                  
       .          
                      
                      
                 
                    
                           
      .             
      .                  
                      
                   
reactivatedbyL therapyy′,andfreevirusv:
_ z =  (a + a
′)z   dzz
_ y = az   dyy
_ y′ = a




_ v = ky + k
′y
′   dvv
( .  )
    eseequationsincorporatethesimplifyingassumptionsthatfullyeﬀective




conditionsz( ) = z ,y( ) = az  dy,y′( ) =  ,theseequationscanbesolved:




dy   αz
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( .  )








onlyslightlyoverestimateviremiaonthe rstdaya erL isstarted.
 eamountbywhichL therapyincreasesthereactivationrate(a′)canbe
relatedtothefractiontowhichthereservoirisreduced(q),orequivalently,tothe
log-eﬃcacyQ = log  (q),a eratreatmenttime τ:
z(τ) = z e
 αzτ
= qz  
( .  )




  (a + dz)
=
ln(  )   Q
τ
( .  )
NotethatsomenaturalactivationandcelldeathcontributetoQ,sothatthe
absenceoftreatmentdoesnotcorrespondtoQ =  butto
Q = log  (e)(a + dz)τ,whichisgenerallysmall.
Fromtheseequations,wecandeterminetheexpectedchangesinresidualviral
loadovertimeduringL therapy.  econtributiontoresidualviremiafrom















y)   ln(αz)
d
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y   αz
  ( .  )




















































ln(  )   Q
aτ
 
( .  )
wherew  = ky  dv istheresidualviralloadbeforeL therapyandu = αz d
′
y.
 e rstapproximationholdswhenuissmall(ifQ τ issmallcomparedtod
′
y),
andthesecondholdswhena + dz ≪ a′ (Q τ islargecomparedtoa + dz).  e
peakviralloadoccursduringtreatmentwhentmax   τ,whichholdsifandonlyif
both τd
′
y    andln(  )   Q   τd
′
y,whichplacesrequirementsonbothtreatment
time(τ     d
′
y)andtreatmentstrength(Q    
ln(  )       ). WhenL is
started,viralloadapproachesthepeaklinearlywithaninitialslopeofa′z .
Viremiaattheendoftreatmentcanbefoundbysubstitutingin τ fortin
Eq.( .  ).
 .  M                    
 . .  I             
 ismanuscriptisbeingsubmi edas:
   HillAL,RosenbloomDIS,FuF,NowakMA,SilicianoRF.Predicting
outcomesoftreatmentstoeradicatetheHIV- latentreservoir.
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Imitationdynamicsofvaccination
behavioronsocialnetworks
 .  I           
P                                          forcontrolling
infectiousdiseases[  ]. Whilethereisvigorousdebateaboutthecivilliberties
implicationsofmandatoryversusvoluntaryvaccinationpolicies[  ],mounting
evidenceshowsthatvoluntaryvaccinationplansfailtoprotectpopulations
adequately[  –  ,  ,  ,  ,  ,  ,   ,   ]. Arecentexampleofthisfailure
   isthesharpdeclineintake-upofthecombinedmeasles-mumps-rubella
vaccinationinBritainsoona eradministeringittochildrenwasmade
voluntary[   ]. Becauseofdecliningfamiliaritywiththediseaseandrisingfears
ofvaccinecomplications,parentshopedtoavoidtheallegedvaccinationhealth
risktotheirownchildrenwhileimplicitlyrelyingonenoughotherchildren





byunilaterallychangingtoadiﬀerentstrategy[  ,  ]. Althoughthis
equilibriumistheresultofeachindividualfollowingherself-interest,itmaylead










populations[  ,  ]orrandomnetworks[   ]. Instudieswherethe
   assumptionofrationalityisrelaxed,deterministicevolutionarydynamicsstill
recoverequilibriumstatesequivalenttothosepredictedbymodelsofrational
agents[  ]. Itisworthnotingthataggregatepopulationmodelshavebeen
parameterizedwithempiricaldatatoquantitativelypredictvaccinatingbehavior




ofdiseaseriskandprevention[   ,   ,   ].  erisetoprominenceinthe
Britishmediaofisolatedcaseslinkingthepertussisvaccineandbraindamage
triggeredasharpdeclineincoverageinthelate    s,demonstratingthepower
oftheanecdote[  ,   ]. Apartfromtheseprominentcases,eachpersoncan
encounterdiﬀerentanecdotalevidence,dependingonhersocial
network[  ,   ]. Illnessofaclosefriendcanimpactone’sperceptionof
infectionriskandtheimportanceofpreventioninfarmorepowerfulwaysthan
mediareportscan[   ].
Motivatedbytheaboveconsiderations,weproposeasimpleagent-based






   topredictwhetheravaccinationprogramwillhaltanepidemicbeforeitspreads










immunity[  ,   ].
 .  M    &       
Considerawell-mixedpopulationofindividualswithavoluntaryvaccination
option. Wemodelthevaccinationdynamicsasatwo-stagegame(asillustratedin







   spreadsaccordingtoSIRdynamics,withper-daytransmissionraterandrecovery
rateg(seethesupplementarymaterialsformodeldetails).  eepidemic
continuesuntiltherearenomorenewlyinfectedindividuals(whichoccurredin





    x
=     e
 R R( )  ( . )
whereR( )isthe nalsizeoftheepidemic(fractionthathavebeeninfectedat











infection.  eNashequilibriumofthisgamecanbesolvedbyse ingthe
expectedcostofvaccinationequaltothatofnon-vaccination,whichimpliesthe
   Figure 4.2.1: Schematic illustration of our model. We model the vaccination
dilemma as a two-stage game. At Stage 1 (vaccination choice), a proportion x
of the population decides to vaccinate. Vaccination costs V and provides per-
fect immunity from the infectious disease. At Stage 2 (health outcome), we
use the Susceptible-Infected-Recovered model to simulate the epidemiological
process. Each unvaccinated individual faces the risk of infection during the
seasonal epidemic outbreak. The cost of infection is I. Those unvaccinated
individuals who remain healthy are free-riding oﬀ the vaccination eﬀorts of
others, and they are indirectly protected by herd immunity.
mixedstrategy
x
  =   +
ln(    c)
cR 
  ( . )













function[  ,   ,   ,   ]
f(Pj   Pi) =
 
  + exp[ β(Pj   Pi)]
  ( . )












   payoﬀ,evenifthepayoﬀdiﬀerenceissmall. Previousworkusingthesameupdate







structuredassquarela ices,Erdős-Rényirandomgraphs[  ],and







populationisequalacrossallpopulationstructures[   ](seesupplementary
materials). Eachsimulationwasrunfor ,   iterations.  elongrun
equilibriumresultsshownin gures . . – . . representtheaverageof
frequenciesoverthelast ,   iterationsin   independentsimulations. Our
presentedresultsarerobusttopopulationsizeNforallpopulationstructures
examined,aslongasN      .








risk ( . )andanin nite-populationapproximationoftheimitationdynamics
(describedinsupplementarymaterials).
Forweakselection(β =  in gure . . ),theimitationdynamicsapproximate
therationalequilibriumx  giveninequation( . ). Onecanunderstandthis
observationanalyticallybynotingthatthestrategyupdateequation( . )is
roughlylinearforsmall β. First-orderapproximationoftheimitationdynamics
closelyapproximatesthereplicatordynamics[   ,   ,   ],whichinthisgame
convergetotheuniqueevolutionarilystablestrategy–theNashequilibrium(see
supplementarymaterials). Asvaccinationfallswithincreasingc,the nalsizeof
theepidemicgrows. AboveahighcostthresholdcH        ,noonechooses
vaccinationandtheepidemicreachesitsmaximumsize.
Strongselectionintheimitationdynamics(representedby β =   in
 gure . . )candecreasevaccinationuptakebelowthelevelpredictedbythe
   Figure 4.3.1 (following page): Vaccination dynamics in well-mixed popu-
lations. The fractions (a) vaccinated and (b) infected are shown as functions
of the relative cost of vaccination, c, for the intensity of selection β =   and
  . The lines are analytical predictions from deterministic equations (see sup-
plementary materials). The deviation between simulation and theory is largely
due to stochasticity in disease transmission: holding vaccination constant at
some level below the herd immunity threshold (      R  =    ), simulated
infection risk is smaller than the prediction in equation ( . ) (see suppl. ﬁg-
ure 4.5.1b). Individuals in the simulation respond to this decreased risk by
vaccinating less than in the theory, which in turn leads to a larger epidemic
versus the theory. Strong selection magniﬁes individuals’ responses, producing
larger deviations. For vaccination coverage above the theoretical herd immu-
nity level, the deterministic approximation underestimates infection risk, lead-
ing to an opposite deviation at low c. Parameters: population size N =     ,
R  =     (realized by setting r =   ( N) and g =    ), number of infection
seeds I  =  .
   Figure 4.3.1 (continued)
   rationalequilibrium. Inotherwords,individualswhocarefullya endtopeers’
healthoutcomesandreliablycopythebehaviorofsuccessfulpeerswillendup
a emptingtofree-ridemorethantheyrationally“ought”to. If,forexample,
infectionistwelvetimesascostlyasvaccination(namely,c =     ,areasonable
assumptionforin uenza,seesupplementarymaterials),thenstrongselectionin
ourmodellowersvaccinationcoverageby percentagepointsversusweak
selection( gure . . a),whichincreasestheepidemicsizefrom %ofthe
populationto  %ofthepopulation( gure . . b). Withincreasingcost,the
equilibriumvaccinationcoveragefollowsarotated“S”curve,droppingrapidly
(slope   
β
 )fromtheherdimmunitythresholdatlowvaluesofc,reachinga
plateaunear     ln 
R  forintermediatevaluesofc,andthendroppingrapidlyto
zeroascgrowslarge.  ethresholdcH increaseswithselectionstrength
( gure . . a).
ResultsarequalitativelysimilarforanybasicreproductiveratioR  ofthe
infection. suppl.  gures . . , . . comparethecasesR  =    andR  =  .  e
highervalueincreasesinfectionrisk,makingthepopulationrespondwith
increasedvaccination. IncreasingR  alsoraisesthethresholdcH.
Restrictinginteractiontolocalneighborhoodspartlyamelioratesthe
free-ridingproblem,butintroducesgreatersensitivitytothecostparameterc
( gure . . ). Weconsiderapopulationofindividualsarrangedonasquare
la icewhereeachindividualhasfourimmediatelyadjacentneighbors. Whilethe
vaccinationcoverageinwell-mixedpopulationsdropsfromherdimmunitylevels
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Relative cost of  vaccination, c
  = 1




Figure 4.3.2: Vaccination dynamics in lattice populations. Left panels (a),
(b) show the fractions vaccinated and infected, respectively, as functions of
c for the intensity of selection β =   and   . right panels (c), (d) show snap-
shots of the system at equilibrium frequencies with weak and strong selection,
respectively. Blue denotes vaccinated individuals, red successful free-riders,
and yellow infected individuals. Strong selection breaks apart clusters of vac-
cinators:   % of vaccinated individuals’ neighbors are also vaccinated in (c),
versus only   % in (d). Parameters: population size N =           with von
Neumann neighborhood, disease transmission rate r =     , recovery rate
g =    , number of infection seeds I  =   , (c)(d) c =     , (c) β =  , (d)
β =   . The lines in (a) and (b) are visual guides.




sizeoftheinitialinoculum. De neascL thecriticalvaccinationcostbelowwhich
theepidemicisprevented. Forweakselectiononthela ice(β =  in
 gure . . ),wegetcL        . Abovethisthreshold,thevaccinationleveldrops
precipitously,causinganepidemicthatisevenlargerthaninthewell-mixedcase.
Athigherselectionstrength,thethresholdcL islower,andvaccination





vaccinators,thusallowingalargerepidemictooccur( gure . . cversus . . d).
Mostactualpopulationsareheterogeneousinthesensethatdiﬀerent






populationswithgreaterdegreeheterogeneity[   ](seealsosuppl.
    gures . . – . . ).  isincreasedvulnerabilitytoepidemica acksreducesthe
temptationtofree-ride,actuallymakingiteasierforapopulationofsel sh
imitatorstoachievethehighvaccinationthresholdrequiredforherdimmunity.
 ethresholdcostcL thereforeincreasesversusthela icecase. Vaccination
coveragedropsa ercostexceedsthisthreshold,althoughtheeﬀectisnotquite




behavior. Speci cally,anindividual’svaccinationstrategyisnowin uencedby
herroleinthepopulation,and“hubs”whohavemanyneighborsaremostlikely
tochoosetobevaccinated,astheyareatgreatestriskofinfection( gures . . c
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Number o f  neighbo rs
Figure 4.3.3: Vaccination dynamics in random network populations. Left
panels (a), (b) show the fractions vaccinated and infected, respectively, as
functions of c for the intensity of selection β =   and   . Right panels: (c)
Snapshot of a single simulation on a random network at equilibrium frequen-
cies. The size of a node corresponds to its degree (number of neighbors).
Blue nodes are vaccinated, yellow are infected, and red are successful free-
riders. (d) The frequency of vaccination on a random network, as a function
of the number of neighbors an individual has. The inset in panel (d) shows
the degree distribution of the random network. Parameters: (a)-(d) average
degree  k =  , disease transmission rate r =     , recovery rate g =    ;
(a)(b)(d) N =     , I  =   ; (c) N =    , I  =  ; (c)(d) c =    , β =   . The
lines in (a) and (b) are visual guides.
   replicatordynamics,convergingtotheNashequilibrium. Strongselection,on
theotherhand,drivesindividualstoimitatesuccessfulfree-ridersbasedona
singleobservation,evenwhenarationalagentwithcompleteinformationwould
realizethata emptedfree-ridingdoespoorlyinexpectation.  is“paradoxof
imitation”isaverygeneralphenomenon[   ]andmayinpartexplaincases
wherepublicvaccinationlevelsarelow. Inparticular,fortherangeofvaccination









[  ,  ]. Suchcascadesmayalsobeobstaclestohighvaccinationcoverage[  ].
Toexploreconformism(or,alternatively,stubbornness)inthecontextofour
model,onemightincludeanadditionalcost τ ofswitchingstrategyinthe




towidespreadconformismandadoptionofsub-optimalstrategies[  ,  ].
   Itiswidelyknownthatpopulationstructurecanpromotetheevolutionof





example,therandomnetworkpopulationunderstrongselection(β =   )can
preventtheepidemiccompletelyforcostsuptoc =     ,but  %ofthe
populationbecomeinfectedatcostc =     . Inthewell-mixedpopulation,the
epidemicgrowsgradually,from %to  %,overthesamecostrange.  is
thresholdeﬀectisrobusttochangesinpopulationstructureandexistsinla ice
( gures . . aand . . b)andscale-freenetwork(suppl.  gures . . aand
 . . b)populationsaswell.
Insocialnetworks,individuals’degreesvarygreatly,andhighly-connected
individuals(hubs)canspreaddiseasetoalargenumberofpeersifinfected.  e
vaccinationofhubscanplayavitalroleincontaininginfections[   ],andpublic
healthprogramso entrytopromoteherdimmunitybyallocatingvaccinations
preferentiallytothesehubs[  ]. Physicianswhoarehubsina
disease-transmissionnetwork,forinstance,havehighratesofvaccine
uptake[  ]. Ourmodelshowsthatevenindividualswithincomplete
informationcanself-organizetoachievethispro-socialoutcome( gure . . ).
Sincehubsgenerallyfacegreaterinfectionriskthansmall-degreeindividualsdo,
theyhaveincreasedincentivetovaccinate;hubs’self-interestistherefore
   relativelywell-alignedwithoverallwelfare.
Recentworkwithadetailedmodeldesignedtomimicasmallpoxoutbreakon




















[   ],asherdimmunityprovidesacommunalbene t. Individuals’useofsalient







fearsconcerningvaccinesafety.  esefearso enhaveatremendousimpacton
vaccinetake-upandpublichealth[  ,   ].
 .  S                     
















=  rNSI  ( . )
dI
dt
= rNSI   gI  ( . )
dR
dt
= gI  ( . )
 einitialconditionforanepidemicintroducedbyoneinfectedindividualis
S( ) =       N    ,I( ) =   N,andR( ) =  . DenoterN gbyR ,commonly
calledthe“basicreproductiveratio”[   ]. HereR  isthemeannumberof
secondaryinfectionscausedbyasingleinfectedindividual,duringhis/herentire
infectiousperiod,inacompletelysusceptiblepopulation.
DividingEq.( . )byEq.( . ),weobtain
dS
dR
=  R S  ( . )
Integratingaboveequationfromtime to ,wegetthetranscendentalequation
   forthe nalepidemicsizeR( ):
S( ) = S( )e
 R [R( ) R( )]  ( . )
UsingtheinitialconditionS( )    andR( ) =  ,andthe nalstateI( ) =  
andS( ) =     R( ),weobtain:
R( ) =     e
 R R( )  ( . )
R( )isthe nalfractionofindividualswhohadbeeninfectedduringthe
epidemicoutbreak,i.e.,the nalepidemicsize,whichcanbecalculated
numericallyfromtheaboveequation. DiﬀerentiatingbothsidesofEq.( . )with
respecttoR( ),wecanseethatthe nalsizeispositiveifandonlyifR     . If
R     ,thediseasedoesnotspread.
Ifweconsiderpreemptivevaccinationbysupposingthataportionxofthe
populationinitiallyvaccinated,Eq.( . )canberewri enas
R( ) = (    x)(    e
 R R( ))  ( .  )
Increasingvaccinationdecreasesthe nalsizeoftheepidemic,andif
x   xh =      






















theory:   S     I     R






















Fraction of vaccinated individuals
 theory
 simulation
Figure 4.5.1: Epidemic spreading in well-mixed populations. (a) The frac-
tions of susceptible, infected, and recovered individuals as a function of time.
(b) The fraction of individuals who had been infected as a function of preemp-
tive vaccination level. The solid line in panel (b) is numerically determined
from Eq. ( .  ). Parameters: (a) N =    , g =    , R  =    , the number of




section . . ). Tolowerthechancethatanepidemicoutbreakfailsmerelydueto
stochasticeﬀects,wemaketheinitialnumberofinfectionseedsI  morethanone.
Figure . . showstheepidemicspreadinginwell-mixedpopulations. For
R  =    ,the nalepidemicsizewithzerovaccinationis       ,andtheherd
immunitythresholdisxh =    . Oursimulationresultsagreewiththe
deterministicmodelgivenbyEqs.( . )–( . )( gures . . aand . . b). Note
thatforintermediateinitialfractionsofvaccinatedindividuals(      x      ),
the nalepidemicsizeresultingfromsimulationsislowerthatthantheanalytical
prediction(Eq. .  ). Stochasticeﬀectsdueto niteinfectionsizecausethis
   deviation.
E                                       
Itisnottypicallypossibletoderiveexplicitequationsforepidemicspreadingin
structuredpopulations[   ],soweusestochasticsimulations. Itiswidely
acceptedthatpopulationstructurecansubstantiallyalterepidemiological
dynamicsfromthewell-mixedcase[   ]. Toidentifyonlytheeﬀectsof
populationstructure,wemustcalibrateepidemicparameterstoensurethat
infectionriskisequalinallstructuresexamined[   ]. Weuseasthebasecasea
well-mixedpopulationwithR  =    ,whichiswithinthetypicalR  valuesfor









thenrNI(i)[   ].
Forla icepopulations,the nalepidemicsizeshowsaclearphasetransition
fromzerotoonewithincreasingrvalues( gure . . a). Forlowrvalues,the
epidemicspreadingisinhibitedduetolocalspatialclusteringeﬀects. Weselect


























































Fraction of vaccinated individuals
(b)
Figure 4.5.2: Epidemic spreading in lattice populations. (a) The ﬁnal epi-
demic size is shown as a function of the transmission rate r with zero vacci-
nation coverage. (b) The ﬁnal epidemic size as a function of vaccination level
(preemptive, random vaccination). The arrow notes where vaccination brings
the ﬁnal epidemic size below    % (twice the size of initial inoculum), repre-
senting an approximate herd immunity threshold. Parameters: N =          
with von Neumann neighborhood (four adjacent neighbors), (a)-(b) g =    ,
I  =   , (b) r =     . Results are averaged over 100 runs.
r =     ,whichgivesa nalepidemicsizeof       ,approximatelyequaltothe
basecase. Usingthistransmissionrate,wesimulatetheeﬀectofpreemptive,
randomvaccinationontheepidemic( gure . . b).  e nalepidemicsize
decreasesmoreprecipitouslythaninthewell-mixedcase(cf.  gures . . band
 . . b). Atvaccinationlevelsgreaterthanabout   ,thediseasecannotpersistin





( gures . . and . . ). Usingthesamemethodasabove,wechooser =     


























































Fraction of vaccinated individuals
(b)
Figure 4.5.3: Epidemic spreading in Erdős-Rényi random networks. (a) The
ﬁnal epidemic size as a function of the disease transmission rate r with zero
vaccination coverage. (b) The ﬁnal epidemic size as a function of the vaccina-
tion level (preemptive, random vaccination). The arrow notes where vaccina-
tion brings the ﬁnal epidemic size below  %, representing an approximate herd
immunity threshold. Parameters: (a)-(b) N =     , average degree  k =  ,
I  =   , g =    ; (b) r =     . Results are averaged over 100 runs.
forrandomgraphs( gure . . a)andr =     forscale-freenetworks( gure
 . . a). Noticethatevenforvanishinglysmallrvalues,scale-freenetworksare
fragiletoepidemica acks,consistentwithprevious ndings[   ]. Accordingly,
thevaccinationlevelneededtocontainthediseaseisthehighestamongallthe
populationstructureswestudied( gure . . ).
S                            : G                 





























































Fraction of vaccinated individuals
(b)
Figure 4.5.4: Epidemic spreading in Barabási-Albert scale-free networks. (a)
The ﬁnal epidemic size as a function of the disease transmission rate r with
zero vaccination coverage. (b) The ﬁnal epidemic size as a function of the
vaccination level (preemptive, random vaccination). The arrow notes where
vaccination brings the ﬁnal epidemic size below  %, representing an approxi-
mate herd immunity threshold. Parameters: (a)-(b) N =     , average degree
 k =  , I  =   , g =    ; (b) r =     . Results are averaged over 100 runs.
pi(t) = r   numberofinfectedneighbors.  erateatwhichaninfected




Step :  etimeatwhichthenexttransitioneventoccursist′ = t + Δt,
where Δtissampledfromanexponentialdistributionwithmean  
λ(t). (Generate
auniformrandomnumberu   [   ).  enthetimeintervalis Δt =  
ln(  u)
λ(t) .)
Step : Choosetheindividualwhosestatechangesattimet′ bysampling
proportionaltopi(t). Generateauniformrandomnumberv   [   ). If
∑k  
j=  pj(t) λ(t)   v  
∑k
j=  pj(t) λ(t),thenindividualkischosentochange
state. (De ne
∑ 
j=  pj(t) λ(t) =  .)
Step : RepeatSteps – untilthenumberofinfectedindividualsI(t)iszero,
orstopa erapredeterminedtimeperiod.
    . .  C                                                     
Valuesofcaresupportedbydatafrom[  ],whichestimatesthecostofhealth
outcomes: Vaccinationcosts   onaverage,andtheexpectedcostofinfection
fornon-vaccinatedindividualsisgivenforfourcases:
• Youngindividuals(    years)duringnormalseasons:     
• Elderlyindividuals(    years)duringnormalseasons:   ,   
• Youngindividualsduringpandemics(e.g.,    in uenza):    ,   




  % =     and  
  % =     foreachgroup,respectively.  erelative
vaccinationcosts(asafractionofinfectioncosts)arethen:
• Young,normalseasons: c =     
• Elderly,normalseasons: c =     
• Young,pandemics: c =      
• Elderly,pandemics: c =      
Basedontheseestimates,weproposethatitisreasonabletousevaluesofcin
therange     to   inourmodeltodiscussin uenza.
    . .  N                              






adiﬀerentstrategyycandonobe erthantheresident. Foran ε-sizeinvasion
(ε ≪  ),thenewvaccinationcoverageisp := x(   ε)+yε.  eexpectedpayoﬀ
tostrategyyisthen






   
   
y=x
= w(x)   c   ε(    x)w
′(x) =    ( .  )
  E(y p)
 y 
   
   
y=x
=  εw
′(x)   (    x)ε
 w
′′(x)      ( .  )
Notethatw(x)strictlydecreaseswithx,untilxreachestheherdimmunity
thresholdxh. Forx   xh,theinequality ( .  )isthereforestrictforasuﬃciently
smallinvasion ε,andsohigher-orderconditionsarenotrequired. Also,forsmall
   invasions,the ε terminEq.( .  )canbesafelyneglected.  evaccinationcost
fallsintooneofthreeranges:
• Case ,    c   w( ). Sincew(x)strictlydecreases,thereisauniquex 
thatsolvesw(x ) = c.  isvaluex  istheNashequilibrium.
• Case ,c   w( ). AsthederivativeinEq.( .  )isnegative,thebest
responseisxassmallaspossible;thatis,thepureNashequilibrium
x  =  .
• Case ,c    . AsthederivativeinEq.( .  )ispositive,thebestresponse
isxaslargeaspossible;thatis,thepureNashequilibriumx  =  .
Moreover,strictnessoftheinequality ( .  )inCase impliesthatan
alternativestrategyy ̸= x  doesstrictlyworse,meaningthattheNash
equilibriumisalsoevolutionarilystable[   ].
Furthermore,wecanshowthattheuniqueNashequilibriumx  inthisgameis
globallystable. Foranyproportion ε   (   )ofindividualsplayingstrategy
y ̸= x ,wealwayshave
ΔE = E(x
  p)   E(y p) = (x
    y)[w(p)   c]      ( .  )
whichmeansthatthestrategyx  isfavoredagainstanyalternativestrategyatany
frequency.
C             N                                           
Forwell-mixedpopulations,w(x)istheratioofthenumberofindividualswho




    x
=     e
 R R( )  ( .  )
UsingEq.( .  )andtheNashconditionw(x ) = c,wehavee R R( ) =   c
andR( ) = (    x )c. WethenobtaintheNashEquilibrium
x
  =   +
ln(    c)
cR 
  ( .  )
whichisplo edin gure . . .  isequationholdsfor    c   w( )(recall,
w( ) =     e R w( )). Cases and abovecoverthealternatives.




E(x) = N xc + (    x)     [    w(x)] + w(x)        ( .  )
= N[xc + R( )]  ( .  )
= N
[
xc + (    x)(    e




   xh =       R .












dx    ;that
is,that nalinfectionsizedecreaseswithvaccinationcoverage. Furthermore,




eR R( )    
eR R( )   (    x)R 
  ( .  )









isnegativeforc    andx   xh.
SinceE(x)decreasesforx   xh andincreasesforx   xh,thesociallyoptimal
vaccinationlevelispreciselyxh.
Foranyc   (   ),theNashequilibriumfallsshortofthesocialoptimum,
leadingtothewell-knowndilemmaofvoluntaryvaccinationinapopulationof
sel sh,rationalindividuals.
E        R                        
Fora xedrelativecostofvaccination,theNashequilibriumincreaseswithrising
R  ( gure . . ): givenahigherriskofinfection,rationalindividualsaremore
likelytovaccinate. InthelimitingcaseR     ,unvaccinatedindividuals
cannotfree-rideontheimmunitygeneratedbyothers,andsotheyeventuallyget
infected. Inthiscase,theNashequilibriumandsocialoptimumconvergeto
   %vaccination. FortheoppositelimitingcaseR     ,individualshavezero





















Figure 4.5.5: Nash equilibrium as a function of relative cost of vaccination
cost c with diﬀerent disease transmissibility R . The horizontal lines corre-
spond to socially optimal vaccination levels.
riskofinfection,sothattheNashequilibriumandsocialoptimumagainagree 
nooneisvaccinated.






comparisonrule,whichpreferentiallycopiesotherswithhigherpayoﬀs[   ].
Eachround,arandomlychosenindividualiselectsanotherrandomindividualj
   asrolemodel,andcomparesherownpayoﬀtothatoftherolemodel. Individuali
adoptsthestrategyofindividualjwiththeprobabilitygivenbytheFermi
function
φ(si   sj) = f(Pj   Pi) =
 
  + exp[ β(Pj   Pi)]
  ( .  )
where βrepresentstheintensityofselection.  epopulationcanchangeonlyif
individualsiandjhavediﬀerentstrategies. Hence,theprobabilitythatthe
numberofvaccinatedindividualsincreasesfrommtom +  (denotedT+
m)and







N   m
N
{
[    w(m N)]
 
  + e β(PA PB ) + w(m N)
 
  + e β(PA PB )
}
 
( .  )
wherePA isthepayoﬀofvaccinatedindividuals,PB  thepayoﬀofunvaccinated
(andhealthy)individuals,andPB  thepayoﬀofunvaccinated(andinfected)
individuals(seeTable . . ).
Forlargepopulations[   ],thisprocesscanbeapproximatedbyastochastic
diﬀerentialequationwithdri T+




m + T 
m) N,
yielding
_ x = x(  x)
{














x(    x)
N
ξ
( .  )
wherex = m Nisthefractionofvaccinatedindividualsandξ isGaussianwhite
noisewithvarianceone. ForN    ,thestochastictermvanishes. Asaresult,
   Table 4.5.1: The fraction of individuals with diﬀerent states and their corre-
sponding payoﬀs.
vaccinated unvaccinatedandinfected unvaccinatedandhealthy
fraction x R( )     x   R( )
payoﬀ PA =  c PB  =    PB  =  
forlargepopulations,wecanusethedeterministicapproximation
_ x = x(    x)
{










( c +  )
]}
 
( .  )
Atequilibriumwhereafractionxisvaccinated,thefractioninfectedis
expectedtobeR( )(asgiveninEq.( .  )),andthefractionthataresuccessful
free-riders(unvaccinatedandhealthy)isexpectedtobe  x R( )(seeTable
 . . ).
A.F        β, wehavetanh(βx)   βx.  usEq.( .  )simpli esto
_ x = x(    x)
[











x(    x)[w(x)   c]  ( .  )
 ereplicatordynamicsisrecoveredinthislimit, β ≪  ,butwiththetimescale
adjustedbyafactor
β
 . Foranyvaccinationcost    c   w( ),thesystem
convergestotheinteriorequilibriumx  =   + ln(    c) (cR ),whichis
evolutionarilystableasremarkedabove.
   B.F        β:
B . F  c    (c     β), 
βc
     , Eq.( .  )becomes





c[    w(x)] + w(x)
]
  ( .  )
whichhasastableinteriorequilibriumx  =     (  +
βc
  )ln(  +
βc
  ) (
βc
  R ). For




R  . Comparing
thisapproximationtotheNash






B . c    (c         β),  
β(  c)
     , Eq.( .  )becomes
_ x = x(    x)
{
 [    w(x)] +
β
 
(    c)w(x)
}
  ( .  )
 ethirdfactorinEq.( .  )equalszeroforvaccinationlevel
~ x :=    
( +β(  c))ln(
 +β(  c)
β(  c) )
 R  . Ifthisvalueispositive,thenthestableinterior
equilibriumisx  = ~ x;otherwise,x  =  .
B . F              c(  β   c         β), thevaccinationlevel
Eq.( .  )dependsli leon βandcanbeapproximatedas
_ x = x(    x)[ w(x)    ]  ( .  )
   whichhasastableinteriorequilibriumx  =      ln 
R  .  ereforethevaccination
levelhasaplateauat     ln 
R  forlarge βandintermediatecvalues.
Noticethatatc =    ,x  =      ln 
R  isanequilibriumforany βvalue
( gure . . ).
Figure . . showstheeﬀectsofselectionstrength βandR  onequilibrium
vaccinationcoverage( gures . . aversus . . c)and nalepidemicsize






outcome(cf.  gures . . aand . . c).




scale-freenetworkmodel[  ]. Scale-freenetworksgenerallypossesslarger
degreeheterogeneitythanrandomgraphs,leadingtomoreseverepersistenceof
epidemicoutbreaks,makingherdimmunitymorediﬃculttoachieve(cf.  gures
 . . and . . ). Asaconsequence,networkheterogeneityfurtherpromotes
individuals’vaccinationonscale-freenetworks( gure . . ).  erangeofcthat
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Relative cost of vaccination, c
  = 1
  = 10
(b)
  = 1
  = 10
 
 
Relative cost of vaccination, c
(d)
Figure 4.5.6: Imitation dynamics in a large, well-mixed population (diﬀusion
approximation). Upper panels (a), (c) show the equilibrium vaccination level,
as a function of relative cost of vaccination c with diﬀerent intensities of se-
lection β. Lower panels (b), (d) show the ﬁnal epidemic size, as a function of
relative cost of vaccination c with diﬀerent intensities of selection β. Parame-
ters: (a)(b) R  =    , (c)(d) R  =  .
   promotes    vaccinationislargerthaninthecaseofrandomgraphs(for
β =  : c      forscale-freeversusc      forrandom;for β =   : c      




 . . d).  eparticularstructuralcharacteristicsoftheBarabási-Albertscale-free
networkmodelseemtocomplicatethispa ernslightly,inthatthemostlikely
free-ridersactuallyhaveintermediatedegree(k =      in gure . . d)rather








threshold( gure . . a)andthe nalsizeoftheepidemicgrows( gure . . b).
Forin uenza,theestimatedrelativecostofvaccinationtoinfectionislessthan
   ,whichisapproximatelythethresholdfoundinthe β =   case. Misperceived
vaccinationrisksandindividualvariationina itudestowardsvaccinationmay,
however,tiptheeﬀectivevalueofcabovethisthreshold.















































































Relative cost of vaccination, c
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Relative cost of vaccination, c
   = 1
   = 10
(b)
Figure 4.5.7: Vaccination dynamics on scale-free networks. Left panels show
the fractions of (a) vaccinated and (b) infected individuals as a function of
relative cost of vaccination c with the intensity of selection β =   and   . Right
panels: (c) Snapshot of a single simulation on a scale-free network. The size
of a node corresponds to its degree. Blue nodes are vaccinated, yellow are in-
fected, and red are successful free-riders. (d) The frequency of vaccination on
a scale-free network, as a function of the number of social contacts an indi-
vidual has (node degree). Parameters: (a)–(d)average degree  k =  , disease
transmission rate r =     , recovery rate g =    , I  =   ; (a)(b)(d) N =     ,
(c) N =    ; (c)(d) c =    , β =   . Results in panels (a), (b), and (d) are
averaged over 100 runs. The lines in (a) and (b) are visual guides.
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Frequency-dependentsele ioncanlead
toevolutionofhighmutationrates
 .  I           
I                       -                           ,most
mutationsareneutralordeleterious,andwemaygenerallyexpectmutationrates
toevolvetolevelsaslowasfeasible,givenphysicalconstraintsandcosts
associatedwithfaithfulDNAreplication[   ,   ,   ,   ]. However,
theoretical[  ,  ,   ,   ,   ,   ,   ,   ,   ]and






frequentenoughtooutweighdeleteriousload[ ,  ,   ,   ,   ].
Moststudiesthatexaminetheroleofenvironmentalchangeinmutationrate
evolutionhaveconsideredexogenous uctuationsinthe
environment[   ,   ,   ]. Morerecently,researchershavestudiedhow
host-parasitecoevolutionmaygenerateanenvironmentalfeedbackloopthat




phenotypes[   ],cangeneratecomplex,unstabletrait
dynamics[   ,   ,   ,   ,   ],whichmayinturngenerateselection
pressuresonthemutationrate. Frequencydependenceiscommonin
nature[   ]andoccursinawiderangeofinteractions: predator-prey
systems[  ,   ,   ],host-parasitesystems[   ,   ],niche
competition[  ,   ],cooperativedilemmas[  ,   ,   ,   ,   ],and
nontransitivecompetitiondynamics[   ,   ,   ,   ].
 eevolutionofhighmutationratesmaybeanimportantforcedetermining








mutation-selectionequilibrium[ ,   ]. UnlikeMuller’sratchetandtherelated








theory[  ,   ,   ,   ,   ,   ,   ,   ]andadaptive
dynamics[  ,   ,   ,   ,   ]to ndandunderstandevolutionarilystable
mutationrates(ESMRs,   ). Wepreviouslyintroducedourmathematical
frameworkandusedittoshowthatiftraitfrequenciesconvergetoastable
equilibrium,thenmutationratesevolvedownward[ ].  isresultextendsthe
classicalobservationthatmutationratesevolvetozeroinconstant tness



















mutation,thusgivingita tnessadvantageoverotherstrains.  isscenario,in
whichasteadysupplyofbene cialsubstitutionscanselectforhighmutation
rates,issimilartothosecontemplatedbyotherauthorsinvestigatingconstant
selection[   ,   ,   ]. Weprimarilystudythisscenarioinanidealizedin nite
   population,usingreplicator-mutatorequationstotracktheexpectedpopulation
trajectory. Strainswithrelativelylowmutationratesfaceadisadvantageduring
eachsubstitutionevent,asittakeslongerforthemtoproducetheoptimaltraitat
highfrequency.  isidealizedframeworkcontrastswith nite-population
modelsinwhicheachstrainmustwaitforabene cialmutationtoarrive
stochastically,a erwhichthemutatoralleleassociatedwiththatbene cial
mutationmayhitchhiketo xation[   ,   ]. Tohighlighttherelevanceofour
in nite-populationmodelto nitepopulations,wedemonstratethatboththe
ESMRandtheinvasiondynamicsofmutatorlineagesinthein nite-population














   recombination. Moregenerally,whilesuﬃcientlystrongrecombinationcandrive
theESMRtozero,therestillexist,foranyfrequencyofrecombinationlessthan
unity,evolutionarygamesthatselectforpositivemutationrates.  is nding












rapidevolutionofmutationrates[  ,   ]. Appealingtothisseparationof
time-scales,wefocusoncompetitionbetweenjusttwomutationratesatatime,





   fromthedynamicsoftheresidentandinvadertraitdistributions.
 . .  S        -     :                       
Frequency-dependentcompetitionisstudiedusingevolutionarygame








thenonnegativecolumnvectorx = (x      xn)T,the tnessoftraitiis(Ax)i.







presentinthepopulation,thoughpossiblyatverylowfrequency[   ,   ]:
_ ri = ri(Ar)i   φri  ( . )
   Fig.  . . (A)depictsonepossibletrajectoryofthereplicatorequationswhere
payoﬀmatrixAdescribesarock-paper-scissorsgame(formallyde nedbelow,Eq.
( . )).  isisthesimplestmodelofcyclicalpopulationdynamics.
 ereplicator-mutatorequationsmodifythisbasicmodelbyassumingthat
eachoﬀspringadoptsthetraitofitsparentwithprobability    uandotherwise
choosesfromamongalltraits(includingthatofitsparent)withequal
probability[   ,   ,   ]:
_ xi = (    u)xi(Ax)i +
u
n
φ   φxi  ( . )




interactions;spatialpopulationstructure[  ,   ]andalterationsinthepayoﬀ
matrix[   ]alsopromotecoexistence.
 . .  C                              
Toextendthismodeltocompetitionbetweentwomutationrates,wedescribe
thesystemstatebytwononnegativevectorsr = (r      rn)and
z = (z      zn),givingtherelativeabundances(withrespecttothewhole
population)ofresidentsandinvadersofeachtrait. Wedenotethetotalrelative
   Rock Paper
Scissors Scissors!
Rock! Paper! Rock Paper
Scissors Scissors!
Rock! Paper! (A)Withoutmutation (B)Withmutation
Figure 5.2.1: Example trajectories depicting evolution of the population ac-
cording to (A) the replicator equations ( . ) and (B) the replicator-mutator
equations ( . ) with n =   traits. Payoﬀ matrix A determines a rock-paper-
scissors game (described in Eq. ( . )). Each trajectory is drawn on the “pop-
ulation simplex,” where each point represents the trait distribution of the
population at a particular time: points close to a vertex represent popula-
tions consisting mostly of one trait, while points close to the center of the
simplex represent populations with a nearly equal mixture of traits. The tra-
jectory in panel (A) starts near the center of the simplex and proceeds for 50
timesteps, spiraling outward and converging to the simplex boundaries. Once
near the simplex boundaries, the population spends most of the time consist-
ing mostly of one trait, and it transitions infrequently to the next trait in the
cycle. The trajectory in panel (B) starts at the lower-left vertex, representing
a population of 100% rock, and proceeds for 100 timesteps, spiraling inward
and converging to a limit cycle. Once on this cycle, the population is always
highly polymorphic, and the trait frequencies oscillate periodically. Compar-
ing this limiting behavior to that of panel (A) shows that mutation acts to
maintain trait diversity. The light blue vectors in both panels show the action
of selection, directing the population counterclockwise around the simplex as
determined by the game. The short red vector in panel (B) shows the action
of mutation, pointing toward the center of the simplex, generating increased
trait diversity. The trajectory determined by the replicator equations follows
the selection vectors (A). The trajectory determined by the replicator-mutator
equations follows the sum of the selection and mutation vectors — the re-
sultant vector, in purple (B). Thin gray lines are axis guides meeting at the
center of the simplex. Parameters: Fitness beneﬁt for winning a =     (both
panels); mutation rate u =      (panel B only).








Wenotethatateverypointintime,R + Z =  .  eseassumptionsleadtothe
dynamicalequations
_ ri = (    u)ri(A(r + z))i +
u
n
Rφr   φri 
_ zi = (    u
′)zi(A(r + z))i +
u′
n
Zφz   φzi 
( . )
where
φ = (r + z)







































φz   φ
)
dt  ( . )
 esede nitionscoincidewithothernotionsof tnessastime-averaged
exponentialgrowthrate[   ,   ]. Asapracticalma er,thedynamics( . )can
beusedtocomputepositiveinvasion tnessvaluesonlyifthelimitingvalueofT
usedinequations( . ),( . )isnotsolargeastoallowZtoreachasubstantial
frequency. InEq. ( .  )inMethodswedescribemodi eddynamicsthatkeep
theinvaderforeverrare,avoidingthiscomplication.
Replicator-mutatordynamicscanyieldawidevarietyofbehaviors,including
multiplea ractors,limitcycles,andchaos[   ,   ,   ]. Invasion tnessis
thereforediﬃculttocomputeingeneralandmaydependoninitialtrait
distributions. Incertaincases,thelimitstakeninEqs.( . ),( . )donoteven














population(N =    )(seeMethods).
 . .  L       -     :                                 
Strainu′ isfavoredtoinvadestrainuifsu(u′)    . Inallcasesexaminedinthis
article,iftheinvadingrateu′ issuﬃcientlyclosetou,aninitiallysuccessful









againstinvasionbyanyothermutationrate;thatis,forallu′ ̸= ~ u,itisthecase
   thats~ u(u′)    . WhileitispossibleformultipleESMRstoexist,allexamples
thatweexplorehavenomorethanoneESMR.Whenitexists,theESMRcanbe
thoughtofastheuniquemutationratefavoredbyevolution[ ].
 . .  U                                 
 etwo-strainreplicator-mutatorequations( . )treatthemodi erlocusas
determiningthemutationrateonasingletraitlocus. Inanactualgeneticse ing,
amutatorallelemaytargetothergenomicregionstocauseunconditionally
deleteriousmutations.  iseﬀectisknowntoweaken oreliminate 




equilibrium[   ]. Toensurenonnegative tness,wealsoaddasuﬃcientlylarge






realized[  ,   ,   ].
    . .  R            
Recombinationbetweenthemutation-controllinglocusandthetraitlocusisalso
knowntoweakenoreliminateselectionforhighmutation
rates[  ,   ,   ,   ]. Recombinationcanbemodeledusingthefollowing































  φri 
_ zi =
(
























  φzi 
( . )
wherefi;u isthe tnessoftraitisubjecttomutationrateu,
fi;u = A(r + z)i + f    uℓ.  e rsttwolinesofeachequationprovidethe
contributionfromnon-recombinantandrecombinantindividuals,respectively.
    .  R      
 . .  C                                             
Rock-paper-scissorsgamesareasimpleclassofinteractionsthatcanexhibit
cyclicalreplicator-mutatordynamics[   ]. Westudyann-traitgeneralizationof
thegame(n    ),withn   npayoﬀmatrixAgivenby
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  ( . )
Foreachtrait,thereisanothertraitthatgetsa tnessbene ta    fromit(that
is,thereisa“scissors”forevery“paper”),whileallothertraitsdoworse.  e
traditionalrock-paper-scissorsgamecorrespondston =  . Selectioncausesthe
populationtocyclethroughsuccessivetraits,whilemutationincreases









(usingEq.( . )),this xedpointisstableifa   n    . Wefocusonthecase
a   n    ,whichguaranteesthatanonmutatingpopulationwillproduce
unstablecyclicaldynamics: anypopulationthatstartsasamixofalltraits(but
   notatthe xedpoint),convergestoaheteroclinicorbit[   ],meaningthatit
cyclesbetweennearly-monomorphicstatesinorder,aseachtraitisdisplacedby
















)  ( . )
theinterior xedpointbecomesastableequilibrium(calculationinOnline
AppendixB),atwhicheachtraithas tness  +a
n .
M                           
Beforecarryingoutanynumericalsimulationsofmutationratecompetition,we
showthatthezeromutationrateisevolutionarilyunstableintheabsenceof




consistingofasingletrait,whichhas tnessφr =  ,givenbythediagonalentries
ofpayoﬀmatrixA. Whiletheinvadingstrainisofnegligiblesize,trait tnessesare
thereforeconstant:  fortheresidenttrait,  + aforthefavoredtrait,and forall
   othertraits.  edynamicsoftheinvadingstrain,givenby ( . ),canthenbe
rewri eninmatrixformas





     
     
 
    n  
n u′ u′
n     u′
n
u′
n     n  
n u′     u′
n
. . .








     
     
 
  ( .  )
andFisadiagonalmatrixwithfi,the tnessoftheithtrait,astheithdiagonal
entry.
Basedonthisdynamic,invasion tnesss (u′),de nedby ( . ),isequaltothe
largesteigenvalueoftheproductmatrixQu′F,minus . Sincethismatrixhasonly
twononzerocolumns,theconditionforinvadersuccess,s (u′)    ,canbe
computeddirectlyas
    u
′  
a(n    )
(  + a)(n    )




   mutationratelessthan a
 +a caninvadenonmutatorsforanycombinationofaand
n.  isconditioncanbederivedbytakingthelimitasn    ofEq.( .  ),or
alternatively,byrecognizingthatthemutatingstrainincursa tnesscostequalto
themutationrateu′,buta ains tnessadvantage a
 +a versustheresident(relative
tothe tnessoftheoptimaltrait).  emutatorcaninvadewheneverthisbene t
exceedsthecost.
 eanalysisissimilarifrecombinationcandloadℓareintroduced,again
assuminga   n    .  eequationdescribinginvaderdynamics,analogousto
( .  ),isnow
_ z =
(
CQu′Ff    I(  + f  + u
′ℓ)
)
z  ( .  )





     
     
    c + cri fori = j 
cri otherwise.
Inthepresentscenario,recallthatr  =  andri =  foralli    . Invasionnow
succeedsifandonlyifthelargesteigenvalueofCQu′Ff  exceeds  + f  + u′ℓ. In
   thecasef  =  ,thisconditionsimpli esto
    u
′  
a(    c)(  +  )    c
a(    c)(    ℓ) +  (    c + ℓ)
  ( .  )
where  = nℓ + (    c)(n    ). Selectionfavorspositivemutationratesifthis
thresholdvalueofu′ ispositive,whichoccurswhen a
 
 + +a   c. Forarbitrarily
highnandℓ,thisboundcanbenoworsethan a
 +a   c. Ifthebaseline tnessf  is
positive,however,theexpressionforthemaximuminvadingu′ admitsnosimple
formula. Selectionisguaranteedtofavorpositivemutationratesifthelargest
eigenvalueofCQ Ff  exceeds  + f ,whichisequivalentto
a
  + f  + a
  c  ( .  )







   C                                                      ,        
                                                 
Interactionbetweentwostrainsofnonzeromutationratesu    u  introduces
newfeaturesintotheevolutionarydynamics. Ournumericalanalysisof ( . )
(seeMethods)hasshownthreepossibleoutcomes:
(i)  ehigher-ratestraincaninvadeandreplacethelower,andnotvice-versa,
su (u )       su (u );
(ii)  elower-ratestraincaninvadeandreplacethehigher,andnotvice-versa,
su (u )       su (u );




betweenstrainswithmutationratesu =     andu′ =     ,usingn =  and
a =    .  efaster-mutatingstrainsucceedsbecauseitisbe erabletoadaptto
thechanging tnesslandscapecreatedbythepopulationdynamics,showninFig.





   timesteps    and     inthescenariodepicted,duringwhichtimethe
invaderreaches : paritywiththeresident. Attheendofeachepisode,the
substitutionhasoccurredintheresidentstrainaswell,causingmutationrate
evolutiontopause,butalsose ingthestageforfrequency-dependentselection
tofavoranewsubstitution.  eaverageslopeofinvadergrowthinFig.  . . in






betweenmutationrateso entakestheformofacooperativedilemma[  ],with
thestrainofhighermutationrateplayingtheroleofdefector. Whensuchastrain
invadesandgrows,itincreasespolymorphisminthepopulation,decreasing
overallpopulation tness. Fig.  . . showshow tnessdependsonthe
frequenciesofAandB. Speci cally,whenAisabundantandBisrare,thetwo
strainshavetime-averaged tnessesφA =     ,φB =     . WhenBisabundant
andAisrare,the tnessesareφA =    ,φB =     . Wri eninmatrixform,this
“Mutator’sDilemma”is
   Rock Paper
Scissors Scissors!
Rock! Paper! Rock Paper
Scissors Scissors!
Rock! Paper! (A) (B)
Rock Paper
Scissors Scissors!
Rock! Paper! Rock Paper
Scissors Scissors!
Rock! Paper! (C) (D)
Figure 5.3.1: Dynamics of a faster-mutating strain successfully invading a
slower-mutating resident. Trait distributions of residents (blue trajectories)
and invaders (red trajectories) are shown at time intervals (A)   to   , (B)    
to    , (C)     to    , and (D)     to    . For each interval, the trajectories
proceed counter-clockwise, indicated by shading from darker to lighter. Thick-
ness of each curve indicates relative abundance of the corresponding strain;
the thicker trajectories of the invaders in (C) and (D) partially obscure the
resident trajectories. At t =  , the resident strain is at the point on its stable
limit cycle where frequency of Rock is greatest, and the invading strain is at
100% Scissors with a total frequency of     . Invaders initially decline due to
their disadvantageous trait distribution, but eventually sweep to ﬁxation. Thin
gray lines are axis guides meeting at the center of the simplex. Parameters:
Resident mutation rate u =     , invader mutation rate u′ =     , ﬁtness
beneﬁt for winning a =    , and n =   traits.













































































































































Figure 5.3.2: Ratio of faster-mutating invader frequency to slower-mutating
resident frequency (log-scaled), showing the indirect route to ﬁxation of a mu-
tator allele. The slope equals the relative ﬁtness of the invading strain. The
shaded regions correspond to the panels of Fig. 5.3.1, highlighting the four
phases of a successful mutator invasion: (A) a possible initial decline due to
disadvantageous invader trait distribution, (B) a ﬁrst growth phase in which
ﬁtness ﬂuctuations result from trait dynamics of the slower-mutating residents,
(C) a rapid transition as invader abundance surpasses resident abundance, and
(D) a second growth phase in which ﬂuctuations are due to the now-abundant
invaders. The top-left inset shows one ﬂuctuation during (B), corresponding
to one trait substitution; this ﬂuctuation includes a small dip and a rapid rise
in invader frequency. The bottom-right inset shows one ﬂuctuation during
(D), also corresponding to a substitution of the predominant trait; here fre-
quency increases smoothly since trait substitutions are less dramatic. Both
insets use a linear scale. Parameters (same as Fig. 5.3.1): Resident mutation
rate u =     , invader mutation rate u′ =     , ﬁtness beneﬁt for winning
a =    , and n =   traits.

































































Figure 5.3.3: Time-averaged ﬁtnesses of fast-mutating invaders (upper
curve) and slow-mutating residents (lower curve), as functions of invader fre-
quency. To calculate the strain ﬁtnesses at a particular invader frequency,
equation ( . ) was modiﬁed so that the resident / invader frequency remains
constant, permitting only trait ﬂuctuations within a strain (see equation ( .  )
in Methods). Evolution always favors the invading strain, but each strain’s ﬁt-
ness decreases monotonically with invader frequency; mutator competition is
therefore a cooperative dilemma. Inset: Average ﬁtness of the population os-
cillates and falls over time, as invader abundance increases. Parameters (same
as Figs. 5.3.1, 5.3.2): Resident mutation rate u =     , invader mutation rate
u′ =     , ﬁtness beneﬁt for winning a =    , and n =   traits.
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A  .    .  







invasibilityplotFig. . . (A)showsinvasion tnesssu(u′)asafunctionofuand








Forthetraditionalrock-paper-scissorsgame(n =  )with    a    ,our
simulationsshowthatanyresidentstrainofmutationrateu   uΩ =  +a
 +a canbe




    




   Resident mutation rate!


















































0! 0.05! 0.1! 0.15! 0.2! 0.25!
Figure 5.3.4: Pairwise invasibility plots describe the adaptive dynamics of
mutator competition (A) without recombination and (B) with recombination.
Panels show contour plots of invasion ﬁtness su(u′), computed using Eq. ( .  )
in Methods, as a function of resident and invader mutation rates u and u′.
The white x’s in (A) mark the region of bistability, where neither mutation
rate in a pair can successfully invade the other (negative invasion ﬁtness at
a point and at its reﬂection across the diagonal). The black +’s in (B) mark
the region of coexistence, where both mutation rates in a pair can successfully
invade the other (positive invasion ﬁtness at a point and at its reﬂection).
Recombination reduces the ESMR from ~ u        to ~ u       . Since dynamics
are discontinuous at resident mutation rate u =  , invasion ﬁtness against
resident nonmutators is plotted separately, in Suppl. Fig. 7.4.1. Parameters:
n =  , a =    , c =   (A) or     (B).





Forthegeneralizedgamewithn    ,oursimulationsconsistentlyshowa
singleESMR~ ubetween anduΩ,whichisalsoanevolutionaryendpoint[ ],as
plo edinFig.  . . .  evalueof~ uincreaseswitha(uptothepointwhere




Fig.  . . plotstheeﬀectiveinvasion tnessimpliedbythe xationprobabilityof
theinvadingstrain,inapopulationofsizeN =    ,wheretheinvaderstartsasa




thantheneutralvalue  N.  eESMRisapproximatelythesameinboththe
in nite-populationand nite-populationscenarios(~ u       ,seeFigs.  . . and
 . . ).  emagnitudesoftheeﬀectiveinvasion tnessesareoverallsmallerinthe
 nitecase,likelyowingtoadditionalstochasticeﬀectsintroducedbymutator
dynamics;forinstance,thetimethataloneinvadermustwaitbeforeitproduces






Fitness beneﬁt for winning (a)!
ESMR!











Figure 5.3.5: The ESMR increases with ﬁtness beneﬁt a (plotted on a log
scale) and decreases with number of traits n; no recombination is shown in
this ﬁgure. Points show simulated ESMR values (see Methods), and solid lines
show approximations using Eq. ( .  ). Dashed lines plot uΩ, which is “quasi-
stable” for cases where an actual ESMR is not deﬁned (see text). For the case
n =   (black), there is no ESMR and only uΩ is shown. For n =   (dark red)
and n =   (not shown), the ESMR increases with a until it reaches uΩ; for
higher values of a there is no ESMR. For n =   (medium red), the ESMR
appears to converge to uΩ as a increases. For n     (n =    in pink), the
ESMR is bounded below uΩ, which is greater than    .
   abene cialmutationvariesbetweenruns. Ingeneral,thisfactorsubstantially
in uencessurvivaland xationofaninvadingmutatorstrain[   ,   ].
R                     ESMR
Fig.  . . (B)showstheeﬀectofrecombinationonaninvasion tnesslandscape,















   Resident mutation rate!



















































Figure 5.3.6: Stochastic simulation conﬁrms that deterministic replicator-
mutator-recombinator equations can be used to determine the structure of
mutator competition in ﬁnite populations without (A) and with (B) recom-
bination, as long as ~ uN ≫  . Panels show contour plots of eﬀective invasion
ﬁtness se;u(u′), computed using Eq. ( .  ) in Methods, as a function of res-
ident and invader mutation rates u and u′. If se;u(u′)    , then the invader
has ﬁxation probability greater than neutral probability   N; the opposite is
true for se;u(u′)    . The white x’s in (A) mark the region of bistability, where
neither mutation rate in a pair is favored to invade the other (negative eﬀec-
tive invasion ﬁtness at a point and at its reﬂection across the diagonal). The
black +’s in (B) mark the region of coexistence, where both mutation rates
in a pair are favored to invade the other (positive eﬀective invasion ﬁtness at
a point and at its reﬂection). The black region between positive and negative
ﬁtness shows nearly neutral competition (eﬀective invasion ﬁtnesses within (A)
         or (B)          of zero). Population size N =    , other parameters
(same as Fig. 5.3.4): n =  , a =    , c =   (A) or     (B).
   U                                          ESMR
Introductionofunconditionallydeleteriousmutationwithatargetsizeℓfurther
decreasestheESMR.Intheabsenceofrecombination,theESMRscalesroughly
as  ℓ. Withrecombination,itdecreasesbyalargernegativepowerofℓ(Fig.
 . . ).
E            ESMR                           
TogaininsightintohowtheESMRdependsonthecostsandbene tsof
mutation,wedevelopananalyticalapproximationoftheESMRasafunctionof
 tnessbene tforwinningaanddeleterioustargetsizeℓ. Weadaptanargument
madeinafrequency-independentse ing[   ]thatitselfhasitsrootsinan
earliermodeloftrade-oﬀsbetweentimerequiredforadaptivesubstitutions
(minimizedbyahighmutationrate)andmutationalload(minimizedbyalow
mutationrate)[   ,   ].
We rstconsiderthecasewithoutunconditionallydeleteriousmutation,
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Figure 5.3.7: The ESMR declines with the target size of unconditionally dele-
terious mutation (ℓ) and the recombination rate (c). Solid trend lines (shown
for all series except c =      ) on the log-log axes track the decline of ESMR
with ℓ; the slope for the series c =   is approximately   , as predicted by
Eq. ( .  ). Series with higher c have steeper slopes and lower intercepts. The
horizontal dashed line at u =           represents a typical per-site, per-
replication mutation rate for eukaryotes; below this level, simulation was not
reliable due to numerical error in the stiﬀ system. The dotted line for the se-
ries c =       is a rough estimate; only one reliable ESMR value was com-
puted. Though the ESMR falls rapidly with increasing c and ℓ, Eq. ( .  )
guarantees a positive ESMR for any c   a
 +a =  
 . Parameters: n =   traits,
ﬁtness beneﬁt for winning a =    , baseline ﬁtness f  =   .





u .  isratiorepresent’stheinvader’srelativeadvantagedueto
mutation;ifu′   u,thentheinvaderhasa“headstart”intheracetoincreaseits
frequencywithinthesoon-to-be-majoritytrait.
Astraiti +  grows,itsrepresentativesineachstrainexperienceamutational
loadpergenerationequaltotheirrespectivedeleteriousmutationrates un  
n
fortheresident,u′ n  
n fortheinvader[   ,   ]. Sincenearlyallmutationsaway
fromtheoptimaltraitarelethal,thiscostisfullyrealized,withnegligibledelay




load)duringthislegise u′ fT n  










T(u) f(u)(n    )
  ( .  )
Iftherate~ uisanESMR,thenthemutationratebestequippedtoinvade~ uis~ u
   itself.  us~ usatis es
~ u f(~ u)  
n 
T(~ u)(n    )
  ( .  )
Both f(u)(calculatedasthegeometricmeanoftheoptimaltrait’s tness)and
T(u)canbeobtainednumericallyasfunctionsofuthroughsimulationofthe
residentreplicator-mutatorequations( . )(seeMethods).  ismethodyields
anaccuratepredictionofESMRvalues,particularlyforsmalla(Fig.  . . ).  e
ESMRincreaseswitha,unlessitreachesuΩ,a erwhichthereisnoESMR,as




 f(u)   (  + a)
(
    u






  ( .  )
 isapproximationisbasedonthenotionthatthetransientequilibriumstate
describesthetypicaltraitdistributionandrepresentsamutation-selection
balance,atwhichonetraithasfrequency      u + u
n andtheremaining
populationisdividedroughlyequallyamongtheotherstrategies. Usingthis
approximationinEq.( .  )givesanESMRestimatorthatonlyrequires
measurementoftheperiod.  isapproachisappropriateforn    anda ≪  ,
butEq.( .  )substantiallyoverestimates tnessforlargeraorsmallern,
producinganESMRpredictionwellbelowtheactualvalue(Suppl. Fig. . . ).







resident,withureplacedbyu′ fortheinvader.  eESMR~ uthensatis es
~ u f(~ u)  
n 
T(~ u)(n(  + ℓ)    )
  ( .  )
whichscalesas  ℓinthelimitoflargeℓ. Numericalsimulationcon rmsthis
asymptoticrelationshipbetween~ uandℓ(Fig.  . . ,c =  ).
 .  D         








cyclicalcompetitionsuchasthatconsideredinFig. . . ( tnessbonusa =    
asafractionofmaximum tnessf  +   + a =     correspondingtoaselection
coeﬃcientof   %)selectsforparticularlyhighmutationratesintheabsenceof
recombination,evenforlethalmutationtargetsizesof    –    sites(Fig. . . ).
 ismechanismisonemeansbywhichglobalhypermutatorsmaybeselected
   for,anditmayhelpexplaintheprevalenceinthewildofmismatch
repair-de cientbacterialstrainswithgenome-widemutationrates   -to
     -foldthatofwildtype[  ,   ]. Recentexperimentalandtheoreticalwork
suggeststhathost-pathogencompetition,whichcanbethoughtofasatypeof
cyclicalcompetitionwithtwoseparatepopulations,alsosupportsevolutionof
highmutationrates[   ,   ,   ].
Whetheramutatorstraincaninvadearesidentwithlowmutationrate
dependsontheperiodoftheresident’straitsubstitutions;ashorterperiodfavors
faster-mutatinginvaders(Eq.( .  )). Ifthemutatorachieves xation,it
generallydoessoinasuccessionof“mini-sweeps,”eachonecorrespondingtoa
singletraitsubstitution(Fig. . . ). Pa ernsofepisodicpartialsweepshavealso











alleles[   ,   ,   ,   ],andourmodelagreeswithothersinthisrespect. We
   introducedandanalyzedreplicator-mutator-recombinatorequations( . )to
concludethattheselectiveadvantagefromwinningthecyclicalcompetition
mustexceedtherecombinationfrequencybetweenthetraitandmutatorlociin
orderforamutatingstraintobefavoredovernonmutators(Eq.( .  )).  is
conclusionholdsregardlessofthedeleteriousloadincurred.  efavoredpositive
mutationratesmay,however,becomeverysmallasloadandrecombination
increase: Foraselectioncoeﬃcientof   %anddeleterioustargetsizeof   ,
introducingrecombinationatadistanceof   centimorgansbetweenthetwo
locicausestheESMRtodropfrom         to    . Doublingthedistanceto




(Figs. . . (B), . . (B))byallowinga“divisionoflabor”inadaptation:
bene cialtraitsarisemorefrequentlywithinthehigh-ratestrain,buttheyare






mutator’schanceof xation[   ]. Stablecoexistencewasnotobservedinthat
study,however,asthesimulatedgenomecontainedfewsitesatwhichbene cial

















Fig. . . );iftherearemanygenerationsbetweenmutations(eventhosecaused
bythehigh-ratestrain),then tnessdiﬀerencesbetweenthetwostrainswillbe
negligibleforlongperiodsoftime,duringwhichmutationratecompetition
wouldbegovernedbyneutraldri [   ];thisscenarioisnotcontemplatedby
ourmodel. Second,theframeworkrulesoutcasesofrunawayselectionforhigh
   mutationrates: ifthemutationrateisitselflabileandmostdeleteriousmutations
aremild,itispossibleforrapidincreasesinthemutationratetooccur,subjecting
thepopulationtorapid tnessdeclines(orerrorcatastrophe)whenmutational



















   mechanismbywhichmutatorallelesmayprevailbutsubvertnaturalselection.











modulatedbythefrequencyofcertainshort( bp)sequencesupto   bp









   duplicationordeletionwouldresultinadownstreamframeshi ,theincreased
mutationratecancauserapidswitchingbetweenalternategene
products[  ,   ,   ,   ,   ,   ]. Eveniftherepeatitselfdoesnotappearin
acodingregion,thesequencelengthheterozygositythatitgeneratescanincrease
nucleotidesubstitutionratesbyanorderofmagnitudewithina   bpradius,
withsmallernoticeableeﬀectsoutto   bp[  ,  ,   ].
Sincealocalmutatortendstoremainlinkedtothenearbymutationsthatit
causes,recombinationisunlikelytosubstantiallyimpedeselectionforincreased
mutation. Considerthe -traitcompetitioninFig. . . withatrait-controlling
siteattheendofa   bpeﬀectradiusofalocalmutator.  edeleterioustarget
sizeℓwouldbeontheorderof   ,thesequencelengthaﬄictedbyincreased
deleteriousmutation.  eESMRinthisscenariois~ u =         . Toobtain
 ve-foldreductionintheESMR,therecombinationprobabilitywouldneedtobe
c =         ;over   bp,thisvaluerequiresarecombinationrateof   
cM/Mb,extraordinarilyhighamongmulticellulareukaryotes,evenat








   wouldintroducegeneticincompatibilities,requiringmodi cationstothemodel.
 . .  O      
 epredictionsofourmodelapplybroadly,ascyclicalcompetitionispresentin
diversebiologicalscenarios.  estrategicdynamicsamongmalemating




types[   –   ]. Similardynamicshavealsobeenobservedintheviviparous
lizard,Lacertavivipara[   ]. E.colialsoexhibitsrock-paper-scissorsdynamics
withregardtoproductionofandresistancetocolicins,aformof
bacteriotoxin[   ,   ]. Moregenerally,cyclicalcompetitionshouldbe
commonwhereverindividualsface tnesstradeoﬀsonmultipleinteracting
dimensions,suchaslifehistorycharacters,sexualbehaviors,andsocial
behaviors[   ]. Sinceselectioncoeﬃcientsforsocialorsexualtraitstendtobe





    .  M      
 . .  N                    ODE                             
Numericalanalysisofthereplicator-mutator-recombinatorequations( . )was
doneusingMathematicaversion . forLinuxx  (  -bit),usingdefaultoptions
unlessotherwisespeci ed. Tocomputeinvasion tness,thefollowingmodi ed
dynamicswereusedtotreattheinvaderstrainasforeverrare:




φr   φrri 
_ zi = (    c)
[
















  φzzi 







i zi =  
atalltimes. Fitnesscomputationignorestherareinvader,andsofi;u = Ar   uℓ.
Fromtheresidentperspective,recombinationwithaninvaderneveroccurs,and
sotheequationfor _ ri recapitulatestheformofthereplicator-mutatorequation.
Fromtheinvaderperspective,allofthefractioncoﬀspringthatrecombinedoso
witharesident.  edynamicsweresimulatedusingtheNDSolveoption,
“MaxSteps-       ”,andnumericalintegrationofequation( . )wasdone
   usingtheNIntegrateoption,“Method- LocalAdaptive”.  epopulationstarted
withonlytrait ,andthe rst    timestepswerediscardedtoensure
convergencetothelimitingtrajectory.  etimelimitsofintegrationin( . )
werethenchosentocontainanintegernumberofoscillations(atleast  as
countedbythemethodbelow,andnotmorethan    timesteps). Inthecase
wheretheresidentwasanonmutator,therearenooscillations,andthelimitsof
integrationwere[         ].
Forthetime-averaged tnesscalculationinFig.  . . ,amodi edversionof
( . )wasusedtokeeptheinvader/residentratioconstant:
_ ri = (    u)ri (A((    Z)r + Zz))i +
u
n
φr   φrri
_ zi = (    u
′)zi (A((    Z)r + Zz))i +
u′
n
φz   φzzi 




 . .  M                               
Tomeasuretheperiodofoscillationswhenjusttheresidentstrainispresent,a
piecewiseprojectionfunction π wasdevisedtotracktheresidentpopulation
   vector’sprogressaroundthecycle:
π(r) =
 
             
             
m +
rm+  rm  
rm+rm+   rm   ifrm     rm+ ,
m  
rm   rm+ 
rm+rm    rm+  ifrm     rm+ ,
m ifrm   = rm+  
( .  )
wherem = argmax(r),m +  isreplacedwith ifm = n,andm    isreplaced
withnifm =  .  isquantityprogressesfrom ton +  ,thoughnot
monotonicallyorcontinuously,asthevectorrtraversesthecycle. Forthe
purposeofcountingthenumberofoscillations,thesmalldiscontinuitiesand
declinescanbehandledbythefollowingalgorithm: Datafromthe rst    
timestepswerenotused,toallowtheperiodtostabilize,andthenthevalueof
π(r)wascalculatedfromtimestep    to    ,inincrementsof . . Each
timestepwhere π(r)   (       )wasmarkedwithanA,eachtimestepwhere




 . .  ESMR           
Abinarysearchalgorithmwasusedto ndtheESMRviasimulationof ( . ).
Mutationratesstrictlybetween anduΩ wereexploredto ndavalue~ uthat
couldresistinvasionbothby       ~ uandby~ u     .  isanalysisisjusti edfor
thegeneralizedrock-paper-scissorsgamebasedontheobservationsthat( )ifu
   canbeinvadedfromslightlyabove,then~ u   u,( )ifucanbeinvadedfrom
slightlybelow,then~ u   u,( )ifuresistsnearbyinvaders,thenuresistsall
invaders.  eseobservationsneednotholdformorecomplicatedgames.  e
rateuΩ (   + ℓ)wasusedasaninitialguessfor~ u. Attime ,allindividualswere
oftrait andtheinvadingstrainfrequencywas    . Invasionwasdeemedtofail
iftheinvaderfrequencya er    timestepswaslessthanthisinitialvalue.
 . .  F                         
Finitepopulationdynamicsweresimulatedasafrequency-dependentMoran
processwithconstantpopulationsize   . Eachtimestep,everyindividual
interactedwitheveryindividual(includingitself),receiving tness from




reproductionevent,theoﬀspringinheriteditsparent’straitwithprobability    u
andselectedarandomtraitwithprobabilityu,whereuistheparent’smutation











for    timesteps,a erwhichthepopulationfrequenciesweresampledevery




pairofvalues(u u′),         separateinvasiona emptsweresimulated,each





     
 +s
     
( +s)N
  ( .  )
(see[  ],Eq.  .  )whereN =    isthepopulationsizeand ρisthefractionof





   high- tnessparent. Inthatcase,astrainwouldbefavoredtoinvadeagainsta
residentoftheverysamemutationrate,invalidatingtheESMRconcept.
All nitepopulationsimulationswerecarriedoutusingMatlabR    b.
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Mutationrateevolutioninreplicator
dynamics
 .  I           
T                                                       ,




   replication[   ,   ,   ,   ]. However,
theoretical[  ,   ,   ,   ,   ,   ,   ,   ,   ]and




genescodingforincreasedmutationmay“hitchhike”to xation.  esuccessof
mutatorstrainsdependsonwhetherbene cialmutationsoccurwithsuﬃcient
frequencyandstrengthtooutweighload[   ].
 eoreticalstudyofmutationrateevolutionhasfocusedprincipallyoncases
wheretheenvironmentiseitherstaticor uctuatesindependentlyoftheevolving
population. Casesof tness uctuationsgeneratedbytheevolvingpopulation
itselfremainunexplored. Such uctuationsmayarisethrough
frequency-dependentselection[   ,   ]inscenariossuchaspredator-prey
systems[  ,   ,   ](includingRedQueendynamics[  ,  ,   ,   ])
host-parasitesystems[   ,   ],cooperativedilemmas[   ,   ,   ,   ],and




replicatordynamics[   ,   ,   ,   ,   ,   ],whichstudiesthe
demographicdynamicsoftraitfrequenciesinalargepopulation,andadaptive
dynamics[  ,   ,   ,   ],whichstudieslong-termevolutionthrough





















cancoexistinde nitely.  iscoexistenceispossible andoccurs
generically wheneverthereexistsanevolutionarilystablestateofthereplicator






neighborhood[  ,  ,  ,  ,  ,   ,   ,   ,   ,   ,   ,   ,   ,   ].
Mutatorallelesofglobaleﬀect,ashavebeendiscoveredinanumberofbacteria
[  ,   ,   ,   ,   ,   ],couldbeincorporatedintoourmodelbyadding
termsthatdescribegenome-widemutationalload[   ];however,wedonot
pursuethisavenuehere.
We rstreviewnecessarybackgroundondynamicalsystemstheoryand
standardizeournotationinSect. . . Section . presentsourtwo-locusmodel
anddescribeshowevolutionproceedsoneachlocus. Ourresultsonthe
evolutionofmutationratesarediscussedinSect. . .
 .  D                                          
We rstintroduceseveralnotionsfromdynamicalsystemstheorythatareusedin
ourwork. Forthissection,letDbetheclosureofaboundedopensetinRd.
ConsideradiﬀerentialequationonDoftheform _ x = g(x),whereg : D   Rd is
smooth.  esolutiontothisequationcanbedescribedbyasmooth owonD,
thatis,acollectionofsmoothmaps ψt : D   Dsatisfying ψs+t = ψs   ψt.  e
orbitassociatedwithagiveninitialconditionx( ) = x    Disdescribedby
   x(t) = ψt(x ). Weassumegissuchthat ψt(x)   Dforallx   D t   R(thatis,
solutionspersistinde nitelybothforwardsandbackwardsintime).
 . .  ω-L        
 e ω-limitset ofapointx   D,whichwedenoteω(x)   D,isthesetofpoints









ψt(x)ast    . ω-Limitsetsareinvariant(bothforwardsandbackwards);that
is,ify   ω(x)then ψt(y)   ω(x)forallt   R(e.g.,  .
 . .  A        
Ana ractorisasettowhichanopensetofpointsconvergeundera owas
t    .  isnotionhasbeenmathematicallyformalizedinvariousways.  e
de nitionweuseisadoptedfromGyllenbergetal.[   ]andGeritzetal.[   ].
Wede neana ractor asasubsetA   Dsatisfyingthefollowingconditions:
 .  ereexistsanopenneighborhoodUofAforwhich
lim
t  
dist(ψt(x) A) =   
forallx   U.
    . ForeachopenneighborhoodVofA,thereexistsanopenneighborhoodW
ofAforwhich ψt(x)   Vforallx   Wandt    .




amountoftimehaspassed.  ismeasurewasintroducedbyTakens[   ]and
wasnamedthesojourntimemeasurebyBonneuil[  ].










t :     t   T dist(ψt(x) U)   ε
})
  ( . )
where λ istheLebesguemeasureonR.  eclosedsubsetsofDforwhichthe
abovelimitsexistaretakenasabasisforaσ-algebra,towhichthemeasureσx is
extended. Informally,σx(U)quanti estheasymptoticproportionoftimethat
theorbit ψt(x)spendsinornearU,ast    .
 esojourntimemeasureisaprobabilitymeasure,meaningthatσx(D) =  ,
foreachx   D. Moreover,itsatis esσx(ω(x)) =  ;thatis,itisconcentrated
entirelyontheω-limitsetofx.  esojourntimemeasureisalsoinvariant: for
eachmeasurableU   D,σx(ψt(U))isconstantint.
Asatrivialexample,weobservethatiftheorbitassociatedwithxconvergesto
a xedpoint~ x,thenthesojourntimemeasureisapointmass(Dirac
   δ-distribution)at~ x.
 .  M    
Hereweoutlineamathematicalframeworkforstudyingtheevolutionof
mutationratesunderfrequency-dependentselection. Section . . introduces
thetwolociinourmodel: onecontrollingthetraitssubjectto
frequency-dependentselection,andtheothercontrollingthemutationrate.
Section . . presentsourmodelforevolutiononthetraitlocus,usingthe
frameworkofreplicatordynamics.  emodelforevolutionofthemutationrate,
basedontheadaptivedynamicsapproach,ispresentedinSect. . . .




traitlocus,indexedi =       n. Eachalleleproducesadistincttrait.
•  emutationratelocuscontrolstherateofmutationonthetraitlocus.
Allelesonthemutationratelocusarerepresentedbythemutationrate
u   [   ].
Weassumethatmutationonthemutationratelocusisrare,comparedto
typicalmutationratesonthetraitlocus.  us,evolutionofthemutationrateu
occursonalongertimescalethanevolutionofthetraitsi =       n. (Hereand









 . .  S    -                            
Wemodelfrequency-dependentselectiononthetraitlocususingreplicator
dynamics[   ,   ,   ,   ,   ,   ],whichdescribethedynamicsof
competingtraitsinalargepopulationbyasystemofordinarydiﬀerential
equations.
R                 
Replicatordynamicsstudythedynamicsofthefrequencyvector




(x      xn) : xi     
∑
i
xi =  
}
 
Frequencydependenceisdescribedbythe tnessfunctionsfi : △n   Rfor
i =       n,wherefi(x)givesthe tnessoftraitiwhenthepopulationstateis





_ xi = xi(fi(x)   φ)  ( . )
fori =       n,withφ =
∑n
i=  xifi denotingaveragepopulation tness.
Equation . canalsobewri eninvectorformas
_ x = (F(x)   φI)x 
whereF(x)isthen   ndiagonalmatrixwithithdiagonalentryfi(x).
R         -               
Incorporatingmutationofrateuintothereplicatorequationyieldsthe
replicator-mutatorequations[   ,   ,   ]:
_ xi = (    u)xifi(x) +
u
n
φ   φxi  ( . )
orinvectorform:
_ x = (QuF(x)   φI)x  ( . )
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n u u
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n
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 . .  L   -                                   
Westudythelong-termevolutionofthemutationrateundertheassumptionsof






Section . . extendsthereplicator-mutatorequationstocompetition
betweentwostrainsofdiﬀerentmutationrates.  eninEq. . . weformally
stateourmodelforevolutiononthemutationratelocus,inspiredbyadaptive
dynamics. Items . . and . . introducetheconceptofinvasion tness,and
   discusstheextenttowhichitpredictstheoutcomeofinvasionevents.
C                        
Hereweextendthereplicator-mutatorequations,Eq. . ,tothecaseoftwo
competingstrains: aresidentstrainofmutationrateu,andaninvadingstrainof
mutationrateu′. Wedenotetheresidenttraitfrequenciesbyr = (r      rn),




(r z) : ri     zi     
∑
i




_ ri = (    u)rifi(r + z) +
u
n
Rφr   φri
_ zi = (    u
′)zifi(r + z) +
u′
n































△ n Z=  =  (r z)   △ n z =    
△ n R=  =  (r z)   △ n r =    
( . )
thenEq. . reducestoEq. . (withu := u′ inthela ercase).
ForagivenorbitofEq. . ,wesaythattheinvading(resp.,resident)strain
 xatesifZ(t)    ,(resp.,R(t)    )ast    .  equestionofwhether
invadersorresidents xatedepends,ingeneral,ontheinitialconditions
(r( ) z( ))   △ n thatde nethisorbit. Itisalsopossibleforneitherstrainto
 xate,aswediscussinEq. . . .
T                                
 issectionpresentsamodelofmutationrateevolutionasaniterativeprocess.
Ineachiteration,aninvadingstrainarises,competeswiththeresidentstrain,and
   eitherdisplacestheresidentstrain(becomingthenewresident)orgoesextinct.
 isprocessismotivatedbytheadaptivedynamicsframeworkdiscussedinthe
beginningofSect. . . .
 isprocessdependsonthefollowingdata:
• the tnessfunctionsfi : △n   R   fori =       n,
• theinitialmutationrateu    [   ],
• theinitialtraitdistributionx    △n,




ν    . WealsorequirethatMassignpositiveprobabilitytotheintervals[ ν  )
and(  ν],andzeroprobabilityto   . (Inotherwords,mutationonthe
mutationratelocuscaneitherincreaseordecreasethemutationrate,butdoes
notleaveitunchanged.)
Toformallyde nethisiterativeprocess,letuk andxk bethemutationrateand
traitdistribution,respectively,a erk    iterationsofthisprocess.  enext
iterationthenproceedsasfollows:
 . Atraitdistributionx 
k   △n issampledfromthesojourntimemeasureσxk
associatedwiththe owon△n de nedbythereplicator-mutator
   equations,Eq. . . ( epointx 
k representsthetraitdistributionstateof
theresidentpopulationwhenaninvadingstrainappears.)
 . Avertexv 
k of△n israndomlychosen,withtheprobabilitythatvertexiis
chosengivenby
























             
             
uk + Δuk ifuk + Δuk   [   ] 
  ifuk + Δuk     
  ifuk + Δuk    .
 . Apoint(r 
k z 
k)   △ n issampledfromthesojourntimemeasure
σ((  α)x 
k;αv 
k) associatedwiththe owon△ n de nedbyEq. . ,with
u := uk andu′ := u′




 .  e(k +  )stmutationrateandtraitdistributionarede nedasfollows:
   • ifr 
k =  ,thenxk+  := z 
k anduk+  := u′ (invadersreplace
residents),
• ifz 
k =  ,thenxk+  := r 
k anduk+  := u(invadersgoextinct).
Iteratingthisprocessyieldsasequence (uk xk)  




k =  norz 
k =  tobesatis edinStep ,aswe
discussinEq. . . . Inthiscase,theprocessceasestoadequatelydescribe
mutationrateevolution,andisformallyterminated.
Althoughthisprocessiswell-de nedforanyvaluesoftherequireddata,we
willbemostinterestedinthecasewhere ν andα aresmall.  ismeansthatwe
considermutationonthemutationratelocustobeincremental,andinvading
strainstoinitiallycompriseonlyasmallfractionofthepopulation.
I              
 einvasion tnessofastrainisde nedasitsexponentialgrowthratewhenrare






Wecanthereforequantifyinvasion tnessbyassumingthatx = x(t)has
dynamicsgivenbyEq. . ,andthatzevolvesaccordingtothetime-dependent
   linearequation,
_ z =
(
Qu′F(x(t))   φr(t)I
)
z  ( . )
whereφr(t) =
∑n
i=  fi(x(t))xi(t)istheaverage tnessoftheresidentstrainat
timet.  estatespaceforEq. . isthesetofallnonnegativevectorsinRn.













dt  ( . )
ifthislimitexists(otherwisetheinvasion tnessisunde ned). Above,
Z(t) =
∑n
i=  zi(t),thedynamicsofzaregivenbyEq. . withinitialcondition
z( ) = x′,andxgivestheinitialconditionforEq. . .  isextendsprevious
de nitions[  ,   ,   ]tothecaseinwhichboththeresidentandinvading
strainscontainanumberofsub-populations(inourcase,bearersofdiﬀerent
traits),whicharethemselvesevolvingonafasttimescale. Wecaution,however,
thattime-averagedquantitiesoftheform . maybeunde nedfororbits
approachingheteroclinicorstrangea ractors;seeRef. [   ]forageneral
discussion.
T                                   
Positiveinvasion tnessdoesnotnecessarilyimplythattheinvadingstrainwill
ultimatelydisplacetheresidentstrain.  etwostrainsmayevolvetowardsa




functionsx(x′)isnonsingularatx′ = x,andifx′ issuﬃcientlyclosetox,then
positiveinvasion tnessimplies xationoftheinvadingstrain[  ].  is
proposition,knownas“invasionimplies xation”(herea er,IIF),wasa
long-standingconjectureuntilproofswerediscoveredbyDercole[  ]and




Conjecture (InvasionImpliesFixation;IIF). Considergiven tnessfunctions
fi : △n   R,mutationrateu   [   ],andtraitdistributionsx x′   △n. Suppose
that
• xliesinthebasinofa ractionofana ractorofthereplicator-mutator
equations,Eq. . ,withmutationrateu,
• thereisaδ    suchthatsu;x(u′ x′)isstrictlymonotonic(eitherincreasingor
decreasing)inu′,ontheintervalu′   (u   δ u + δ)   [   ].
 enthereexists ε    suchthatforallu′ with u′   u    ε andall    α   ε,
invaders(resp.,residents) xateinEq. .  omtheinitialconditions
(r( ) z( )) = ((    α)x αx
′)  ( .  )
   ifsu;x(u′ x′)    (resp.,su;x(u′ x′)    ).
Wewillspecify,intheremainderofthiswork,thoseofourresultsthatdepend
onthisconjecture.
 .  R      
Replicator-mutatordynamicscanyieldawidevarietyofbehaviors,including





Section . . showsthatsuchdownwardevolutioncanbeexpectedwhenever
residentsareatmutation-selectionequilibrium.  isdownwardevolution
continuesuntileitherthisequilibriumislostorthemutationratereacheszero.
WetheninvestigatetheupwardevolutionofmutationratesinSect. . . . We
deriveconditionsunderwhichamutatorstraincaninvadeandpersistina
non-mutatingresidentpopulationinitiallyatequililbrium. Wethenshowthatif
thereplicatordynamics,Eq. . ,admitsagloballya ractingheterocliniccycle
betweenmonomorphicstates,thezeromutationrateisevolutionarilyunstable.
Last,Sect. . . explorescasesinwhichmutatorsandnon-mutatorscanstably
coexist.  iscoexistencecanoccurwhenthereplicatordynamics,Eq. . ,admits
astablepolymorphic xedpoint.
    . .  D                                                 -




areavailable[   ,   ,   ].
Westartbyshowinghowinvasion tnesscanberelatedtoaneigenvalue
characterizingthegrowthrateoftheinvadingstrain. Consideraresidentstrainof
mutationrateu    ,andsupposethetraitdistributionwithinthisresidentstrain
isata xedpoint~ xofthereplicator-mutatorequations,Eq. . . Weintroducethe
notation~ fi = fi(~ x)forthe tnessoftraitiatthisequilibrium, ~ φr =
∑
i~ fi~ xi forthe
average tnessoftheresidentstrain,and~ Fforthediagonalmatrixwithentries~ fi.
Lemma . Foranyinvadingstrainwithtraitdistributionx′   △n andmutationrate
u′    ,theinvasion tnessofthisstrainisgivenby
su;~ x(u
′ x
′) = ^ φz   ~ φr 
where ^ φz denotesthelargesteigenvalueofthematrixQu′~ F.




Qu′~ F   ~ φrI
)
z  ( .  )
    esolutionisgivenby
z(t) = exp
(





Sinceu′    and~ fi    foreachi,thenQu′~ Fhasstrictlypositiveentries. By
thePerron-Frobeniustheorem,Qu′~ Fhasapositivesimplelargesteigenvalue ^ φz,
withassociatedstrictlypositiveeigenvector^ z(whichwenormalizesothat
∑


















′ = k^ z 


















t(^ φz   ~ φr)
)








= Z k^ z 
( .  )






t(^ φz   ~ φr)
) = Z k  ( .  )
Separately,le -multiplyingbothsidesofEq. .  byQu′~ F   ~ φrIand






t(^ φz   ~ φr)
) = Z k(Qu′~ F   ~ φrI)^ z
= Z k(^ φz   ~ φr)^ z 
( .  )






t(^ φz   ~ φr)
) = Z k(^ φz   ~ φr)  ( .  )





= ^ φz   ~ φr 
Comparingtothede nitionofinvasion tness,Eq. . ,weconcludethat
su;~ x(u
′ x




   frequencyissmall.  ecorrespondingeigenvalue ^ φz equalstheaverage tnessof







thissectionandinSect. . . ).
 eorem . Consideraresidentstrainofmutationrateu    ,andsupposethetrait
distributionwithinthisresidentstrainisata xedpoint~ xofthereplicator-mutator
equations,Eq. . .  enforallx′   △n andu′    ,
• Ifthe~ fi = fi(~ x)areallequal,su;~ x(u′ x′) =  .
• Ifthe~ fi arenotallequal,su;~ x(u′ x′)       u′   u.
Proof. Weclaim,andprovebelow,that
d^ φz
du′    ,withequalityifandonlyifallthe
~ fi areequal.  usbyLemma ,su;~ x(u′ x′) = ^ φz   ~ φr isdecreasinginu′ ifthe~ fi are
notallequal,andconstantinu′ otherwise. WealsonotethatbyEq. . ,the xed
point~ xisaneigenvectorofthe(strictlypositive)matrixQu~ F,witheigenvalue ~ φr.
BythePerron-Frobeniustheorem, ~ φr istheuniqueeigenvalueofQu~ Fwhose
associatedeigenvectorisnonnegative. Inthecaseu′ = u,thiseigenvalueis,by
de nition, ^ φz.  usforu′ = u, ^ φz = ~ φr,andthereforesu;~ x(u x′) =  . Combining
thiswiththeabove-mentioneddecreasingbehaviorofsu;~ x(u′ x′)inu′ provesthe




symmetricmatrix ~ F = Qu′~ F =  hasPerron-Frobeniuseigenvalue ^ φz andassociated
eigenvector~ F = ^ z. Applyingastandardformulaforthederivativeofthe




~ F = ^ z




~ F =  (
~ F = ^ z
)
(
~ F = ^ z
)T (




















i= ~ fi^ zi
) 
^ zT~ F^ z








i(~ fi^ zi) 
n
 
HencethenumeratorofEq. .  is   ,withequalityifandonlyiftheterms~ fi^ zi
areequalforalli. Inthela ercase,wewrite ~ F^ z = α ,forsomeconstantα,where
 denotesthevectorwitheachentryequaltoone. Wethenhave
^ φz^ z = Qu′~ F^ z = Qu′(α ) = α .  usthetraitabundances^ zi = α ^ φz areconstant
overi,andthe tnessfunctions~ fi mustbeconstantoveriaswell. Wealsonote
thatthedenominatorofEq. .  ispositiveinallcases,since ~ Fisadiagonal
matrixwithstrictlypositiveelementsandisthereforepositivede nite.  is
provestheclaimthat
d^ φz
du′    ,withequalityifandonlyifthe~ fi areallequal.
   Asimilarresultholdswhentheinvadingstrainisnon-mutating(u′ =  ).
However,inthiscase,theinvasion tnesssu;~ x(  x′)dependsontheinitial
distributionx′ oftraitswithintheinvadingstrain,aswestateinthefollowing
proposition.
Proposition . Consideraresidentstrainofmutationrateu    ,andsupposethe
traitdistributionwithinthisresidentstrainisata xedpoint~ xofthe
replicator-mutatorequations,Eq. . . Foranyx′   △n,su;~ x(  x′)    ifandonlyif
max ~ fi : x′
i     exceeds ~ φr =
∑
i~ fi~ xi.
Proof.  isfollowsimmediatelyfromobservingthatforu′ =  ,Eq. .  
simpli esto
_ zi = zi(~ fi   ~ φr) 
foreachi =       n.
Inparticular,ifx′   int△n,thentheconditionmax ~ fi : x′
i        ~ φr of
Proposition becomesequivalenttotheconditionof eorem thatthe~ fi are
notallequal.  isisbecauseforx′   int△n,max ~ fi : x′
i        ~ φr holdsifand
onlyifthereisanyiforwhich~ fi   ~ φr. Since~ xmustalsobeinint△n bythefact
that~ xisa xedpointofEq. . withu    ,then ~ φr isaweightedaverageofthe~ fi
withpositiveweightingforeachcomponent.  us~ fi   ~ φr forsomeiifandonlyif
the~ fi arenotallequal.
Attheotherextreme,ifx′ isavertexof△n (asisalwaysthecaseforinvading
strainsthatappearinthemutationrateevolutionprocessdescribedinEq. . . ),
thentheconditionofProposition becomessimplyfi   ~ φr,whereiistheindex
   ofthetraitrepresentedbyx′.




 issituationcanonlyoccurinveryparticularcircumstances. Indeed,se ing
fi(~ x) = φforeachiata xedpoint~ xofthereplicator-mutatorequations,Eq. . ,
yields
  = uφ
( 
n
  ~ xi
)
 
foreachi.  eaverage tnessφispositivesincefi(~ x)    foreachiand
∑n
i=  fi(~ x)    . Henceifalltraitsareequally tat~ x,theneitheru =  (mutation
isabsent)or~ xislocatedatthecentroid  n = (  n       n)   △n (alltraitsare
equallyabundant). Weexploretheu =  casefurtherinSect. . . .
Ournextresultapplies eorem tothemutationrateevolutionprocess
de nedinEq. . . . Itshowsthatif,atsomestepkintheprocess,theresident
traitdistributionisatastablemutation-selectionequilibrium,andif ν andα are
suﬃcientlysmall,thennotonlywillthemutationrateatstepk +  belessthanor
equaltothemutationrateatstepk,butthenewresidenttraitdistributionwill
againbeatastablemutation-selectionequilibrium.
 eorem . IntheprocessofmutationrateevolutionoutlinedinEq. . . ,suppose
thatforsomek    ,uk    andthatxk ̸=   nisastablehyperbolic xedpointofthe
replicator-mutatorequations,Eq. . ,withmutationrateuk.  enif ν andα are
suﬃcientlysmallandIIFisassumed,thenuk+    uk andxk+  isastablehyperbolic
    xedpointofEq. . withmutationrateuk+ .
Proof. Webeginbynotingthat,asaconsequenceoftheimplicitfunction
theorem,thereissomerelativelyopenneighborhoodU   [   ]ofuk,anda
diﬀerentiablecurve γ : U   △n suchthatforeachu   U, γ(u)isastable
hyperbolic xedpointofEq. . withmutationrateu.
Wewillprovethat,forthemutationalstep Δuk sampledinStep ,
(a) If Δuk    andu′
k    ,thenuk+  = u′
k withprobabilityone.
(b) If Δuk    andu′
k =  thenuk+  =  withpositiveprobability(otherwise
uk+  = uk).
(c) If Δuk    thenuk+  = uk withprobabilityone.
(d) Inallcases,xk+  = γ(uk+ ).
 eclaimsofthetheoremfollowfromtheabovestatements.
Wenotethatsincexk isa xedpointofEq. . ,thenx 
k = xk. Bytheremarks
followingProposition ,sincex 
k ̸=   nanduk    ,thenthe tnessfunctions
fi(x 
k)arenotallequal.  erefore,inthecaseu′




k)    ifandonlyif Δuk    ,regardlessofwhichvertexv 
k issampled
inStep . Inthecaseu′




k)    ,andthisvertexhasnonzeroprobabilityof
beingsampledinStep sincex 
k   int△n. Insummary,
• If Δuk    andu′
k    ,thensuk;x 
k(u′
k v 
k)    withprobabilityone.
• If Δuk    andu′
k =  ,thensuk;x 
k(u′
k v 
k)    withpositiveprobability.
   • If Δuk    thensuk;x 
k(u′
k v 
k)    withprobabilityone.
IIFnowguaranteesthat(a),(b),and(c)aresatis edaslongas ν andα are
suﬃcientlysmall.
Toverifyclaim(d),weinvoketheTube eorem[   ]. AppliedtoEq. . 
andEq. . ,theTube eoremguaranteesthefollowing: Let~ xbeastable
hyperbolic xedpointofEq. . .  enforeach ε    thereexistsaδ    such
thatif u′   u    δ and r( ) + z( )  ~ x    ε,then r(t) + z(t)  ~ x    ε forall
t    underthedynamicsofEq. . . Inwords,thetraitdistributioninthewhole
population(residentsandinvaderscombined)staysclosetothe xedpoint~ x,as
longasthediﬀerenceinmutationrates u′   u issuﬃcientlysmall.
Considertheω-limitsetωk := ω((    α)x 
k αv 
k)   △ n associatedwiththe
 owde nedbyEq. . withu := uk andu′ := u′
k (thatis,the owconsideredin
Step ). IIFandtheTube eoremjointlyimplythatforeach ε    thereexists
δ    suchthatif ν   δ andα   δ,then
 
     
     
ωk  
{





k)    ,
ωk  
{





k)    .
( .  )
Let  ωk   △n denotetheimageofωk undertheidenti cations△n   △ n R= 
or△n   △ n Z= ,inthecasessuk;x 
k(u′
k v 
k)    andsuk;x 
k(u′
k v 
k)    ,
respectively. ByEq. .  ,  ωk isasubsetoftheopenballB(γ(uk) ε)ofradius ε
around γ(uk). Additionally,sinceωk isaninvariantsetofEq. . ,then  ωk isan
invariantsetofEq. . . Since γ(uk+ )isanondegenerate xedpointofEq. . ,
   thereissomeneighborhoodofU   △n of γ(uk+ )suchthat γ(uk+ ) isthe
onlyinvariantsubsetofU.  econtinuityof γ impliesthatB(γ(uk) ε)   Ufor
suﬃcientlysmall ε. Consequentlythereexistsaδ    suchthat Δuk    δ
implies  ωk   U. Since  ωk isaninvariantsetofEq. . andasubsetofU,then  ωk
mustconsistonlyofthesinglepoint γ(uk+ ). Finally,sincesojourntime
distributionsareconcentratedonthecorrespondingω-limitsets,thepointxk+ 
assignedinStep canonlybe γ(uk+ ),aslongas ν issuﬃcientlysmall.  is
provesclaim(d),completingtheproof.
Onecanguaranteethatthedownwardevolutionofmutationratewill
continueforanydesired nitenumberofstepsbyse ing ν andα suﬃciently
smallandapplying eorem inductively. However,itisnotpossibleingeneral
toguaranteethatthisdownwardevolutionwillcontinueinde nitelyoruntilthe
zeromutationrateisreached.  isisbecausetheboundson ν andα neededto
guaranteethatuk+    uk andxk+  = γ(uk+ )arenotnecessarilyuniforminuk.




 . .  E                               
Havingidenti edconditionsunderwhichmutationratesevolvedownwards,we
nowturnoura entiontotheupwardevolutionofmutationrates. InSect. . . ,
 eorem andCorollary giveconditionsunderwhichastrainofpositive
   mutationratecaninvadeanon-mutatingresidentpopulationwhichisata
(possiblyunstable)selection-inducedequilibrium.  eorem showsthat,inthis
case,successfulinvasionimpliespersistenceofthemutatorstrain.
Equations . . focusesonthecasewherethereplicatorequations,Eq. . ,admit
agloballya ractingheterocliniccycle. Inthiscase,thezeromutationrateis
evolutionarilyunstable.
C                                     -                          -
       
Inthissectionweaskwhetherastrainofpositivemutationrateu′ caninvadea
non-mutatingresidentstrainatequilibrium. Asdiscussedintheproofof
 eorem (andusingthenotationde nedthere),theinvasion tnessisequalto
thelargesteigenvalueofQu′~ F   ~ φrI.  efollowingtheoremgivesnecessaryand
suﬃcientconditionsforthisinvasion tnesstobepositive,avoidingtheneedfor
aneigenvaluecalculation:
 eorem . Let~ xbea xedpointofthereplicatorequations,Eq. . ,andlet
~ fi = fi(~ x)and ~ φr =
∑n
i= ~ fi~ xi.  enforanyx′   △n andu′    ,s ;~ x(u′ x′)    if
andonlyifeither









Proof. Letthematrix ~ F,thePerron-Frobeniuseigenvalue ^ φz ofQu′~ F,andthe
associatedeigenvector^ zbede nedasinSect. . . .  eeigenvectorequation




^ φz   (    u′)~ fi







^ φz   (    u′)~ fi
  ( .  )
Equation .  andthepositivityof^ zand ^ φz implythat(    u′)~ fi   ^ φz foralli.
 us,if(    u′)~ fi   ~ φr foranyi,then ^ φz   ~ φr andhences ;~ x(u′ x′)    by
Lemma .  isprovesthatcondition(a)issuﬃcient.







y   (    u′)~ fi
 
Aslongas(    u′)~ fi   yforalli,g(y)ismonotonedecreasinginy. Equation .  
impliesthatg(^ φz) = n u;hence, ^ φz   ~ φr ifandonlyifg(~ φr)   n u,whichis
equivalenttocondition(b). Since ^ φz   ~ φr isequivalenttos ;~ x(u′ x′)    ,this
provesthetheorem.
Wecanalsoaskwhetherthereexistsanystrainofpositivemutationratethat
caninvadenon-mutatingresidentsattheequilibrium~ x.  isquestionhasamuch
simpleranswer: ifthereisanytraitwhose tnessislargerthantheaverage
   resident tness,thenthereexistsamutatorstrainthatcaninvade. Westatethis
formallyas:
Corollary . Let~ xbea xedpointofthereplicatorequations,Eq. . .  en~ fi   ~ φr
forsomei          n ifandonlyifthereexistsu′    suchthats ;~ x(u′ x′)    for
allx′   △n.
Proof.  e“onlyif”directionfollowsimmediatelyfrom eorem . Forthe“if”
direction,suppose~ fi   ~ φr foralli.  en ^ φz =
∑
i~ fi^ zi and^ z   △n implythat
^ φz   ~ φr,andhences ;~ x(u′ x′)    forallx′   △n.
 eIIFconjecturedoesnotnecessarilyapplytothescenariosconsideredin
 eorem andCorollary . Inparticular,ifthenon-mutatingresidentstrainis
monomorphic(thatis,if~ x = visavertexof△n)ands ;v(u′ v)    ,thenthe
monotonicityconditionoftheIIFconjectureisnotsatis ed: thereisnoδ    
forwhichs ;v(u′ v)ismonotonicinu′ foru′   [  δ).  isfollowsfrom
observingthat(a)s ;v(  v) =  ,(b)s ;v(u′ v)    forallsuﬃcientlysmall




positiveinvasion tness)willeventuallyriseto xation. Wecan,however,provea
weakerresult: ifs ;v(u′ v)    ,thenaninvadingstrainofmutationrateu′ will
persistinde nitely. Westatethisformallyinthefollowingtheorem:
    eorem . Letvbeavertexof△n andsupposes ;v(u′ v)    forsomeu′    .
 en,fortheorbitofthetwo-strainreplicator-mutatorequation,Eq. . ,withu =  
andinitialconditions(r( ) z( )) = ((    α)v αv),theresidentstraindoesnot
 xate.
Proof. Withoutlossofgenerality,supposev = (         ). Notethatfori ̸=  ,
ri(t) =  foralltimest    . Wecanthereforedisregardthecoordinates
r      rn andrewriteEq. . as
_ r  = r 
(
f (r + z)   φ
)
_ zi = (    u
′)zifi(r + z) +
u′
n
Zφz   φzi 
( .  )
fori =       n.
Assumeforcontradictionthattheresidentstrain xates;thentheorbitin
questionmustconvergetothe xedpoint(r  z) = (   ). Bythe
Hartman-Grobmantheorem,thedynamicsofEq. .  are,inaneighborhoodof
this xedpoint,conjugatetothedynamicsofthelinearizedsystem




_ z = (Qu′~ F   ~ φI)z 
( .  )
Above,~ fi, ~ φand ~ Farethevaluesoffi,φandF,respectively,atthe xedpoint
(r  z) = (   ).
Fromanyinitialconditions(r ( ) z( ))withz( ) ̸=  ,thedynamicsof
   Eq. .  willconvergeto(r  z) = (   )ifandonlyifthedynamicsof
_ z = (Qu′~ F   ~ φI)z 
withinitialconditionz( ),convergetoz =  . Bythereasoningusedinthe rst
partoftheproofof eorem ,thiscanonlyoccurifthePerron-Frobenius
eigenvalue ^ φz ofQu′~ Fislessthanorequaltothan ~ φ,whichcontradicts
s ;v(u′ v)    .
R                                          
Anotherinterestingcaseoccurswhenthereplicatordynamicsadmitaglobally
a ractingheterocliniccycle,the xedpointsofwhichareverticesof△n. Such
cyclesmayoccurin“rock-paper-scissors”systems,inwhicheachtraitisbestedby
another[   ,   ].
Letthe tnessfunctionsfi besuchthatthereplicatorequations,Eq. . ,admit
agloballya ractingheterocliniccyclewhose xedpointsareverticesof△n. In
thiscase,theinvarianceofthesojourntimemeasureimpliesthatforeach
x   △n,σx isconcentratedentirelyonthe xedpointsofthiscycle,i.e.the
verticesof△n.¹
Considerthemutationrateevolutionprocessde nedinEq. . . ,andsuppose
¹Perhapscontrarytointuition,thevalueof σx isin generalunde nedontheindividual xed
points of such a heteroclinic cycle.  is is because, if v is a  xed point on this cycle, and if all
 xedpointsarehyperbolic thegenericcase thenσx( v )willnotconvergeaccordingtothe
limit de nition  .  [   ,    ].  us, according to our de nition, the singleton  v  is a non-
measurable subset, as is any proper subset of the vertex set. However, this does not aﬀect our
currentargument,whichrequiresonlythattheentirevertexsetisassignedprobabilityone.
   thatuk =  forsomek    . Bytheaboveremarks,thestatex 
k sampledinStep 
willbeavertexof△n. By eorem ,theinvadingstrainofmutationrateu′
k    
thatarisesinStep willpersistinde nitely,solongasu′
k issmallenoughthatthe









theprocessoutlinedinEq. . . ,inthecasethatthe tnessfunctionsfi inducean




 . .  C                               -               
Aninterestingsituationoccurswhenthereplicatorequations,Eq. . ,admitan
equilibrium~ xatwhichalltypesarepresent(thatis,~ x   int△n). Inthiscase,
Eq. . impliesthatalltrait tnessfunctionsfi(~ x)areequal.
Stablecoexistencebetweenmutatingandnon-mutatingstrainsispossiblein
   thiscase. Toseethis,considerthetwo-strainreplicator-mutatorequation,
Eq. . ,andsupposethatonlytheinvadingstrainhaspositivemutationrate(i.e.
u =  ,u′    ).  enthepoint(r z)   △ n isa xedpointofEq. . whenever
z Z =   n(thatis,alltraitsareequallypresentintheinvadingstrain),and





























   ( .  )
withT   R   S   P    .  isgameadmitsamixedevolutionarilystable
state thatis,astablehyperbolic xedpointofthereplicatorequations,
Eq. .  withtraitfrequencies
~ xC =
S   P
T   R + S   P
  ~ xD =
T   R
T   R + S   P
 
 enthe xedpointsofEq. . thatdescribecoexistencebetweenaresident
   non-mutatingstrainandaninvadingmutatorstrainaregivenby
~ rC =
S   P








T   R












situations,orwhetheroneofthetwostrainswillgenerally xate.  eIIF
conjectureisuninformativeonthisquestion,sinceif~ xisa xedpointofEq. . 
forwhichalltraitsarepresent,thenalltraitsmustbeequally taccordingto
Eq. . ,andthus eorem impliesthats ;~ x(u′ x′) =  ,foranyu′   [   ],
x′   △n. Sosuchaninvadingstrainwillhavezeroinvasion tness.
Toinvestigatethisquestion,wesimulatedEq. . numericallyinthecaseofthe
snowdri gamediscussedabove(seeFig. . . ). Wefoundthatwheneverboth
traitsarepresentintheinitialnon-mutatingresidentpopulation(rC( )    and
rD( )    ),thedynamicsofinvadingmutatorsandresidentnon-mutators


















































































Figure 6.4.1: Numerical simulation of the two-strain replicator-mutator equa-
tions, Eq. 6.5, for the snowdrift game, varying the initial proportion of trait C
(cooperation) within the non-mutating resident strain (rC( ) (    α)). Panels
show features of the stable equilibrium (~ r ~ z). (a) Equilibrium proportion of
strategy C within the resident strain
(
~ rC ~ R, dashed line and circle), within the
invading mutator strain
(
~ zC ~ Z, dotted line and triangle), and within the popu-
lation overall (~ rC + ~ zC, solid line). The value ~ xC = ~ rC + ~ zC =     is the stable
ﬁxed point of the replicator equations, Eq. 6.2. (b) Equilibrium frequency of
the invading mutator strain
(
~ Z, solid line and square). The open/closed sym-
bols in both panels indicate the discontinuity at rC( ) (    α) =  ; at this
point, the non-mutating resident strain contains only trait C and goes extinct,
while the invading strain converges to the mutation-selection equilibrium of
the single-strain replicator-mutator equations, Eq. 6.3. Parameters: game pay-
oﬀs R =  , S =  , T =  , P =  ; mutation rates u =  , u′ =     ; initial invader
frequency α =    ; initial invader trait distribution zC( ) =    zD( ) = α (i.e.,
the invading strain starts with only trait D, defection).
    .  D         
Ourworkinvestigateshowfrequency-dependentselectionwithinapopulation











[  ,   ,   ,   ,   ,   ,   ,   ,   ,   ,   ,   ]tothecasewherethe
 tnesslandscapedependsonthepopulationitself.
Ourworkalsohighlightsaninterestingscenarioofcoexistencebetween






   scenario therelevanceofthisresultremainstobeshown.
Ofcourse,thereplicatorandreplicator-mutatorequationscanyieldawide







[   ]tomutationrateevolution. Moregenerally,adaptivedynamicscanleadto
awidevarietyofbehaviors,includinglimitcycles,chaos,andevolutionary









evolution[  ,  ,  ,   ]. Invariantmeasuresarisenaturallywhenconsidering
twodynamicalprocessesondiﬀerenttimescales. Aninvariantmeasurecanserve
asprobabilitydistributionforthestateofafastprocess(e.g.,demographic
   dynamics)whenarareevent(e.g.,mutation,environmentalchange)occurs.
Finally,ourworksuggestsnewempiricalhypotheses. Anumberofspecies,
includingEscherichiacoli[   ,   ],thecommonside-blotchedlizardUta
stansburiana[   ,   ],andtheyeastSaccharomycescerevisiae[   ],show
nontransitivecompetitionbetweenbearersofdiﬀerenttraits. Wehaveshownin
Eq. . . thatinsomecases,suchnontransitivecompetitioncaninduceupward
evolutionarypressureonthemutationrate. Wethereforeconjecturethatinsuch
species,themutationrateonlocicodingforthesetraitsmaybeabnormallyhigh.
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   Table 7.1.1: Pharmacokinetic and pharmacodynamic parameters for anti-HIV
drugs used in the study [265]
Class Drug IC   (μMol) slope Cmax (μMol) half-life(hrs) dosing(d  )
NRTI  TC  .      .     .    .   
ABC  .      .     .    .   
AZT  .      .    .   .   
d T  .      .    .   .   
ddI  .      .     .    .   
FTC  .      .    .    .   
TDF  .      .    .    .   
NNRTI EFV  .      .     .    .   
ETV  .      .    .      
NVP  .      .     .    .   
PI ATV  .      .    .   .   
ATV/r  .      .    .   .   
DRV/r  .      .     .    .   
IDV  .      .    .   .   
IDV/r  .      .    .   .   
LPV/r  .      .    .   .   
NFV  .      .    .   .   
SQV  .      .    .   .   
SQV/r  .      .    .   .   
TPV/r  .      .     .   .   
II EVG  .      .    .   .   
 L  .      .    .    .   
FI ENF  .      .    .   .   
   Table 7.1.2: Parameters for all single-point mutations considered in the study
[265]
Class Mutation Cost(s) u Drug ρ σ
NRTI K  R  .               TC    - .  
ABC     .  
ddI    - .  
FTC    - .  
TDF     .  
M   V  .               TC     - .  
ABC  .  - .  
AZT  .   - .  
ddI  .  - .  
FTC      - .  
TDF  .  - .  
M  L  .              AZT  .   .  
d T  .   .  
T   Y  .   * AZT  .  - .  
d T  .   - .  
NNRTI G   S  .              EFV    - .  
NVP     - .  
K   P  .  * ETV  .   - .  
K   N  .             EFV    - .  
NVP    - .  
Y   C  .              EFV  .  - .  
ETV    - .  
NVP     - .  
Y   I  .   * ETV     - .  
NVP      - .  
*Indicatesmutationthatrequirestwonucleotidechanges;
mutationratedependsonprevalenceofintermediatestates.
   Table 7.1.3: Parameters for all single-point mutations considered in the study
(Cont’d) [265]
Class Mutation Cost(s) u Drug ρ σ
PI D  N  .              NFV  .  - .  
G  V  .              SQV  .  - .  
I  A  .  * LPV  .  - .  
I  V  .              LPV  .  - .  
I  L  .              ATV  .  - .  
I  V  .              DRV  .   - .  
I  L  .              DRV  .   - .  
I  V  .              ATV  .   - .  
DRV  .   - .  
IDV  .   - .  
TPV  .   - .  
L  F  .              TPV  .   .  
L  M  .              NFV  .   .  
SQV  .  - .  
M  I  .              IDV  .  - .  
M  L  .              IDV  .   - .  
N  S  .              ATV  .  - .  
V  I  .              LPV  .   - .  
V  A  .              LPV  .   - .  
V  F  .              IDV  .   - .  
LPV  .   - .  
V  T  .   * IDV  .   - .  
LPV  .   - .  
TPV  .   - .  
II G   S  .               L  .   .  
N   H  .              EVG     .  
 L     .  
Q   H  .              EVG  .  - .  
 L     .  
Q   K  .              EVG     .  
 L     - .  
Q   R  .              EVG     .  
 L     .  
Y   C  .               L  .   .  
Y   H  .               L  .  - .  
Y   R  .   *  L    - .  
FI G  D  .              ENF  .  - .  
N  T  .              ENF  .  - .  
N  D  .              ENF    - .  
Q  H  .              ENF    - .  
V  A  .              ENF    - .  
*Indicatesmutationthatrequirestwonucleotidechanges;
mutationratedependsonprevalenceofintermediatestates.
   Table 7.1.4: Parameters for pre-existing frequency of mutations and exit rate
from the latent reservoir. See Methods and Supplementary Methods for
explanations.
class mutation equilibriumfrequency reservoirexit(days)
NRTI K  R              
M   V              
M  L              
T   Y * *
NNRTI G   S              
K   P * *
K   N              
Y   C             
Y   I * *
PI D  N             
G  V               
I  A * *
I  V             
I  L               
I  V              
I  L              
I  V              
L  F              
L  M              
M  I                 
M  L              
N  S              
V  I             
V  A              
V  F               
V  T * *
II G   S              
N   H               
Q   H               
Q   K              
Q   R              
Y   C              
Y   H              
Y   R * *
FI G  D             
N  T               
N  D              
Q  H              
V  A             
*Indicatesmutationthatrequirestwonucleotidechanges;
equilibriumfrequencydependsonprevalenceofintermediatestates.
   Table 7.1.5: Parameters for pre-existing frequency and exit rate from the
latent reservoir for best “synthetic” mutation for each drug. See Methods and
Supplementary Methods for explanations.
class drug equilibriumfrequency reservoirexit(days)
NRTI AZT              
d T              
 TC              
FTC              
ABC              
ddI              
TDF              
NNRTI EFV             
NVP             
ETV             
PI DRV              
NFV             
SQV              
LPV             
ATV              
IDV                 
TPV              
II  L              
EVG              
FI ENF             
   Table 7.1.6: Viral dynamics parameters in the absence of drug therapy
Parameter Value Units Reference
R   Baselinebasicreproductionratio    (unitless) Seetext
dy Deathrateofactivelyinfectedcells   d   [   ]




A Latentreservoirexitrate      cells.d   Basedonv ,
seetext
Table 7.1.7: Nucleotide substitution rate parameters for HIV. Each entry
gives the per-site transition probability from row base to column base in one
round of viral replication. For derivation and source see Section 2.5.2. The
extraordinary skew of this matrix (the largest entry, G-to-A mutation, is more
than 300 times the smallest, C-to-G mutation) reﬂects the base composition
of the genome, particularly the bias towards A. Values less than      are par-
ticularly uncertain, as they were computed from fewer than 5 substitution ob-
servations each.
U C A G
U                                 
C                                 
A                                 
G                                 
    .  S                               C       
   3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF




































































































































Figure 7.2.1: Simulated clinical outcomes versus adherence for all drugs. In
“Suppression” trials, patients begin with a realistic distribution of treatment-
naive viral loads (between      and     c.ml  ) and undergo monotherapy
for a full 48 weeks. Virologic failure (VF) is deﬁned as a viral load above 50
c.ml  at Week 48. VF is classiﬁed as “via resistance” if at least 20% of the
viral population at the time of detection is mutant. Adherence (x-axis) is
measured as the fraction of scheduled doses taken. The height of the area
shaded indicates probability of the corresponding outcome at that adher-
ence level. 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavu-
dine; ddI, didanosine, FTC, emtricitabine; TDF, tenofovir disoproxil fumarate;
EFV, efavirenz; ETV, etravirine; NVP, nevirapine; ATV, atazanavir; DRV,
darunavir; IDV, indinavir; LPV, lopinavir; NFV, nelﬁnavir; SQV, saquinavir;
TPV, tipranavir; EVG, elvitegravir; RAL, raltegravir; ENF, enfuvirtide.
   3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF




































































































































Figure 7.2.2: Simulated clinical outcomes versus adherence for all drugs. In
“Maintenance” trials, patients begin with full viral suppression and undergo
monotherapy for 48 weeks or until virologic failure (VF), whichever occurs
ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive weekly measure-
ments (starting at week 5) with viral load above 200 c.ml  . VF is classiﬁed
as “via resistance” if at least 20% of the viral population at the time of de-
tection is mutant. Adherence (x-axis) is measured as the fraction of scheduled
doses taken. The height of the area shaded indicates probability of the corre-
sponding outcome at that adherence level.
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3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF
Figure 7.2.3: Simulated clinical outcomes versus time for all drugs. In “Sup-
pression” trials, patients begin with a realistic distribution of treatment-naive
viral loads (between      and     c.ml  ) and undergo monotherapy for a vari-
able time (x-axis). “Detectable viral load” is deﬁned as above 50 c.ml  and is
classiﬁed as “via resistance” if at least 20% of the viral population at the time
of detection is mutant. The height of the area shaded indicates prevalence of
the corresponding outcome at that time. Patients have a realistic distribution
of adherence levels with an average of 70%.
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3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF
Figure 7.2.4: Simulated clinical outcomes versus time for all drugs. In
“Maintenance” trials, patients begin the trial with full viral suppression and
undergo monotherapy for a variable amount of time (x-axis) or until “de-
tectable viral load” is observed, whichever occurs ﬁrst. “Detectable viral load”
is deﬁned as “conﬁrmed rebound”: two consecutive weekly measurements
(starting at Week 5) above 200 c.ml  . It is classiﬁed as “via resistance” if
at least 20% of the viral population at the time of detection is mutant. The
height of the area shaded indicates prevalence of the corresponding outcome
at that time. Patients have a realistic distribution of adherence levels with an
average of 70%.
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3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF
Figure 7.2.5: Simulated clinical outcomes versus time for all drugs. In
“Maintenance with recovery” trials, patients begin the trial with full viral sup-
pression and undergo monotherapy for a variable amount of time (x-axis).
“Detectable viral load” is deﬁned as “conﬁrmed rebound”: two consecutive
weekly measurements (starting at Week 5) with viral load above 200 c.ml  .
It is classiﬁed as “via resistance” if at least 20% of the viral population at the
time of detection is mutant. We allow recovery, meaning that patients stay in
the trial to see if they will re-suppress, instead of being removed immediately
like in regular “Maintenance” trials. The height of the area shaded indicates
prevalence of the corresponding outcome at that time-point. Patients have a
realistic distribution of adherence levels with an average of 70%.
   3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF




































































































































Failure with wild type only 
 Failure with resistance, 
 mostly de novo  
Figure 7.2.6: Simulated clinical outcomes versus adherence for all drugs,
distinguishing pre-existing from de novo mutations. In the “Suppression” tri-
als shown, patients begin with a realistic distribution of treatment-naive vi-
ral loads (between      and     c.ml  ) and undergo monotherapy for a full
48 weeks. Virologic failure (VF) is deﬁned as a viral load above 50 c.ml  at
Week 48. VF is classiﬁed as “via resistance” if at least 20% of the viral pop-
ulation at the time of detection is mutant. Resistance is classiﬁed as de novo
if the majority of mutants at the time of failure descended from a mutation
event that occurred during replication since the start of the trial. Otherwise,
resistance is classiﬁed as “pre-existing,” which includes mutants arising from
both the pre-treatment plasma population and the latent reservoir. Adherence
(x-axis) is measured as the fraction of scheduled doses taken. The height of
the area shaded indicates probability of the corresponding outcome at that
adherence level.
   3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF




































































































































Failure with wild type only 
 Failure with resistance, 
 mostly de novo  
Figure 7.2.7: Simulated clinical outcomes versus adherence for all drugs, dis-
tinguishing pre-existing from de novo mutations. In the “Maintenance” trials
shown, patients begin with full viral suppression and undergo monotherapy
for 48 weeks or until virologic failure (VF), whichever occurs ﬁrst. VF is de-
ﬁned as “conﬁrmed rebound”: two consecutive weekly measurements (starting
at Week 5) with viral load above 200 c.ml  . VF is classiﬁed as “via resis-
tance” if at least 20% of the viral population at the time of detection is mu-
tant. Resistance is classiﬁed as de novo if the majority of mutants at the time
of failure descended from a mutation event that occurred during replication
since the start of the trial. Otherwise, resistance is classiﬁed as “pre-existing,”
which includes mutants arising from both the pre-treatment plasma popula-
tion and the latent reservoir. Adherence (x-axis) is measured as the fraction of
scheduled doses taken. The height of the area shaded indicates probability of
the corresponding outcome at that adherence level.
   3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF




































































































































Figure 7.2.8: Simulated clinical outcomes versus adherence for all drugs,
R  =20. Results are shown for “Maintenance” trials only. In the “Mainte-
nance” trials shown, patients begin with full viral suppression and undergo
monotherapy for 48 weeks or until virologic failure (VF), whichever occurs
ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive weekly measure-
ments (starting at Week 5) with viral load above 200 c.ml  . VF is classiﬁed
as “via resistance” if at least 20% of the viral population at the time of de-
tection is mutant. Adherence (x-axis) is measured as the fraction of sched-
uled doses taken. The height of the area shaded indicates probability of the
corresponding outcome at that adherence level. As compared to R  =10, in-
creasing R   to 20 leads to higher adherence levels being required for treat-
ment success, and it extends the range of adherence levels (in both directions)
for which resistant strains can cause failure. Mutant VF becomes a possible
outcome for the PIs ATV, ATV/r, IDV, IDV/r, and SQV/r, and treatment
success cannot occur at any adherence level for ddI and NFV.
   3TC  ABC ddI d4T AZT FTC
TDF EFV ETV NVP EVG RAL
ATV/r DRV/r IDV/r LPV/r SQV/r TPV/r
ATV IDV NFV SQV ENF




































































































































Figure 7.2.9: Simulated clinical outcomes versus adherence for all drugs,
R  =5. Results are shown for “Maintenance” trials only. In the “Mainte-
nance” trials shown, patients begin with full viral suppression and undergo
monotherapy for 48 weeks or until virologic failure (VF), whichever occurs
ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive weekly measure-
ments (starting at Week 5) with viral load above 200 c.ml  . VF is classiﬁed
as “via resistance” if at least 20% of the viral population at the time of de-
tection is mutant. Adherence (x-axis) is measured as the fraction of sched-
uled doses taken. The height of the area shaded indicates probability of the
corresponding outcome at that adherence level. As compared to R  =10, de-
creasing R   to 5 leads to lower adherence levels being required for treatment
success, and it reduces the range of adherence levels for which resistant strains
can cause failure. A range of high adherence levels appears where there is
treatment success for ABC and AZT, and near-perfect adherence is no longer
required for ddI and NFV success. Mutant VF no longer occurs for SQV, and
for AZT and ddI, wild-type failure may be the ﬁrst outcome to occur as ad-
herence levels decrease from the successful range.
   T1/2 = 10 hrs T1/2 = 16 hrs T1/2 = 7 hrs T1/2 = 4 hrs   T1/2 = 22 hrs T1/2 = 11 hrs
T1/2 = 3.5 hrs T1/2 = 7 hrs T1/2 = 10 hrs T1/2 = 15 hrs T1/2 = 18 hrs T1/2 = 20 hrs
T1/2 = 60 hrs T1/2 = 120 hrs T1/2 = 180 hrs





































































































Figure 7.2.10: Simulated clinical outcomes versus adherence for NRTIs with
large inter-experimental variation in half-life. The ranges included were {10,
16, 22} for 3TC, {4, 8.5, 11} for AZT, {3.5, 7, 10} for d4T, {15, 18, 20}
for ddI, and {60, 120, 180} for TDF. Results are shown for “Maintenance”
trials only. In the “Maintenance” trials shown, patients begin with full viral
suppression and undergo monotherapy for 48 weeks or until virologic failure
(VF), whichever occurs ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two con-
secutive weekly measurements (starting at Week 5) with viral load above 200
c.ml  . VF is classiﬁed as “via resistance” if at least 20% of the viral popu-
lation at the time of detection is mutant. Adherence (x-axis) is measured as
the fraction of scheduled doses taken. The height of the area shaded indicates
probability of the corresponding outcome at that adherence level. Compared
to the half-lives used throughout the rest of the paper (see Supplementary
Table 7.1.1), the results barely change for 3TC or d4T. For AZT, varying the
half-life changes the adherence level where wild-type failure becomes more
likely than mutant failure. For ddI, the adherence level where treatment suc-
cess occurs shifts. For higher TDF half-lives, mutant VF becomes the only
outcome, with the exception of rare (   %) wild-type failure at the lowest
adherence levels for t =  =     hours.























































Figure 7.2.11: Selection regimes for DRV/r-RAL two-drug therapy. Depend-
ing on the length of a treatment interruption to one or both drugs, treatment
may be fully suppressive or select for the wild-type strain, a mutant resistant
to DRV, a mutant resistant to RAL, or combinations of these strains. The yel-
low region, where the MSW for both drugs overlap, is barely visible, and it is
located where the other MSW regions meet, near the center of the graph.
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Figure 7.2.12: Relative risk of wild type- vs. mutant-caused virologic failure
for anti-HIV drugs, considering the best “synthetic” mutation deﬁned in Sec-
tion 2.5.3. Two metrics can be used to compare the risk of resistance to the
likelihood of wild-type growth, shown on both axes. The x-axis measures the
time until a patient interrupting treatment reaches the MSW, divided by the
time until that patient reaches the WGW. The y-axis measures the number
of days that a patient spends in the MSW during a treatment interruption.
Drugs tend to cluster near the endpoints of the x-axis: most NRTIs, the IIs,
and the FI are on the left, meaning that the patient enters the MSW immedi-
ately or soon after interruption, and most PIs are on the right, meaning that
the patient waits relatively long to enter the MSW. Section 2.5.7 further de-
scribes the two metrics and explains how they were used in Fig 2.2.2f in the
main text to rank the drugs by relative risk of mutant-based versus wild type-
based VF. Note that the symbol for DRV/r is obscured behind the symbol for
d4T at (   ).

































































Figure 7.2.13: Distribution of a) viral load setpoints [160] (data available at
www.hiv.lanl.gov/content/immunology) and b) adherence levels [16] used in
simulations.
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Figure 7.3.1: Clearance probabilities and rebound times following LRA ther-
apy predicted from model, versus infectivity variance λ. A) Three cases for
the population-level distribution of LR size (see Section 3.4.1). Case i) All
patients have the same latent reservoir size, MLR =    , estimated from the
geometric mean number of cells that are capable of producing infection in lab-
oratory co-culture assays. Case ii) Latent reservoir size is distributed according
to variation observed in co-culture assays, with geometric mean    . Case iii)
The latent reservoir includes many cells that fail to be detected in co-culture
but have intact viral genomes. B) Probability that the reservoir is cleared by
LRA. Clearance occurs if all cells in the reservoir die before a reactivating lin-
eage leads to viral rebound. C) Median viral rebound times, among patients
who do not have clearance. Each point shows the average of           sim-
ulated patients. D) Survival curves for patients following LRA therapy. The
percentage of patients who have not yet experienced viral rebound is plot-
ted as a function of the time after LRA therapy and interruption of HAART.
Curves are colored based on the eﬃcacy of LRA in reducing the size of the LR
(Q =   to 6, see legend). Results are shown for          patients, a half-life of
44 months, R  =  , and a =          day  .
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Figure 7.3.2: LRA therapy eﬃcacies required for diﬀerent goals, plotted ver-
sus reservoir size MLR for diﬀerent infectivity variances λ. A) The threshold
Q that takes the patient into the activation-limited regime, where stochastic
waiting time contributes substantially to rebound time (deﬁned in Sec. 3.4.5).
B) The target eﬃcacy Q at which at least 50% of patients still have sup-
pressed viral load one month after treatment interruption. C) The target ef-
ﬁcacy Q at which at least 50% of patients still have suppressed viral load one
year after treatment interruption. D) The target eﬃcacy Q at which at least
50% of patients have eradicated the reservoir without experiencing viral re-
bound. Because some patients may go for a year without rebound but then
rebound later, the target Q for one year oﬀ therapy is always less than that for
a lifetime oﬀ therapy. Results are shown for           patients, a half-life of 44
months, R  =  , and a =          day  .
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Figure 7.3.3: Survival curves for patients following LRA therapy depend on
the size of the latent reservoir and the reservoir half-life (varying dz).The per-
centage of patients who have not yet experienced viral rebound (viral load
      c ml  ) is plotted as a function of the time after LRA therapy and
interruption of HAART. Curves are colored based on the eﬃcacy of LRA in re-
ducing the size of the LR (Q =   to 6, see legend). A) dz =   day  , half-life
is 330 months (27 years). B) dz =            day  , half-life is 44 months.
C) dz =          day  , half-life is 6 months. Decreasing the LR half-life
(increasing dz) makes survival times longer and clearance more likely. Includ-
ing interpatient variation (ii) makes the survival curves fall oﬀ more gradually,
while allowing for higher reservoir sizes (iii) increases the required drug eﬃ-
cacy. Solid lines represent simulations, and open circles represent approxima-
tions from a branching process calculation (Section 3.4.3). Results are shown
for           patients, λ =   , R  =  , and a =          day  
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Figure 7.3.4: Survival curves for patients following LRA therapy depend on
the size of the latent reservoir and the infectivity variance λ. The percentage
of patients who have not yet experienced viral rebound (viral load       c
ml  ) is plotted as a function of the time after LRA therapy and interruption
of HAART. Curves are colored based on the eﬃcacy of LRA in reducing the
size of the LR (Q =   to 6, see legend). Increasing the infectivity variance λ
makes survival times longer and clearance more likely. Including interpatient
variation (ii) makes the survival curves fall oﬀ more gradually, while allow-
ing for higher reservoir sizes (iii) increases the required drug eﬃcacy. Solid
lines represent simulations, and open circles represent approximations from a
branching process calculation (Section 3.4.3). Results are shown for a half-life
of 44 months, R  =  , and a =          day  .
   Figure 7.3.5 (following page): Clearance probabilities and rebound times
after LRA predicted from model for alternate parameter choices. i) Best-
estimate parameter values shown in the main text: reservoir size is pre-
dicted by the distribution of co-culture results (case ii), a =          day  ,
dz =            day   (half-life of 44 months), R  =  . ii) Best-case-scenario,
where reservoir size is predicted by mean co-culture results (case i), half-life
is short and strong stochastic eﬀects decrease clearance probability. Param-
eter values are a =      day  , dz =          day   (half-life 6 months),
R  =    , λ =   , and MLR =    . This low estimate for a follows from the
assumption that all cells with HIV-DNA contribue to the residual viral load
observed during HAART. iii) Worst-case-scenario, when LR is large (case iii),
cells reactivate frequently, are extremely long lived, and smaller stochastic
eﬀects mean most reactivating cells lead to rebound. Parameter values are
a =          day  , dz =   day  , R  =  , λ =  , median MLR          .
This high estimate for a follows from the assumption that all virions in the
residual viral load come from cells with virus with intact provirus. The lower
limit on dz is realized if homeostatic proliferation or other mechanisms balance
reservoir decay caused by mechanisms other than reactivation. R  is always
adjusted to ensure that the baseline rebound time following HAART interrup-
tion was constant. All results are for           simulated patients.
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Figure 7.3.5 (continued)
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Figure 7.4.1: Invasion ﬁtness of a mutating invader against a nonmutating
resident, for varying levels of recombination c, computed as the largest eigen-
value of the matrix CQu′F minus  , from Eq. ( .  ). There is a discontinuity
at u′ =   not shown in the graph: the invasion ﬁtness s ( ) is zero for all
parameter values. Parameters are as in Fig. 5.3.4: n =  , a =    .
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Figure 7.4.2: ESMR (plotted on a log scale) versus ﬁtness beneﬁt a and
number of traits n, comparing the estimate presented in Fig. 5.3.5 (thick solid
lines) to an alternate estimate (thick lines with white stripe in middle). Points
show simulated ESMR values (see Methods) and dashed lines plot uΩ. The
alternate estimate uses Eq. ( .  ) to approximate ﬁtness of the optimal trait
within the resident strain; it only requires simulation to measure the resident
strain’s period. The ﬁtness approximation is accurate if n     and a ≪  . No
recombination is shown in this ﬁgure.
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